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Characterizing the genomic abnormalities underlying hepatocellular 
carcinoma (HCC) is crucial for understanding the molecular mechanisms of liver 
cancer development. Most cytogenetic analyses of HCC were however performed 
using low resolution conventional comparative genomic hybridization (CGH). In this 
study, copy number changes in the HCC genome and corresponding de-regulated 
transcription was characterized by performing high-resolution array CGH and 
genome-wide expression profiling on HCC tumors and their adjacent non-tumorous 
lesions. To address the validity of using cell lines as in vitro models of tumors, a 
collection of 12 HCC cell lines were also investigated on how closely they mirror the 
genomic alterations found in HCC tumors.  
By array CGH of 15 paired tumorous and non-tumorous lesions from HBV-
infected patients, it was demonstrated that copy number gains on 1q and 8q, and 
losses on 4q, 8p, 13q, 16q and 17p were the most common alterations in HCC, seen in 
at least half of the tumors. In addition, the sensitivity and fine-resolution of array 
CGH enabled detection of chromosomal regions with copy number change on 1p, 2q, 
4p, 5pq, 6pq, 7pq, 9p, 10pq, 11pq, 13q, 14q, 16p, 19pq, 20pq, 21pq, 22q and Xpq 
occurring in at least one-third of the tumors. These observations were supported by a 
subsequent meta-analysis of this study and another 793 CGH-analyzed HCCs from 
published studies that also additionally highlighted the presence of etiology-
independent and etiology-associated chromosomal aberrations in HCC. 
Integrative analysis of data from array CGH and genome-wide transcriptome 
profiling of the HCC tumors further identified 268 genes whose copy number and 
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expression were up-regulated or down-regulated by at least 1.5 fold in at least 30% of 
tumors. Of these, 44 genes demonstrated positive correlation between copy number 
and expression levels implying that changes in their transcript levels were directly 
attributable to copy number gain or loss. Notably, more than half (57%) of the 44 
genes were down-regulated, of which many were located on 8p. This implied that 
chromosomal losses, particularly 8p loss, were important events in HCC that bring 
about changes in the transcriptome. Furthermore, ontology analysis of genes 
differentially expressed in HCC also indicated that chromosomal instability and 
immune evasion are important events in HCC. 
Array CGH of the HCC cell lines demonstrated that the common 
chromosomal imbalances on 8q, 16q and 17p in patient tumors were not reflected in 
the cell lines, and additional aberrations on 9p, 18q and 20q were accumulated 
possibly during in vitro culture. Gain on 1q and losses on 4q, 8p and 13q however, 
remained prevalent in cell lines. Computation of pairwise Pearson’s correlation 
between log2 fold change values of corresponding array CGH probes in the cell lines 
and a pooled tumor sample that was derived from the average of the 15 tumors 
revealed that Hep3B was most representative of copy number changes in patient 
tumors. It reported an average correlation of 0.6 across all somatic chromosomes. 
HepG2 was the least representative cell line with an average correlation of 0.11. 
The data suggests that HCC cell lines mirror genomic changes in HCC tumors 
poorly and careful interpretation of results is warranted when cell lines are used to 
study tumor molecular biology. The consistent involvement of 8p in HCC and cell 
lines supported an important role for it in tumor formation and growth. 
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1.1 Epidemiology and etiology of Hepatocellular carcinoma (HCC) 
1.1.1 Overview of HCC 
 Primary liver cancer is one of the most prevalent cancers in the world, being 
the fifth most common cancer amongst the male population worldwide, and the 
seventh most common cancer amongst the females1. An estimated 74,000 new cases 
were expected to be diagnosed globally in 2008. In addition, primary liver cancer has 
an extremely high mortality to incidence ratio of 0.93, making it the third leading 
cause of cancer death worldwide, with an estimated 70,000 deaths in 20081. 
Hepatocellular carcinoma (HCC) is the predominant histological subtype of primary 
liver cancer. It is responsible for 70% to 85% of the global total liver cancer burden2. 
In view of the high incidence and mortality rates of liver cancer, HCC is evidently a 
major burden to public health. Epidemiological studies on HCC have revealed several 
interesting features such as distinct variations in incidence rate between geographical 
regions, gender bias in disease rates and strong evidence for environmental risk 
factors. HCC is also one of the rare cancers to be etiologically linked to viruses and it 
uniquely occurs mainly within a background of chronic liver disease and cirrhosis. 
Due to the multi-factorial etiology, HCC often presents a variable course of disease 
clinically. A detailed understanding of HCC epidemiology and the molecular 
mechanisms associated with its various etiologies is hence essential for designing 
better screening and treatment strategies for the disease. 
1.1.2 Distribution of HCC 
 According to the most recent figures published in the GLOBOCAN database, 
a database maintained by the International Agency for Research on Cancer (IARC) 
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that collects data from cancer registries and other sources worldwide, liver cancer 
presents an uneven distribution throughout the world1. Economically, age-
standardized incidence rates are significantly higher in developing countries (18.9 per 
100,000) than developed countries (8.1 per 100,000). Geographically, the highest 
liver cancer rates occurred in Eastern Asia and South-Eastern Asia, followed by 
Middle and Western Africa. Incidence rates are however low in South-Central and 
Western Asia, as well as in Northern and Eastern Europe (Table 1.1). Of note, liver 
cancer cases in China alone had been estimated to account for approximately 50% of 
the global cases and deaths.  
Table 1.1 Global Age-Standardized Liver Cancer Incidence Rates by Gender and World Area1 
World Area Incidence rates in males  (per 100, 000 individuals) 
Incidence rates in females  
(per 100, 000 individuals) 
   
Eastern Aisa 35.5 12.7 
South-Eastern Asia 21.4 9.0 
Middle Africa 18.9 9.6 
Western Africa 16.6 8.8 
Melanesia 12.9 5.0 
Southern Europe 9.8 3.2 
Micronesia/ Polynesia 9.5 3.4 
Northern Africa 7.5 2.5 
Central America 7.3 7.0 
Western Europe 7.2 2.1 
Eastern Africa 7.2 3.6 
Northern America 6.8 2.2 
Caribbean 6.3 4.4 
South America 5.3 3.9 
Australia / New Zealand 5.0 2.0 
Central and Eastern Europe 4.6 1.9 
Western Asia 4.4 2.3 
Northern Europe 3.8 1.6 




  Temporally, while the incidence and mortality rate of HCC remained high in 
Eastern and South-Eastern Asia, decreases in liver cancer incidence rates have been 
reported in the Chinese populations of Shanghai, Hong Kong and Singapore in the 
period between 1978 and 19923. The Japanese population however reported increases 
in incidence rate within the same period, presumably due to higher prevalence of 
HCV infection. On the other hand, discouraging trends have been reported in 
populations usually at low risk for liver cancer. For instance, increasing occurrence 
rates were documented for both male and female populations in North America and 
countries in South and Central Europe, particularly Italy and France from 1978-1992. 
In the United States, the age-adjusted incidence rate for HCC rose by 24% in males 
and 31% in females between 1998 and 20034. From these reports, it is highly likely 
that the global patterns of HCC may be changing. While the reason(s) behind the 
changes is not yet clear, possible factors such as declining HBV infection rates due to 
successful vaccination programs, increasing prevalence of HCV, improved survival of 
cirrhotic patients and a burgeoning population of obese individuals have been 
suggested.       
1.1.3 Risk factors and distribution 
Hepatitis B virus (HBV) 
 Globally, hepatitis B virus (HBV) is the primary underlying cause of HCC, 
accounting for approximately 60% and 23% of the total liver cancer in developing 
and developed countries respectively5. Despite the availability of a vaccine, HBV 
remains a threat to public health today, with more than 300 million HBV carriers in 
the world and 1 million deaths annually from HBV-related liver disease. Association 
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of HBV as an etiological factor of HCC has been supported by numerous pieces of 
epidemiologic evidence as well as case-control and cohort studies. Regions that have 
a high rate of chronic HBV infection, which is defined as prevalence greater or equal 
to 8%, are generally associated with high liver cancer rates. Examples of such regions 
include China, Southeast Asia and sub-Saharan Africa. The dominant route of HBV 
transmission in these regions is vertical transmission from mother to child, and 
infected infants have an approximately 90% risk of developing chronic HBV infection. 
On the other hand, in areas with low prevalence of chronic infection (and low liver 
cancer rate), HBV is primarily transmitted via sexual or parenteral routes, resulting in 
acute infections that are resolved spontaneously over a period of 2-4 months. The 
epidemiological data strongly suggests a role for chronic HBV infection in 
hepatocarcinogenesis that is also supported by observational studies. Based on the 
results of 15 cohort studies and 65 case control studies worldwide that examined the 
association between HCC and chronic HBV infection as determined by hepatitis B 
surface antigen (HBsAg) seropositivity, IARC Monograph classified HBV as a 
biological carcinogen for HCC. In the studies summarized by the Monograph, relative 
risk of HCC in chronic HBV carriers ranged from 5.3-148 in cohort studies to 5-30 in 
case control studies, strongly implicating HBV as an important etiologic agent in 
HCC6. 
 A unique feature of HCC is that it frequently develops within a background of 
liver cirrhosis. This is also reflected in HBV-related HCC whereby a majority of 70-
90% of the tumors developed in patients with liver cirrhosis7. However, HBV per se is 
also a potent cause of HCC in the absence of cirrhosis. Besides cirrhosis, other factors 
have also been documented to increase HCC risk amongst HBV carriers. For instance, 
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HCC risk has been reported to be increased in patients with higher HBV viral load 
and HBV genotype C has also been suggested to be associated with more severe 
forms of HCC than genotype B8. Co-infection with HCV was concluded by several 
meta-analyses as producing an additive effect on HCC risk9,10. However, this factor is 
unlikely to have a great impact due to the rarity of co-infections.  
 Infection with HBV has become preventable with the availability of the HepB 
vaccine, making vaccination arguably the best measure to lowering incidence of 
HBV-related HCC. This has been proven by the successful infant vaccination 
program in initiated in 1984 Taiwan that halved the average incidence rate of HCC in 
children after the first 10 years of implementation11.Despite such success, challenges 
in the implementation of the vaccine in most HBV endemic countries are hampering 
efforts to lower HBV-related HCC rates. Logistics, storage and financial problems are 
preventing many governments from efficiently administering the HepB vaccine birth 
dose i.e. newborns receiving vaccination within the first 24 hours of birth, which is 
crucial for a 70% - 95% effectiveness as post-exposure prophylaxis in preventing 
mother-to-infant transmission. As of 2006, the HepB vaccine birth dose global 
coverage was only 27%12 and this figure is likely to be an overestimation given errors 
in reporting and mis-interpretation of the definition of birth dose for HepB vaccine. In 
view of these limitations, it is arguably too early for HepB vaccination to produce a 
strong impact on global HCC rates. HBV-related HCC is most likely to continue to 





Hepatitis C virus (HCV) 
Hepatitis C virus (HCV) is the secondary underlying cause of HCC. 
Approximately 33% and 20% of the total liver cancer in developing and developed 
countries respectively was estimated to be attributable to HCV5. HCV infection 
affects about 170 million people worldwide and incidence of HCC in HCV-infected 
individuals ranges between 1-5%. Prevalence of HCV-related HCC varies widely 
among countries. While as high as 80% of the primary liver cancer cases in Japan 
were HCV-related13, prevalence is lower in Italy and France ranging from 40%-
71%14,15 and 27%-58%16,17 of liver cancer cases respectively. 
Like HBV, HCV has also been classified as a biological carcinogen for HCC 
by IARC. In a meta-analysis of 21 case-control studies in which HCV positivity was 
evaluated using second-generation anti-HCV ELISA or HCV RNA test, HCC risk 
was found to be elevated by 17.3 fold (95% CI: 13.9 – 21.6) in HCV-positive subjects 
negative for HBsAg9.  In another independent meta-analysis conducted in the Chinese 
population, odds ratio for HCC in anti-HCV/HCV-RNA positive but HBsAg-negative 
subjects was 8.1 (95% CI: 5 – 13)10. Hence, all the evidence presented so far strongly 
supports HCV as a major risk factor for HCC. However, in contrast to HBV, HCV-
related HCC almost occurs exclusively in cirrhotic livers18,19. In addition, unlike HBV, 
there is also no strong evidence that HCV viral factors such as viral load and genotype 
have an influence on HCC risk. Instead, several other non-viral factors such as gender, 
age of infection, alcohol consumption, cigarette smoking, obesity, diabetes and co-




As there is currently no vaccine available for HCV, measures to prevent HCV-
related HCC will have to be aimed at blocking its route of transmission. HCV is 
transmitted predominantly via the blood, the main routes of transmission being 
intravenous drug abuse, blood transfusions and parenteral administration of 
medications. With the introduction of routine screening for HCV in blood transfusion, 
the incidence of post-transfusion HCV infection has dropped significantly in most 
developed countries. Transmission of HCV via intravenous drug injection however 
remains a worrying cause for infection.   
Non-viral etiologies  
 A prominent non-viral etiological agent of HCC is the mycotoxin, Aflatoxin 
B1 (AFB1), which is mainly produced by two species of Apergillus fungus, 
Aspergillus flavus and Aspergillus parasiticus. It has been classified by IARC to be 
carcinogenic after extensive animal experiments demonstrating that it induced 
primarily hepatocellular tumors in animals23. Data from epidemiological studies 
support a tumorigenic role for AFB1 both as an independent risk factor, as well as 
through interaction with chronic HBV infection. In one short-term prospective study 
conducted on middle-aged males residing in Shanghai, China, urinary excretion of 
aflatoxin metabolites was shown to be significantly associated with a 3.4 fold (95% 
CI: 1.1 – 10) increase in HCC risk, independent of HBsAg positivity24. Moreover, 
study subjects positive for both HBsAg and urinary aflatoxin metabolites exhibited a 
dramatic 59.4 fold (95% CI: 16.1 – 212) elevation in HCC risk, clearly demonstrating 
a strong interaction between the two risk factors. Similar findings were echoed in 
another long term prospective study on 145 men chronically infected with HBV from 
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Qidong, China over a period of 13 years25, which reported a relative HCC risk of 3.5 
(95% CI: 1.5 – 8.1) from aflatoxin exposure.  
 Besides aflatoxin, alcohol consumption has also been indicated as a HCC risk 
factor. A well-established association between heavy alcohol consumption, defined as 
intake of more than 50g-70g per day over long periods, and higher risk for HCC has 
been drawn from numerous studies20,26. For instance, alcohol consumption of > 60g 
per day in individuals negative for both HBsAg and HCV RNA increased relative 
HCC risk by seven fold26. Synergism between alcohol intake and HCV infection or 
HBV infection on HCC risk has also been demonstrated in case control studies on the 
human population. Tagger and co-workers, for instance, reported that a daily alcohol 
consumption of 41g-80g or > 80g increased the HCC risk due to HCV infection by 
about two fold and four fold respectively20. Although there is no direct proof of its 
carcinogenicity in animal studies, animal experiments examining the influence of 
alcohol on the potency of known carcinogens had found ethanol to be a promoter of 
tumor formation27,28.  
 Although the majority of HCC cases worldwide can be traced to alcohol 
consumption, aflatoxin exposure or viral etiologies, there remain a proportion of cases 
for which the etiology is cryptogenic. In the United States, these cryptogenic HCC 
cases account for 15%-50% of the total cases29. Severe forms of non-alcoholic fatty 
liver disease (NAFLD), namely non-alcoholic steatohepatitis (NASH), have been 
suggested to be responsible for the majority of these cryptogenic cases. NAFLD refers 
to the buildup of excessive fats (> 5-10% of liver mass) in liver cells that is not caused 
by alcohol. It tends to develop in individuals who are overweight or diabetic or have 
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high blood cholesterol levels. As NAFLD progress, the buildup of fats leads to 
swelling and inflammation of the liver. This more severe form of the disease known 
as NASH causes damage to the liver and may lead to liver cirrhosis that is so often 
followed by HCC development. Once NASH has progressed to liver cirrhosis and 
HCC is established, the pathological features of NASH become hard to identify. This 
makes association studies on NAFLD or NASH as risk factors for HCC hard to 
perform. Adding to the difficulty is the limited number of prospective longitudinal 
studies on NAFLD with long-term histological follow-up. Hence, apart from sporadic 
case reports30,31 and small observational studies32,33, evidence of progression from 
NAFLD to HCC from prospective studies is scant. Much of the evidence for 
association of NASH with HCC risk is provided indirectly instead by studies on two 
conditions strongly associated with NASH – obesity and diabetes. Cohort studies 
from Denmark, Sweden and the United States had shown that there was two to five 
fold higher risk of HCC in obese persons compared to those with normal body mass 
index34-36. A large cohort study of approximately 173,000 diabetic and 650,000 non-
diabetic patients also found that HCC incidence was doubled in diabetic patients37. 
Similar conclusions were also reached in two other large-scale cohort studies on 
diabetic patients with a follow-up period of nearly 20 years38,39. Overall, the evidence 
for association between NAFLD and HCC risk is moderately strong. In view of the 
increasingly larger obese population in developed countries and the expectation of a 
Type 2 diabetes epidemic in the years to come, it is likely NAFLD will play a bigger 




1.2 Genetic alterations in HCC 
1.2.1 Overview 
 HCC, like most solid tumors, is a disease resulting from the accumulation of 
genetic alterations that lead to disruption of normal cellular processes and eventually 
transformation to neoplastic phenotype. In HCC, genetic alterations start 
accumulating from the early stages of hepatocarcinogenesis. Dysplastic cirrhotic 
nodules are widely recognized as precancerous lesions of HCC. In an early study 
examining DNA abnormalities in dysplastic cirrhotic nodules, hyperploidy was found 
in 44% of low-grade dysplasia and 75% of high-grade dysplasia, suggesting 
cumulative gain of genetic material in the transformation process40. In another study 
analyzing chromosomal allelic imbalance (AI) in 180 cirrhotic nodules, 
approximately half of the nodules were found to be monoclonal in origin and of these, 
91% had a least one AI event detected41. Since only 12 chromosomal arms were 
investigated in that study, the frequency of AI in dysplastic nodules is likely under-
estimated. In contrast, specific activating mutation of oncogenes and loss-of-function 
mutation of tumor suppressor genes have not been previously described in liver 
dysplasia, though they were found in HCC tumors. These included mutations of 
important ‘gatekeeper’ proteins such as tumor protein p53 (TP53), retinoblastoma 1 
(RB1) and players of the Wnt/β-catenin pathway, which are closely associated with 
tumor development. Overall, studies on genetic alteration have demonstrated it to be 
an important mechanism by which hepatocytes escape sentinel surveillance to become 
neoplastic. A large number of genetic alterations in HCC have been described to date, 
some of which have been linked to the common risk factors for HCC. 
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1.2.2 Genetic alterations and HBV 
 HBV can promote genetic alteration in HCC by two main ways – HBV DNA 
integration into the host genome and production of the viral oncogene, HBV X (HBx) 
protein. HBV DNA can become integrated into the host genome after reverse 
transcription from an RNA template during viral replication. Integrated HBV DNA is 
frequently detected in HCC tumors as well as non-tumorous chronic hepatitis or acute 
hepatitis tissues42-46. Proof of its presence even in the non-cirrhotic livers of children 
and young adults47 seems to reinforce a role for viral DNA integration in tumor 
initiation. HBV DNA integration into human genomes occurs in a random and non-
selective manner. A multitude of studies have reported viral DNA integration at 
multiple chromosomes and multiple sites, with most integration sites reported in lone 
studies. This random mode of integration suggests that the main oncogenic effect lies 
in the induction of a higher genomic instability. In fact, many of the reported 
integration events took place near or within fragile sites or repetitive regions of the 
human genome that are inherently prone to instability in tumor development and 
progression (reviewed by Feitelson et al)48. In some cases however, integration of 
HBV DNA can occur within cellular genomic regulatory regions (e.g. enhancer or 
promoter) or within coding regions, resulting in deregulation of gene expression or 
modification of the structure or function of the gene products through the creation of 
fusion proteins. An example of insertional mutagenesis is the integration of HBV 
DNA into an intron of the cyclin A (CCNA2) gene49. This produced a HBV-cyclin A 
fusion protein with strong tumorigenic properties50,51. Another interesting integration 
event occurred in the β-retinoic acid receptor (RARB) gene that became placed under 
the transcriptional control of the integrated HBV preS1 promoter. This led to 
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overexpression of the fusion protein with some potentially carcinogenic outcome52,53. 
Other examples of insertional mutagenesis sites include the epidermal growth factor 
receptor (EGFR)54 and mevalonate kinase (MVK) genes55,56. An exception to these 
lone reported mutations is the human telomerase reverse transcriptase (hTERT) gene 
for which HBV DNA integration was detected by several groups57-59.  
 Most of the HBV-related HCCs show integration of viral DNA at the direct 
repeat (DR) sequences located at each end of the viral genome60-62. Flanking the DR is 
the open reading frame of the HBV X (HBx) gene, which is thus also often integrated 
into the host genome63. Although the integrated HBx sequence is very often truncated, 
mutated or rearranged, functionally active proteins with transactivating ability could 
still be generated64,65. In fact, HCC-derived DNA fragments containing the HBx gene 
has been shown to be able to transform a mouse hepatocyte cell line and cause tumor 
formation when injected into nude mice66. Other studies performed on the viral (non-
integrated) form of HBx also support a tumor-promoting role for HBx either when 
expressed at high levels67 or when present in conjunction with additional 
hepatocarcinogenic agents such as diethylnitrosamine68,69. Besides, HBx has also been 
known to cooperate with cellular oncogenes (e.g. MYC) in hepatocyte 
transformation70. It has been hypothesized that HBx can promote genetic instability by 
compromising nucleotide excision repair (NER) and hence contribute to 
tumorigenesis. Indeed, HBx has been shown to disrupt NER in both p53-dependent 
and p53-independent manners71. By binding to p53, HBx was reported to disrupt 
p53’s association with TFIIH basal transcription factor complex helicase XPB subunit 
(ERCC3 or XPB), a component of the TFIIH transcription factor complex that 
functions in NER72 . Independent of p53, HBx was found to repress the expression of 
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XPB and TFIIH basal transcription factor complex helicase XPD subunit (XPD)73. It 
also binds and sequesters DNA damage-binding protein 1 (DDB1) from binding to 
damaged DNA in the first step of NER74, thus compromising DNA repair. In vitro 
evidence for HBx’s role in genetic instability has been provided by experiments in the 
hepatoma cell line, HepG2, whereby HBx-transfected cells displayed higher number 
of chromosome alterations and micronuclei formation75.    
1.2.3 Aflatoxin B1 and TP53 mutations 
The biological effects of AFB1 are mediated through its exo-8,9-epoxide 
metabolite that reacts covalently with DNA to form adducts,  leading to DNA damage 
and mutation. The most frequently induced mutation is a GC  TA transversion. In 
parts of the world where AFB1 exposure is high, a specific G  T transversion at 
codon 249 of the TP53 tumor suppressor gene has been described with higher 
prevalence in HCC. This suggests that AFB1 exposure is associated with this 
transversion that causes an amino acid change from arginine to serine in codon 249 
(R249S). Two studies characterizing TP53 mutation spectrum in HCC cases from 
Mozambique, South Africa76 and Qidong, China77, for instance, consistently found the 
R249S mutation in about 50% of the cases. Both areas are known to be exposed to 
HCC risk from HBV infection and aflatoxin. Experimental evidence for a direct 
causal effect of AFB1 on this mutation hotspot was presented by Aguilar et al who 
showed that exposure of HepG2 cells to rat liver microsome-activated AFB1 induced 
primarily the R249S mutation in TP5378. This mutation renders TP53 incapable of 
binding to p53 response elements and transactivating target genes, thus preventing 
p53 from performing its tumor suppressor role79. A recent study examining the 
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prognosis of HCC tumors carrying the R249S TP53 mutation also suggested that it is 
associated with poorer survival of patient and existence of stem cell-like traits in the 
tumors80. Besides the R249S mutation, loss of heterozygosity at chromosome 17p13, 
which houses the TP53 locus, was detected in 25-60% of HCC tumors. Hence, allelic 
deletions and AFB1-induced R249S mutation are the primary causes for loss of tumor 
suppressor function of TP53 in HCC.  
1.2.4 Genetic alterations of Wnt/β-catenin pathway 
 Aberrant activation of Wnt signaling is an important trait of many human 
cancers, including HCC. β-catenin is an important multi-functional protein that has 
been actively investigated for its pivotal role in Wnt signaling, as well as its function 
in cell-cell adhesion. In the absence of the Wnt signaling ligand, β-catenin is partially 
localized at adherens junctions in a complex with E-cadherin and α-catenin, and 
partially localized in the cytoplasm. Cytoplasmic β-catenin is maintained in an 
inactive state by the GSK3β/APC/axin complex that phosphorylates it at its N-
terminal serine-threonine residues, marking it for subsequent proteosomal degradation. 
Upon binding of Wnt ligand to Frizzled receptor, the GSK3β/APC/axin complex is 
inactivated. β-catenin is allowed to accumulate and translocate to the nucleus where it 
displaces the transcriptional repressor Groucho from the high mobility group domain 
factors TCF/LEF. The resulting complex of β-catenin and TCF/LEF then 
transactivates Wnt target genes such as c-myc (MYC) and cyclin D1 (CCND1)81,82. 
 Activating mutations of β-catenin is one way by which cancer cells deregulate 
β-catenin expression and cause abnormal activation of Wnt signaling. These 
mutations mainly affect the target phosphorylation sites of the GSK3β/APC/axin 
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complex83, thus abrogating degradation of β-catenin. Oncogenic mutations of β-
catenin have been detected in 13%-41% (average 25%) of HCC of various 
etiologies83-91. It has also been observed that β-catenin mutations were more prevalent 
in non-HBV-related HCC90 and associated with fewer chromosome alterations83. In 
addition, chromosome 16p13 that houses the axis inhibition protein 1 (AXIN1) gene, 
which forms the GSK3β/APC/axin complex, was deleted in about 30% of HCC 
tumors. Bi-allelic inactivation of AXIN1 via homozygous deletion or mutation of 
remaining allele after a LOH event were detected in < 10% of HCC tumors83,92. 
Another axin-related gene, axis inhibition protein 2 (AXIN2), was reported to be 
mutated in a very small percentage of HCC tumors91,93.  Mutation in APC is however 
absent in HCC tumors93. 
1.2.5 Genetic alterations of retinoblastoma pathway 
 Retinoblastoma protein (RB1) is an important tumor suppressor protein 
implicated in many cancers. It exerts its tumor suppressor role by preventing cell 
cycle progression from the G1 into the S phase, guarding the cell cycle restriction 
point beyond which cells are committed to complete the cell cycle. RB1 is active 
when hypo-phosphorylated. Active RB1 binds and inhibits transcription factors of the 
E2F family, preventing them from transactivating cyclin proteins that are needed for 
cell cycle progression. In HCC, inactivating mutations in RB1 are rarely found94. 
Nevertheless, RB1 was under-expressed in a large proportion of HCC tumors95. This 
can be attributed in part to LOH at the RB1 locus (13q14) that was found in 25-48% 
of HCC cases96-98. The remaining allele is most likely also inactivated by epigenetic 
silencing as suggested by a study by Zhang et al97.  
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 Also functioning to prevent cell cycle progression, but acting downstream of 
RB1, are two gene products, p16INK4A and p14ARF that are encoded by the same 
CDKN2A gene locus by alternative splicing. p16INK4A competes with cyclin D1 for 
binding to the G1 phase cyclin-dependent kinase, CDK4, thereby inhibiting passage 
through the G1 phase of the cell cycle. p14ARF acts to activate TP53 by inhibiting its 
negative regulator, MDM2. TP53 in turn transactivates cyclin-dependent kinase 
inhibitor 1A (p21CIP1) that binds and inactivates the G1-S phase CDK2-Cyclin E 
complexes, preventing progression from G1 to S phase. Studies have also placed 
p14ARF in the direct path of RB1 when it was identified as a transcriptional target of 
E2F transcription factor 1 (E2F1)99,100. Loss of heterozygosity of the chromosome 9p, 
housing the CDKN2A locus, has been demonstrated in various reports83,101,102. The 
predominant form of alteration in HCC however involves hyper-methylation of the 
p16INK4A promoter103-106. Homozygous deletion in exon 1β of CDKN2A (i.e. p14ARF 
gene) and loss of expression of p14ARF was also found in 10% and 25% of HCC 
tumors respectively105.  
1.2.6 Genetic alterations in TGFβ and insulin signaling pathway 
 A low frequency of missense mutations in the SMAD family member 2 
(Smad2) and SMAD family member 4 (Smad4) genes was previously illustrated in 
HCC107,108. These are members of the Smad family of signal transduction proteins that 
convey transforming growth factor beta-1 (TGFβ) signals from the cell surface to the 
nucleus. Hence, TGFβ signaling pathway might be disrupted in a minority of HCCs. 
Inactivation of the mannose-6-phosphate/insulin-like growth factor 2 receptor 
(M6P/IGF2R) gene in HCC go in support of this view. This gene encodes for a multi-
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functional tumor suppressor involved in several cellular processes, including 
activation of TGFβ signaling. M6P/IGF2R also plays an important role in insulin 
signaling where it negatively regulates insulin-induced growth pathways by 
promoting degradation of IGFII, a potent hepatocyte growth factor. A high proportion 
of HCCs (67%-70%) were heterozygous at the M6P/IGF2R locus109,110, with the 
remaining allele found to be mutated in 21%-25% of tumors displaying LOH, 
suggesting a ‘double-hit’ inactivation mechanism. More importantly, the study by 
Oka et al detected LOH of M6P/IGF2R in three of four dysplastic nodules analyzed 
for allelic loss, implying that alteration of this gene occurs early in HCC.  
1.2.7 Gains and losses of chromosomes 
 As discussed above, multiple genes and at least four signaling pathways have 
been implicated in HCC. Many of the genes (e.g. TP53, AXIN1, RB1) in the signaling 
pathways discussed exhibited LOH of an allele in HCC tumors. Besides, HBV, the 
principal etiological factor of HCC, was also associated with greater chromosomal 
alterations. This implies that like most epithelial cancer, chromosomal instability is an 
important hallmark of HCC.  
 A plausible explanation for the high incidence of chromosome gains and 
losses in HCC is the shortening of telomeres in cancer cells. Telomeres are small 
tandem nucleotide repeats of TTAGGG that cap chromosomal ends to prevent 
chromosomal fusions. However, due to the ‘end-replication inefficiency’ of DNA 
polymerase, telomeres will progressively shorten with each round of cell division. 
Dysfunctional telomeres can activate DNA repair mechanisms such as non-
homologous end joining (NHEJ)111 that can give rise to fusion of chromosomal ends. 
19 
 
When cells with fused chromosomes enter the cell cycle and into mitosis, structures 
called anaphase bridges representing fused chromosomes pulled to opposite spindle 
poles are formed. Stress on the anaphase bridge will cause the chromosome to break 
at random points and be unevenly segregated into the daughter cells. This 
phenomenon, termed fusion-bridge-breakage cycle results in chromosomal gains, 
losses and translocations in the daughter cells. It has been shown telomere length is 
significantly shorter in hepatocytes from HCC than those from adjacent non-
cancerous tissues112,113. At a single-cell level in HCC hepatocytes, shorter telomere 
lengths also correlated with increased aneuploidy114. These pieces of evidence support 
the hypothesis that telomere shortening causes chromosome instability in HCC. Given 
that chromosome gains and losses can be found in dysplastic nodules, and that they 
can lead to oncogene activation and LOH of tumor suppressor genes, one can further 
speculate that telomere dysfunction contributes to HCC initiation. Some evidence for 
this has been provided by a telomerase-deficient mouse model, using which it was 
demonstrated that telomere dysfunction enhanced the initiation of liver neoplasms115. 
 Since chromosomal instability is an essential feature of HCC pathogenesis, 
huge efforts have been dedicated in the past decades to cytogenetic studies on HCC. 
From the early primitive studies using Giemsa and Wright staining, to the recent 
advances in performing cytogenetic analysis at molecular levels, considerable 
information on chromosomal changes in HCC has been accumulated and with 
increasing resolution too. Generally, recurrent losses on chromosomes 4q, 8p, 13q, 




1.3 Molecular cytogenetic studies in HCC 
1.3.1 History of cytogenetics 
 Cytogenetics is a sub-discipline of genetics that addresses the cellular aspects 
of heredity, in particular the description of chromosome structure and identification of 
genomic aberrations that cause disease. The first application of cytogenetics to the 
study of human diseases led to the description of chromosome number aberrations in 
typical hereditary diseases such as Down syndrome in 1958116 and Klinefelter 
syndrome117 and Turner syndrome118 in 1959. It was a year later in 1960 that the era of 
tumor cytogenetics began with the discovery of the Philadelphia chromosome119, a 
minute chromosome that is regularly found in the peripheral blood of patients 
diagnosed with chronic myeloid leukemia. Since then, cytogenetics has remained an 
important tool in the study of tumor as a genetic (but rarely hereditary) disease in both 
research and clinical settings. Huge advancements in cytogenetic techniques have also 
since reshaped the understanding of tumor genetics. 
 The first advancement in cytogenetics is the development of chromosome 
banding in the late 1960s. Early banding was performed using fluorochromes coupled 
to an alkylating agent such as quinacrine mustard (Q-banding). This gave rise to a 
highly characteristic fluorescence pattern for every chromosome, thus allowing for a 
full karyotype to be attained. Later, the Giemsa stain was adapted from its use in 
microbiological identification for chromosome staining. The Giemsa banding (G-
banding) pattern is characterized by a series of darkly and lightly stained bands 
corresponding to the heterochromatic and euchromatic regions of the chromosome 
respectively. As G-banding offered an improved resolution of chromosome structure, 
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hence it quickly displaced Q-banding for karyotyping and is still widely used in 
clinical testing today.  Although chromosome banding is very useful for identifying 
whole chromosomes accurately and detecting chromosomal deletions, amplications 
and translocations, it is greatly limited in terms of resolution. Chromosome 
rearrangements smaller than 5 Mb in size are likely to avoid detection. 
 Improvement in resolution was achieved with the advent of molecular 
cytogenetics. The basis of the application of molecular techniques to chromosome 
cytology is the observation that complementary nucleotide sequences will anneal to 
each other more tightly than non-complementary sequences to form more stable 
complexes. Hence, molecular cytogenetics is usually based on in situ hybridization of 
probe sequences to target sequences on the chromosomes. Initial in situ hybridization 
was performed using radioactive RNA probes120. This was followed by the 
development of safer fluorescently labeled antibodies that demonstrate specific 
binding to DNA-RNA hybrids. Subsequently, methods to directly tag RNA or DNA 
with fluorochromes was invented, allowing for fast and direct visualization of the 
hybridization products121. This type of in situ hybridization became known as 
fluorescence in situ hybridization (FISH). Although direct labeling in FISH allowed 
more rapid detection, signals can be quite weak compared to the background 
fluorescence. This was overcome by the successful synthesis of modified nucleotide 
derivatives bearing non-fluorescent haptens (e.g. biotin)122. Probes incorporating these 
modified nucleotides are indirectly visualized by fluorochrome-labeled primary 
antibodies targeting the hapten. Further amplification of signal can also be achieved 
by adding another layer of fluorochrome-labeled secondary antibodies to non-labeled 
primary antibodies. FISH-based technologies such as spectral karyotyping (SKY) and 
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multiplex FISH (M-FISH) are now routinely applied in clinical diagnosis together 
with chromosome banding to improve chromosome identification. 
 Advances in resolution of chromosome structure and aberrations have been 
made in molecular cytogenetics, namely FISH-based techniques, through 
modifications of the two key elements of the analysis – the target and the probe. 
Similar to conventional analog cytogenetics, FISH also utilizes actively dividing cells 
arrested in metaphase by colchicine (i.e. metaphase spread) as targets for 
hybridization. This offers a target resolution of about 5 Mb. Target resolution 
however has been improved with the use of interphase nuclei. This is due to 
chromatin in interphase nuclei being much less condensed than in metaphase 
chromosomes, thus allowing closer ordering of probes over distances of 50 kb - 2 Mb. 
Also, as no culturing of live cells for subsequent induction of mitotic arrest is required, 
interphase FISH also benefits studies on minimal residual disease or micro-metastases 
where cells are disseminated in low numbers and not amenable for culture. The 
highest resolution target for FISH is produced by removing histones from chromatin 
to prepare released chromatin fibers. These chromatin fibers are the least condensed 
of the three target types, providing a resolution of 1-500 kb. Importantly, highly 
uniform evenly stretched chromatin fibers are producible using techniques such as 
molecular combing123. This allows for accurate sizing of the gaps or overlaps between 
probes, thus enabling measurement of the sizes of deleted regions in the genome124. 
 Besides improvements in target resolution, more effective labeling strategies 
and a wider selection of sequences available for probe design are also important in 
advancing the detection limits of FISH. In FISH, the number of differentially labeled 
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probes available for hybridization and imaging is a limiting factor in determining the 
number of structural anomalies that can be detected and the resolution at which they 
are detected. However, there are only a limited number of spectrally resolvable 
fluorochromes. To circumvent this restriction, smarter labeling strategies like 
combinatorial labeling125 and ratio labeling126 have been devised. In combinatorial 
labeling, each probe is labeled with a unique combination of fluorochromes and 
subsequently identified by the absence and presence of each fluorochrome. In ratio 
labeling, different probes can be labeled with the same combination of fluorochromes 
but differ in the proportion of each fluorochrome used.  
In conjunction with better labeling methods is an increase in the number and 
type of probes that can be labeled. With the sequencing of the human genome, more is 
known about the genetic information encoded in the chromosomes, extending the 
coverage of probe design to potentially the entire genome (except regions that are 
hard to sequence). FISH probes can be classified into three main categories: gene-
specific probes, repetitive sequence probes and chromosome painting probes. Gene-
specific probes have their sequences derived from large insert clones such as bacterial 
artificial chromosomes (BACs), PI derived artificial chromosomes (PACs) and yeast 
artificial chromosomes (YACs). They are available for most genomic regions and can 
be used to identify chromosomal duplications and deletions, translocations and 
inversions, marker chromosomes and contiguous gene syndrome. Repetitive sequence 
probes include centromeric-repeat probes that bind to the AT-rich repeats in 
centromeres, and sub-telomeric probes binding to TTAGGG repeats at the 
chromosome telomeric ends. While sub-telomeric probes are valuable for detecting 
cryptic minute translocations, centromeric probes are popularly used for identifying 
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and counting chromosomes, as well as detecting aneuplodies in interphase nuclei. Due 
to the high resolution of repetitive sequence (~ 0.5 Mb) and ease of performance, 
these probes are often used to in normal screening in cytogenetic laboratories. 
Chromosome painting probes stain entire chromosomes or chromosome regions 
except for the telomeres and centromeres. Their availability is rooted in the 
development of universal PCR approaches that enabled amplification of large DNA 
regions. Degenerate oligonucleotide-primed PCR (DOP-PCR), for instance, uses 
partially degenerate primers to randomly amplify DNA and is frequently used to 
produce painting probes127. Coupled with chromosome micro-dissection (isolating 
entire chromosomes or chromosome regions with a highly focused laser beam), DOP-
PCR can also generate region-specific painting probes, enabling analysis of smaller 
chromosome rearrangements such as interstitial deletions within specific chromosome 
bands128. After labeling by combinatorial or ratio labeling, these painting probes are 
very suited for visualizing all 24 human chromosomes, each in a different color, in a 
single hybridization. This then allows analysis of complex chromosomal 
rearrangements. M-FISH and SKY are examples of technologies using chromosome 
painting probes. They are largely similar techniques except for the imaging process. 
While in M-FISH sequential images of each fluorochrome are captured separately and 
then merged into a composite129, SKY130 combines charged-coupled device (CCD) 
imaging, Fourier spectrometry and a spectral-based classification algorithm to analyze 
a synchronized exposure of the image.  
With the enormous progress made in molecular cytogenetics, it is not 
surprising that many of the techniques, namely the FISH-based techniques, have 
become common tools in clinical diagnostics. However, some restrictions and 
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drawbacks of these techniques still exist, particularly with respect to application in 
research settings. For instance, although FISH using sub-telomeric and centromeric 
probes can achieve reasonably high resolution of 0.5 kb, their application is limited to 
investigations in these chromosome regions. On the other hand, whole chromosome 
painting techniques like M-FISH and SKY have lower resolution of 2-3 Mb, and thus 
have poor detection of small inter-chromosomal rearrangements. Although this can be 
overcome by designing special probe sets that target known structural anomalies, it is 
dependent on extensive a priori knowledge of genetic abnormality. Furthermore, 
FISH-based techniques usually require the preparation of metaphase spreads from 
target cells, necessitating the use of live tumor cells. The performance of these 
techniques on frozen or archived tissues is thus not possible, posing a challenge in 
collection of specimens for tumor research. Besides, it is also often difficult to prepare 
high-quality metaphase spreads from solid tumors. As such, an alternative molecular 
cytogenetic technique, comparative genomic hybridization, was developed to address 
some of these limitations. A summary of the resolution and chromosomal 















Figure 1.1 Comparison of cytogenetic techniques. The genetic resolution achievable by 
various cytogenetic techniques and the types of chromosome anomalies they are able to detect 
are summarized in the figure. A ‘+’ indicates the technique is able to detect the abnormality, 
and a ‘-’ indicates the abnormality will be undetected by the technique. ‘*’ indicates detection 
requires a single-cell approach and multiple experiments. ‘φ’ indicates detection is only 
achievable using SNP arrays. DM: double minute chromosome; HSR: homogeneously stained 




1.3.2 Conventional Chromosome-based CGH (cCGH) 
Principle and methodology of cCGH 
 Chromosome-based comparative genomic hybridization (cCGH), first 
described by Kallioniemi et al in 1992, is based on the comparison of total genomic 
DNA (gDNA) extracted from test sample (e.g. tumor cells) with total gDNA extracted 
from reference sample (e.g. normal cells)132. In cCGH of tumors, peripheral blood 
lymphocytes of healthy donors, who are preferably gender-matched to the patients, 
are often used for extraction of the normal reference DNA. However, a better 
alternative source of reference DNA for CGH analysis of solid tumors for fairer 
comparisons to be made is DNA extracted from the adjacent non-tumorous tissues. 
The extracted test and reference gDNA will be differentially labeled to become probes 
for the analysis. Labeling may be direct or indirect and is usually performed by nick 
translation. In direct labeling, SpectrumGreen-dUTP or SpectrumRed-dUTP are 
incorporated into the nicked test DNA and reference DNA respectively. Alternatively, 
FITC together with TRITC or Texas Red are also commonly used. In indirect labeling, 
biotin-16-dUTP and digoxigenin (dig)-11-dUTP are commonly used to label the test 
and reference DNA respectively. After labeling, the test and reference probes are then 
combined and applied to target metaphase chromosomes, frequently prepared from 
peripheral blood lymphocytes of healthy donors, and the probes will compete for 
complementary hybridization sites. Unlabeled excess human COT-1 DNA is normally 
also added to the hybridization mixture to suppress the repetitive sequences present in 
the two genomes. After hybridization, digital images of the hybridized metaphase 
chromosomes are then acquired and analyzed. For probes that were indirectly labeled, 
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FITC-conjugated avidin and rhodamine-conjugated antibodies against digoxigenin for 
detection of biotin-labeled DNA and dig-labeled DNA respectively were added before 
image capture.  
During the hybridization reaction, if a particular region is amplified in the test 
sample, there will be more of the test probes (e.g. labeled green) to out-compete the 
reference probes (e.g. labeled red) for hybridization onto the metaphase chromosomes. 
The corresponding region on the metaphase chromosome hence fluoresces green. 
Conversely, if a region is deleted in the test sample, the corresponding region on the 
metaphase chromosome will fluoresce red. The fluorochrome intensity ratio of test 
probe to reference probe along each chromosome is quantified by digital image 
analysis. Gains and amplifications in test DNA are reflected as increased fluorescence 
ratio (i.e. ratio > 1), while losses and deletions are identified by decreased 
fluorescence ratio (i.e. ratio < 1). 
Strengths and limitations of cCGH 
 One of the main advantages of CGH is its usefulness as a research tool since 
no a priori knowledge of the genomic imbalance is needed for the analysis. This is 
due partly to the generation of probes from the tumor genomic DNA. In addition, 
since metaphase spreads are prepared from karyotopically normal chromosomes from 
peripheral blood lymphocytes that are both more readily available and easily prepared, 
CGH helped overcome the main difficulty of conventional cytogenetics in getting 
good metaphase spreads of solid tumors with the karyotype fully preserved. Another 
advantage of CGH is that it can also be performed using DNA extracted from 
formalin-fixed and paraffin-embedded archive tissues. This allows comparisons of 
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genotype and phenotype to be made and correlations of genetic alterations with 
clinical progression to be analyzed. Besides, CGH can also be performed on frozen 
specimens, facilitating batch analysis of collected patient samples which minimizes 
inter-experiment variability.  
 However, there are also several limitations of CGH that undermines its power 
as a discovery tool. Firstly, CGH is unable to detect aberrations that do not result in 
copy number changes such as balanced chromosome translocations and chromosome 
inversions. It is also unable to identify specific chromosome rearrangements. Such 
chromosome structural anomalies will have to reply on other cytogenetic techniques 
like SKY and M-FISH for detection. Secondly, chromosome-based CGH performs 
poorer than SKY and M-FISH in terms of resolution. Studies have agreed that the 
minimum detectable size of a genomic segment using cCGH is approximately 3-10 
Mb133-136. Lastly, sensitivity of cCGH in detecting aberrations, defined by the minimal 
proportion of cells in a cell population carrying a particular genetic alteration that is 
required for the alteration to be detected, is not too ideal. Two different studies135,137 
have estimated that the minimal cell population required by cCGH for detection is 
about 25% to 32%. 
1.3.3 Array CGH 
 Array CGH shares the same principle for analysis of chromosome anomalies 
as chromosome-based CGH i.e. comparison of differentially labeled test and reference 
genomes. However as its name suggests, in array CGH, metaphase chromosomes are 
replaced as hybridization targets by large numbers of specific DNA sequences spotted 
on glass slides in an array format. This result in a marked increase in the resolution of 
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screening compared to target resolution offered by metaphase chromosome, 
interphase nuclei or chromatin fiber used in conventional cytogenetics and non-array-
based molecular cytogenetics. Similar to cCGH, the array readout is quantitative, 
taking the form of relative fluorescence intensities (test probe compared to reference 
probe) measured on a continuous scale. There are many types of array CGH platforms 
that have been used for analysis and reported in the literature. These included 
commercially manufactured arrays, as well as many ‘home-made’ arrays that were 
spotted by in-house facilities in research institutes or laboratories. Based on the type 
of DNA sequence that is arrayed, array CGH platforms can be classified into BAC 
arrays, cDNA arrays and oligonucleotide arrays. 
BAC arrays 
 BAC arrays for array CGH use large insert genomic clones such as BACs or 
PACs or a combination of both as the hybridization targets for the array. Typically, 6-
10 µg of gDNA from samples are needed for hybridization of BAC arrays. Due to the 
use of large insert sequences, fluorescence signals measured from BAC arrays are 
strong and therefore provide high sensitivity for measurement of copy number 
aberrations. Copy number changes from as low as a single copy change to as high as a 
hundred fold copy number change can be measured accurately over a linear range138,139. 
With the use of overlapping clones, aberration boundaries can also be mapped to a 
fraction of the length of a clone rather than strictly limited by the size of the clone140. 
However, being single-copy vectors, yields of BAC DNA are low. Sequence 
rearrangements also often occur during propagation of the bacteria culture, thus 
affecting the quality of the clones. Printing viscous solutions of high molecular weight 
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BAC DNA onto the array glass slides also poses difficulties. Hence, instead of using 
whole BACs, methods to prepare representations of BACs such as ligation-mediated 
PCR139 and DOP-PCR using the 6MW primer141-143 have been devised. These methods 
aim to amplify almost all the sequences in the BAC clones into smaller and less 
complex DNA fragments. Comparable performance to whole BACs when using these 
PCR representations has been shown in studies139,143.  
cDNA arrays 
 cDNA arrays were initially designed for interrogating gene expression of cells. 
In order to comprehensively assess the cellular transcriptome, such arrays typically 
contain large numbers of probes and provide more detailed coverage of the genome 
compared to BAC arrays. cDNA arrays have been successfully used in CGH, in place 
of metaphase chromosomes, to survey genomic imbalances in a number of cancers 
including HCC, and using both cell lines and frozen tissues144-149. Besides the better 
genome coverage and higher resolution provided, a great advantage in using cDNA 
arrays is the ability to use the same array to obtain information on both DNA copy 
number and mRNA transcript levels. This enables correlation of gene copy number to 
expression profile146,149, and aids in differentiating passenger genes, whose expression 
are deregulated as a result of carcinogenesis, from driver genes that initiate the tumor 
transformation process. However, this advantage of cDNA array also constitutes its 
weaknesses. These arrays suffer from uneven coverage of the genome since the 
probes (CGH targets) were designed only for investigating known coding genes. In 
view that there are studies suggesting that the human genome may contain 2-10 
fold150,151 higher number of coding genes than the current collection of known 
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annotated genes, cDNA arrays might be short of the capacity needed to address the 
full range of genetic imbalances. In addition, cDNA arrays also are less sensitive to 
small copy number alterations, possibly due to sequence mismatches between cDNA 
and genomic DNA in stretches where intronic sequences have been spliced out during 
post-transcriptional modification to produce the mature mRNA. 
Oligonucleotide arrays 
 With the completion of the human genome project and advances in 
oligonucleotide synthesis reactions, oligonucleotides as short as 25 bp in length and 
targeting the human genetic sequence in almost its entirety have been synthesized as 
targets for CGH. These were printed onto slides152,153 or directly synthesized onto 
glass or silicon substrates154,155. Oligonucleotide arrays offer the highest resolution in 
CGH analysis and the greatest flexibility. Resolution of analysis is only restricted by 
the size of the oligonucleotide and the density of oligonucleotides on the array. 
Automation for high throughput analysis is also relatively easy. In addition, compared 
to BAC arrays that requires micrograms quantity of sample gDNA, commercially 
manufactured oligonucleotide arrays require much smaller quantity (~ 0.5 µg) of 
gDNA. The range of Human Genome CGH Microarrays provided by Agilent 
Technologies, for instance, contain 60 bp oligonucleotides directly synthesized onto 
glass slides at densities ranging from 44,000 to 1000,000 oligonucleotides per array. 
Median probe density ranges between 2.3 kb to 75 kb. The oligonucleotide sequences 
are derived from the sequences of RefSeq genes, promoters, introns, exons, inter-
genic regions, telomeric regions and pseudoautosomal regions on sex chromosomes. 
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 Another type of oligonucleotide arrays is the single nucleotide polymorphism 
(SNP) arrays which are high density oligonucleotide arrays originally designed for 
genotyping purposes. Each SNP is represented by both its sense and anti-sense strands. 
Probe intensities that correspond to the two possible alleles of the SNP will identify 
which of the three genotypes (e.g. AA, AB and BB) is present. Likewise, DNA copy 
numbers can also be estimated from these probe intensities155-157. There is however a 
slight deviation from normal CGH protocol whereby the test and reference gDNA in 
SNP arrays are individually hybridized onto separate arrays before subsequently 
compared. A significant advantage of using SNP arrays is the ability to identify loss 
of heterozygosity at the level of individual nucleotides as well as entire genes. Also, 
since SNP arrays survey for single nucleotide changes, these arrays unlike other CGH 
arrays, can also be used to detect mutations. By incorporating genotype information, 
SNP arrays can also potentially shed light on the heredity aspects of cancer. Large 
regions of uniparental disomy were for example identified in leukemia patients with 
normal karyotypes via CGH using SNP arrays158. Commercial SNP arrays today are 
offering comprehensive SNP coverage ranging from 600,000 (Illumina® Omni1S 
BeadChip) to 900,000 (Affymetrix® SNP 6.0 Array) SNPs per array.  
1.3.4 CGH studies in HCC 
cCGH studies in HCC 
 Since the publication of the first CGH protocol in 1992, chromosome-based 
CGH has been widely applied in the study of chromosomal aberrations in HCC. The 
first CGH study in HCC tumors was published by Marchio et al in 1997, where the 
group reported chromosomal aberrations in 86% of the 50 HBV serologically positive 
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tumors tested159.  Losses were most prevalent on chromosomes 4q, 8p, 16q, 17p, 13q, 
6q and 1p in order of decreasing frequency, while gains were most prevalent on 
chromosomes 8q, 1q, 6p and 17q. Several of the recurrent losses reported by them 
were previously shown by loss of heterozygosity studies, demonstrating the validity 
of HCC CGH studies. Importantly, novel gains on 1q, 6p and 17q, and sporadic 
amplifications at 11q12, 12p11, 14q12 and 19q13.1 were also reported by the group.  
 To date, more than 30 other CGH studies in HCC have been published. These 
included studies performed on HCC of various etiologies, histology and different 
populations (e.g. Chinese, Japanese), as well as a few studies performed on liver 
dysplastic nodules160-162, metastatic HCCs163 and recurrent HCCs164. Studies comparing 
CGH results in HCC and other primary liver cancers (e.g. liver adenomas, 
intrahepatic cholangiocarcinoma) pointed to a higher incidence of genetic alterations 
in HCC and the presence of distinct aberrations in different types of liver cancer165,166 . 
Of the more than 25 CGH studies performed on primary HCC tumors, all studies 
detected chromosomal gains on 1q and 8q. Furthermore, nearly three-quarters of these 
studies reported 1q as the chromosome most frequently gained in primary HCCs, 
suggesting that important carcinogenesis related genes reside on chromosome 1q. In 
addition, gains on chromosomes 6p and 17q were also often reported just as the first 
CGH study had demonstrated. Gains of the q-arm of chromosome 20 were also 
prominent. Although not highlighted by Marchio et al, gains on the q-arm of 
chromosome 20 were detected in 20% of tumors in their study159 and at a frequency of 
15%-62% (mean = 24.9% ± 11.3%) in latter studies. With regards to chromosomal 
losses, 4q and 8p were the most widely reported chromosomes with more than 90% of 
studies detecting loss.  Losses on 4q and 8p were detected in 12%-70% (mean = 40% 
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± 15.6%) and 12%-77% (mean = 39.2% ± 16.8%) of primary HCCs respectively. 
Besides these, chromosomal losses on 16q (mean = 37.9% ± 16.3%), 17p (mean = 38% 
± 17%), 13q (mean = 31.9% ± 12.1%), 1p (mean = 26% ± 11.8%) and 6q (23.9% ± 
11.1%) are also common in HCCs. While some of the chromosome copy number 
changes described in HCC were also described in other tumors (e.g. prostatic cancer167, 
breast cancer168, colon cancer169), specific changes more prevalent in HCC are also 
present. For instance, one CGH study on HCC, biliary tract cancer and pancreatic 
cancer that originated from closely located organs identified common gains on 1q and 
8q, common losses on 8p21-pter and 17p, but found losses on 13q14 and 16q to be 
exclusive to HCCs170. Hence while there are common oncogenes and tumor 
suppressors crucial for tumor formation for all tumors, there are likely also unique 
genes conferring survival advantage for different tumors.    
 Several cCGH studies had also described minimal overlapping regions of gain 
(or high-level amplification) and loss which indicate the smallest region or loci that 
presented copy number gain (or loss) in all (or most) of the tumors tested. Such 
regions therefore are highly likely to house cancer-associated genes. However, limited 
by the resolution of cCGH and the heterogonous nature of tumors, multiple minimal 
overlapping regions were often delineated for each chromosome. An exception is gain 
on 8q that has been consistently mapped to a minimum region at 8q24164,165,171-173 
where the oncogene MYC is located. High level copy number gain at 8q23-24 was 
also seen in 10%-13% of HCCs171,174. Other minimal regions of gain are largely 
located in the loci 1q21-25, 6p21-23 and 17q21 or 17q22-25. High level copy number 
amplification has also been described for the loci 1q12-22163,175, 1q22-23174 and 1q25-
31171. Jumping translocation breakpoint (JTB), SHC transforming protein 1 (SHC1) 
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and chaperonin containing TCP1 subunit 3 (CCT3) are some candidate genes shown 
to be overexpressed at transcript level in these loci176. On the other hand, minimal 
regions of loss have been largely mapped to 8p21-23, 16q21-qter and17p12-13160. 
Candidate tumor suppressors in these loci include fibrinogen-like 1 (FGL1) (8p22), 
deleted in liver cancer 1 (DLC1) (8p22), E-cadherin (CDH1) (16q22.1), WW domain 
containing oxidoreductase (WWOX) (16q23.3-24.1) and TP53 (17p13.1)96,176-179.  
Array CGH studies in HCC 
 The application of array CGH to analysis of HCC tumors has greatly refined 
the boundaries of aberration regions, fulfilling the main goal of CGH studies which is 
to locate cancer-associated genes as accurately as possible. For instance the 
determination of cancer-related genes on chromosome 8q that is frequently gained in 
HCCs and high level amplification of gene dosage was reported in individual patients. 
As mentioned, cCGH studies have recurrently delineated a minimum locus of gain to 
8q24. This was echoed in a BAC array CGH study that found the 8q12-24.3 region to 
be very frequently gained180. The apparent lower mapping resolution is due to the low 
density of probes used for this array that numbered at 800 clones. With a BAC array 
containing about eight times more clones181, the most frequent region of amplification 
was traced to a BAC clone harboring the MYC oncogene on 8q24. Similarly, using 
high density SNP arrays182, this region was mapped to a 0.73 Mb area at 8q24.21-
24.22 in another report, containing MYC and ArfGAP with SH3 domain, ankyrin 
repeat and PH domain 1 (ASAP1 aka DDEF1) genes. On the same note, the minimal 
region of gain on chromosome 1q was refined to a 2.84 Mb region at 1q22.1-23.1181. 
Other minimal regions located by array CGH are +20q13.33 (2.5 Mb)181,183 and -
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17p13.3-13.1 (7.94 Mb)182. A commonly reported amplicon at 11q13 in cCGH 
studies171,184,185 was also narrowed to the CCND1 gene at 11q13.2-13.3 (0.11Mb)182.  
 Besides higher mapping resolution, array CGH is also particularly suitable for 
integrative analysis with gene expression data. Target features on the CGH arrays can 
be mapped to a small subset of gene entities (BAC arrays) or even to individual genes 
(BAC, cDNA, oligonucleotide arrays), allowing copy number analysis down to single 
gene or even single nucleotide levels as in SNP arrays. This facilitates correlation of 
gene copy number to its expression level when microarray expression profiling is 
performed concurrently. Given the complex karyotype of HCC tumors, integrative 
analysis is crucial for identifying the key copy number alterations that will bring 
about actual changes in expression. Conversely, it is also known that many genes are 
aberrantly expressed in tumors due to alterations of key genes upstream in the 
pathway i.e. passenger genes. Identification of genes whose expression is altered due 
to gene amplification, loss of heterozygosity or homozygous deletion will aid in 
distinguishing driver genes from these passenger genes. Most of the array CGH 
studies on HCC are accompanied by microarray gene expression profiling. This led to 
the identification of a number of cancer-associated genes such as JAB1, SPP1, 
TAGLN2, PEG10, MDM4, EEF1A2, SCRIB, NCSTN, TRIM35, HEY1 and SNRPE 
149,182,183,186,187. One such very recent integrative study conducted on Chinese HCC 
patients identified a cluster of six genes on chromosome 8p that were associated with 
poor prognosis when deleted, of which SORBS3, PROSC and SH2D4A were shown to 
act as tumor suppressors in mouse tumorigenicity models188. This clearly 
demonstrates that array CGH coupled with survey of transcriptome is a useful tool for 
finding crucial genes that drive tumorigenesis. 
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Limitations of current studies 
 Currently, more than 30 CGH studies in HCC have been published (Table 1.2). 
These have led to the identification of macro-imbalances on chromosomes 1pq, 4q, 
6pq, 8pq, 13q, 16q, 17pq and 20q as key signatures of HCC. However, more two-
thirds of these were chromosome-based CGH studies with limited power to detect 
micro-imbalances. In particular, only five array CGH studies performed using high 
density and resolution commercial oligonucleotide arrays have been reported in 
literature while seven other studies were based on low density commercial or home-
made BAC and cDNA arrays. Clearly there is a need for more high resolution CGH 
analysis by oligonucleotide arrays in order to locate more of the small aberrations and 
to correlate these to clinico-pathological features. For instance, gains at 8q11.21-24.3, 
17q22-23.2 and 19q12 have been associated with micro-vascular invasion and loss at 
9p24.2-21.1 was associated with higher grade HCCs189. 
 Given the multi-factorial etiology of HCC, it is important to examine whether 
there are genetic alterations that are specific to each etiology. A survey of the tumor 
samples analyzed in the various studies reveals that 16 cCGH studies examined 
clinical samples of mixed viral and non-viral etiologies, six cCGH analyses were 
performed on HBV-infected HCCs only, and two studies were dedicated to 
investigating HCCs of non-viral etiology and HCV etiology each. Similarly, few array 
CGH studies were performed on samples of a particular etiology. Nonetheless, several 
chromosomal aberrations specific for particular etiologies have been highlighted. 
Zondervan et al reported higher frequency of loss of 4p, 16q, 17p and 18q in their 
sample of HBV-related HCCs than HCV-related HCCs, as well as more frequent loss  
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of 17p than HCCs of non-viral etiology160. A study on HCCs serologically negative 
for both HBV and HCV also echoed lower frequency of loss of 17p when compared 
to a previous study on HBV-related HCCs. Furthermore, loss of 4p and 16q were also 
found to be less frequent in the non-viral HCCs. Gain of 10q was found at much 
higher frequencies in HCV infected tumors by two independent studies183,185. In a 
single study that included cryptogenic HCCs, a 10.1 Mb region at 8q21-24.12 
harboring the MYC oncogene was found to be gained in alcohol-related and viral-
related HCCs but not cryptogenic HCCs, suggesting that the latter develops via a 
distinct non-MYC dependent pathway183. Despite these concurrent findings, there are 
also controversial findings. Two cCGH studies reported no marked difference in 
chromosomal aberrations between HBV- and HCV-related HCCs184,190. A useful 
approach to analyze for etiologic-specific chromosomal changes is to conduct meta-
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analysis of the available studies. To date, only one meta-analysis of 785 CGH-
analyzed HCCs from 31 studies was published191. Its findings supported for existence 
of etiologic-specific aberrations such as positive correlation of HBV etiology with 
losses on 4q, 16q, 13q and 8p. More meta-analyses of this nature will inevitably be 
useful in providing insights into how viral and non-viral factors might differentially 
influence chromosome stability in HCC.   
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1.4 Aims of Study 
 This study aims to achieve three primary goals: (1) high-resolution mapping of 
chromosomal regions frequently lost or gained in hepatocellular carcinoma (HCC) 
and examine whether there are chromosomal changes specific to particular etiologies 
(2) identification of major cellular processes that are de-regulated in HCC and genes 
that are transcriptionally altered due to copy number change (3) examination of the 
validity of cell lines as in vitro genetic models of HCC. 
 In order to achieve these aims, commercially manufactured high-resolution 
CGH arrays were employed to profile gene copy number changes in HCC patient 
tumors and cell lines. These arrays provide an average spatial resolution of 35kb, thus 
allowing fine delineation of chromosomal regions that are altered. Commercial 
expression microarrays offering genome-wide coverage with more than 22,000 probes 
were used to survey the transcriptome. This genome-wide coverage and the array 
format of the CGH analysis employed allow for correlation of the transcription levels 
of genes to the gene copy number. With these methodologies, a full-scale and detailed 




Chapter 2:  




2.1.1 Tumor samples 
Surgically resected cancerous lesions as well as the adjacent non-tumor liver 
tissues were obtained from 37 patients diagnosed with primary HCC. Tissues were 
snap-frozen and stored in liquid nitrogen before use. All patient subjects were of 
Chinese ethnicity. Age of patients ranged from 24-71 years old with an average age of 
55. The male: female gender ratio was 5:1. Cancer staging for the tumors was 
determined according to the American Joint Committee on Cancer (AJCC) TNM 
Staging System. With this, 22 primary HCCs were classified to be in stage T1-2 and 
15 HCCs were in stage T3-4. All cases were serologically determined to be positive 
for HBV but negative for HCV, of which 16 cases were positive for HBeAg. 
Histologically, 16 HCCs were well-differentiated and 19 HCCs were moderately 
differentiated. All tumors, except for two, were isolated from patients with fibrotic or 
cirrhotic liver. Copy number and expression profiling were performed on paired 
tumors of 15 of these patients (Cohort 1a). The remaining the paired tumors were 
subjected to expression profiling only.  
2.1.2 Cell lines 
The cell lines used in this study are all of human origin. The human HCC cell 
lines HepG2192 (ATCC HB-8065), Hep-3B192(ATCC HB-8064) , PLC/PRF/5193 
(ATCC CRL-8024), SK-HEP-1194 (ATCC HTB-52), SNU-182195 (ATCC CRL-2235) 
and SNU-449195 (ATCC CRL-2234) were purchased from the American Type Culture 
Collection (ATCC) (Manassas, VA, USA). The other HCC cell lines, Mahlavu196, 
Tong197, Huh-6198, Huh-7199, Huh-1200, Huh-4200 were kindly provided by WHO 
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Immunology Center, National University of Singapore. The cell lines Hep-3B, 
PLC/PRF/5, SNU-182, SNU-449, Huh-1, Huh-4 and Tong are positive for HBV virus 
and carry integrated HBV DNA. 
2.1.3 Chemicals 
 The cell culture materials Dulbecco’s modified Eagle’s medium (DMEM), 
Dulbecco’s Phosphate-buffered saline (DPBS) and 0.125% trypsin/Versene were all 
prepared by and purchased from the Biopolis Shared Facilities (Singapore). Fetal calf 
serum (FCS) was bought from GIBCO (GIBCO®, Grand Island, NY, USA).  
2.1.4 Arrays 
 The Agilent Human Genome CGH Microarray Kit 44B (Agilent Technologies, 
Inc., Santa Clara, CA, USA) is a high resolution tool for genome-wide copy number 
variation profiling without the need for complexity reduction. More than 42,000 
coding and non-coding human sequences are represented on the array by probes 
averaging about 60bp in length and an average spatial resolution of 35kb was 
achieved. Probe selection is biased towards genes, with 84% of intragenic probes and 
16% intergenic probes. Probes were annotated against NCBI Build 36 (UCSC hg18, 
March 2006).  
 The GeneChip® Human Genome U133A 2.0 Array (Affymetrix, Inc., Santa 
Clara, CA, USA) is a genome-wide transcriptome profiling tool that probes the 
expression levels of more than 18,400 human transcripts, including more than 14,500 
well-characterized genes. Sequences used in the design of the array were sourced 
from GenBank®, dbEST, and RefSeq. Probes were selected from the 600 bases most 
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proximal to the 3' end of each transcript, with the transcript end determined using (1) 
the 3' ends of RefSeq and complete CDS mRNA sequences or (2) the position where 
eight or more 3' EST reads terminate at. Each transcript is interrogated by multiple 
probes belonging to a probe set (collection of probes designed to interrogate a given 
sequence). Every array contains 500,000 distinct oligonucleotide features making up 
more than 22,000 probe sets. Like the Agilent CGH microarray, probes in the U133A 
2.0 Array were annotated against NCBI Build 36 (UCSC hg18, March 2006). 
2.2 Methods 
2.2.1 Cell culture 
All HCC cell lines were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) that was supplemented with 10% fetal calf serum and filtered before use. 
No antibiotics were added. All cell lines were maintained at 37oC in a humidified 
incubator with 5% CO2 atmosphere and sub-cultured every two to three days. When 
seeding cells for experiments, the cells were first washed two times with DPBS 
(without Ca2+ and Mg2+), detached from the substratum with 0.125% trypsin/Versene 
and subsequently re-suspended in DMEM. Cell count was taken using a 
hemocytometer and cells were seeded at the desired concentration.  
2.2.2 Genomic DNA extraction and Array CGH hybridization 
Genomic DNA was extracted using the Non-organic DNA extraction kit from 
Chemicon International (Millipore Corporation, Billerica, MA, USA) according to the 
manufacturer’s instructions. Briefly, mammalian cells from tissue culture or solid 
tissues were gently lysed to release the nuclei. The nuclei were enzymatically de-
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proteinated and protein contaminants were removed. Genomic DNA was then 
precipitated by ethanol. Purified DNA was quantified on the NanoDrop ND-1000 
UV-VIS spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA) to 
assess both concentration and purity, and also analyzed by agarose gel electrophoresis 
to assess DNA integrity. 
Array CGH hybridization and wash was performed as described in the 
manufacturer’s protocol. Briefly, 100ng each of reference female (46, XX) gDNA 
(Promega Coporation, Madison, WI, USA) and sample (tumor or non-tumor or cell 
line) gDNA was separately amplified with the phi29 polymerase (QIAGEN, Valencia, 
CA, USA), followed by restriction enzyme digestion with AluI and RsaI (Promega). 
Digested DNA was purified using QIAquick PCR clean-up kit (QIAGEN). For Cy3- 
or Cy5-labeling reactions, 7 g of purified digested DNA was labeled using the 
reagents in the BioPrime Array CGH Genomic Labeling kit (Invitrogen Coporation, 
Carlsbad, CA, USA) according to the manufacturer’s instructions and either Cy3- or 
Cy5-conjugated dUTP (Perkin Elmer, Inc., Waltham, MA, USA). Reciprocal dye 
swap labeling reactions were performed for each experimental sample to minimize the 
effects of labeling biases. Following clean-up with Microcon YM-30 filters 
(Millipore), purified labeled sample and reference DNA for each hybridization were 
pooled and mixed with human Cot-1 DNA (Invitrogen), Agilent 10X blocking buffer 
and Agilent 2X hybridization buffer. Hybridization onto Human Genome CGH 44B 
Oligo Microarray glass slides was performed at 65°C for 40h in a rotating 
hybridization oven (Robbins Scientific, Sunnyvale, CA, USA) at 12rpm. The arrays 
were then dissembled at room temperature, washed in Agilent wash buffers 1 and 2, 
and subsequently scanned using an Agilent 2565AA microarray scanner. 
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Fluorescence intensities were extracted and Lowess normalization was then 
performed using Feature Extraction software version 8.5 (Agilent Technologies). The 
tumor over reference DNA intensity ratios, and the non-tumor over reference DNA 
intensity ratios, were next logarithm-2 (log2) transformed. The log2 fold change of 
tumor over non-tumor intensity ratios i.e. log2 (T/NT) ratio, were then calculated by a 
subtraction of the log2 (tumor over reference DNA) intensity ratio by the log2 (non-
tumor over reference DNA) ratio. If the log2 (T/NT) ratio takes the value of zero, it 
indicates there is no DNA copy number difference between tumor and non-tumor 
samples. Log2 (T/NT) ratios greater than 0.25 indicate DNA copy number gain. Log2 
(T/NT) ratios smaller than -0.25 indicate DNA copy number loss.    
2.2.3 Frequency plot of copy number aberration 
For each array CGH probe, the number of HCC tumors reporting copy number 
gain or loss (abs (log2 (T/NT) ratios) > 0.25) was tabulated. The frequencies of copy 
number gain or loss for all the array probes were plotted as a function of their genome 
location using the Integrative Genomics Viewer (Version 2.2.17) developed by 
Robinson et al at the Broad Institute201. Probes were annotated against the USCS hg18 
(March 2006) assembly. 
2.2.4 Identification of recurrent chromosomal regions of copy number 
aberration 
Delimitation of the boundaries of chromosomal regions that were gained or 
lost in each of the HCC tumors or cell lines was first performed, using the GLAD 
(Gain and Loss Analysis of DNA) R package available in the Bioconductor software. 
This is a set of algorithms that are implemented in the R programming language and 
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describes a methodology that identifies altered genomic regions by two main steps – 
detection of breakpoints and the assignment of a status (i.e. DNA copy number) to 
each maximum spanning homogeneous region (MSHR). A MSHR is a genomic 
region within which all points in the region have the same status and the region is 
bordered by either a chromosome end or another homogenous region of a different 
status. A breakpoint separates two adjacent MSHRs.  Briefly, breakpoint detection is 
first achieved by performing the adaptive weights smoothing (AWS) procedure202. 
This is an iterative data-adaptive smoothing technique that finds the maximal 
neighborhood around each genomic location in which the local assumption (i.e. same 
DNA copy number) holds using weighted maximum-likelihood estimates. The result 
is smoothing of the array CGH data into MSHRs of the same (but unknown) DNA 
copy number. Outliers are detected based on the assumption that all the observations 
(probe signal intensities) in an MSHR are drawn from the normal distribution and 
probes whose signals lie in the α/2-quantile upper or lower tail are removed. 
Assignment of status is then done by a two-step unsupervised clustering of the 
MSHRs (chromosome, then genome level) to correct for the dye bias between 
chromosomes, providing a genomic base level for assigning copy number. This 
defines superclasses of MSHRs sharing same DNA copy number which are then each 
given a status (normal, gain or loss) and the mean log2 (T/NT) ratio is computed. All 
algorithm parameters used in this study were kept at default (e.g. qlambda = 0.999, α 
= 0.001) (See Appendix for R script arguments). Qlambda is the statistical penalty for 
the weighted maximum-likelihood under the χ2 distribution. Decreasing its value will 
increase the number of breakpoints detected, which in turn increases the false positive 
error. The threshold to call gains and losses is specified at 0.25. The boundaries of 
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each altered region across the tumors were then manually reviewed and the frequency 
computed to locate the recurrent regions of copy number change. 
2.2.5 CGH meta-analysis 
CGH studies included in the meta-analysis were selected based on the 
following inclusion criteria: (1) study was performed using primary HCCs (2) 
availability of complete data profile (3) threshold used for detecting copy number 
alterations ranged between 0.75-0.85 for loss and 1.15-1.5 for gain (4) data for array 
CGH studies had been subjected to segmentation copy number analysis using 
breakpoint calling algorithms. SNP arrays were excluded from the analysis as both the 
technical platform and copy number analysis methodology are vastly different and not 
comparable to cCGH that was performed on most of the CGH-analyzed HCCs. 
Overall, 23 published CGH studies (dating till 2009) available through the NCBI 
PubMed database were included in the analysis together with this study. Of these, 
four studies were performed using only HBV-infected HCCs (HBV-HCC), two were 
performed using only HCV-infected HCC (HCV-HCC), two were studies on non-
viral HCCs (NBNC-HCC) and 16 studies had used HCCs of mixed etiologies. A total 
of 793 informative CGH-analyzed HCCs were provided by these studies. Informative 
HCCs are HCCs with at least one aberration detected. Only informative HCCs were 
considered in the meta-analysis so as to remove possible data bias arising from 
varying sensitivity of detection amongst the cCGH studies. Information on the HBV 
status and HCV status was available in 331 cases and 106 cases respectively. Lack of 
infection with either HBV or HCV was confirmed in 109 cases. 
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In the preliminary examination, the 24 CGH studies were classified into four 
categories – studies performed on HBV-HCCs (HBV group), on HCV-HCCs (HCV 
group), on non-viral HCCs (NBNC group) and on HCCs of mixed etiologies (Mixed 
group). Eight CGH studies using HCCs of mixed etiologies, for which CGH data of 
each tumor sample together with the associated etiology was available, were divided 
into sub-studies characterized by a singular etiology and included into the respective 
categories. For each study, the frequency of gain or loss of each chromosome arm was 
calculated and recorded as a percentage of the total number of informative tumors in 
the study. Chromosomal aberration frequencies for all studies in each category were 
plotted onto an aligned dot plot using GraphPad Prism software (version 5.04) 
(GraphPad Software, Inc., San Diego, CA, USA). 
 For the association studies, the frequency of each chromosomal aberration in 
all the studies of each category was first summed and calculated as a percentage of the 
total number of informative HCCs of that etiology. Statistical evaluation of the 
association of HBV, HCV or NBNC etiology with specific chromosome aberrations 
was then performed by pairwise Fisher’s exact test (2-tailed) between the three 
etiologies, using GraphPad InStat software (GraphPad Software, Inc., San Diego, CA, 
USA). Of note, one HBV-HCC study203 did not report the aberration frequency for all 
the human chromosomes but was nevertheless included in the meta-analysis due to its 
large sample size. Data from this study was excluded from consideration for 
chromosomes that it did not report and the sample size of HBV-HCCs used for 




2.2.6 RNA extraction and gene expression microarray hybridization and analysis 
For analysis of transcriptome in the 37 paired HCC tumors or 11 HCC cell 
lines, total RNA was extracted from tissues or cell lines using TRIZOL reagent as 
described by the manufacturer (Invitrogen). Purified RNA was quantified on the 
NanoDrop ND-1000 UV-VIS spectrophotometer to assess both concentration and 
purity, and RNA integrity was assessed on the Agilent 2100 Bioanalyzer (Agilent 
Technologies). Approximately 3-5 ug of total RNA was in vitro transcribed (one 
cycle of in vitro transcription), labeled and hybridized to the GeneChip® Human 
Genome U133A 2.0 Arrays according to manufacturer’s instructions. Briefly, double-
stranded cDNA was first prepared from the purified RNA by reverse-transcription 
using T7-oligo(dT) primer, followed by normal PCR of the resultant first-strand 
cDNA with T4 DNA polymerase. Following clean-up, the double-stranded cDNA 
was used as template for in vitro transcription at 37oC for 16 hours overnight. This 
step also entailed target labeling as biotinylated ribonucleotide analogs were used for 
synthesis of the transcribed RNA (or cRNA). The cRNA was next cleaned-up, 
fragmented into 35-200 bp fragments and finally hybridized onto the array chip at 
45oC for 16 hours in a GeneChip® Hybridization Oven 640 (Affymetrx) at 60 rpm. 
After washing and scanning on the GeneChip® Fluidics Station 450 and GeneChip® 
Scanner 3000 7G (Affymetrix), the raw probe signal intensity data was automatically 
acquired and processed by the three-step Robust Multi-array Average (RMA) probe 
summarization algorithm204 implemented by the apt-probeset-summarize program in 
the Affymetrix Power Tools (APT) software package. This algorithm performs 
background subtraction, normalization and summarization of probe sets in sequential 
order. Briefly, a smoothed background level is computed for each spot using a 
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weighted sum of the individual zone backgrounds. Once a background level for each 
spot is calculated, background correction is performed by subtracting it from the spot 
intensity. Next, to account for the variability between chips (e.g. manufacturing, 
variations in hybridisation and amount of starting material), quantile normalization205 
is carried out. In this procedure, the distribution of probe intensities on each chip (of 
all the chips analyzed in a batch) is sorted and then the arithmetic mean of the 
intensities at each quantile across all the distributions is calculated, giving a reference 
distribution. The intensity of a probe ranked as the ith quantile on its chip’s 
distribution is then transformed to the value of the ith quantile in the reference 
distribution. Transformation is done for all probe intensities in all the chips analyzed, 
giving the final normalized probe intensity in log2 scale. Lastly, the overall signal 
intensity for the entire probe set is summarized from the normalized signals of each 
probe. RMA summarization is based on the assumption that normalized log-
transformed signals follow a linear additive model containing a probe affinity effect, a 
gene specific effect (the expression level) and an error term, where the probe affinity 
effects are assumed to sum to zero, and the gene effect is estimated using median 
polishing.  Median polishing is a robust model fitting technique that protects against 
outlier probes. 
2.2.7 Ontology enrichment analysis of HCC transcriptome 
 The threshold for defining differential expression was set at 1.5-fold fold 
change (i.e. log2 ratio > abs (0.67)). Probe sets that were over-expressed by more than 
two-fold in tumors were considered to be amplified. To examine which cellular 
processes were most perturbed at the transcriptional level in HCC, genes differentially 
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expressed in at least 40% of the HCC tumors were selected for enrichment analysis. 
Probe sets were annotated against the UCSC hg18 assembly. Enrichment analysis was 
implemented using the Enrichment Analysis workflow from the MetacoreTM software 
suite (GeneGo, Inc., St Joseph, MI, USA). This is an ontological analysis tool that 
mapped gene IDs from the list of differentially expressed genes onto gene IDs in 
entities of built-in functional ontologies represented in MetaCore by pathway maps 
and networks, providing a p-value ranked representation of ontologies that are most 
saturated or "enriched" with the input data. Besides, enrichment analysis using GO 
ontology206 is also conducted. A hypergeometric distribution was used for calculating 
the nominal p-values and the Benjamini-Hochberg FDR method was used for 
correction of multiple testing. False positive rates were controlled at no more than 
0.05%. 
2.2.8 Integrative analysis and ontology analysis 
To identify important genes altered in both DNA copy number and expression, 
significantly de-regulated genes from the array CGH dataset and the expression array 
dataset were mapped and common genes in both datasets were singled out. This was 
facilitated by annotating the array CGH probes and Affymetrix U133A probesets 
against the same UCSC hg18 assembly (NCBI Build 36) to ensure accurate mapping 
of gene ids between the two platforms i.e. DNA probe sequence and Affymetrix probe 
set sequence mapping to the same gene will be annotated with the same gene id. The 
criterion for definition of de-regulated genes in the array CGH and expression array 
dataset are gene(s) with log2 (T/NT) copy number or expression ratio > 0.6 or < -0.6 
occurring in at least 30% or 40% respectively of HCC tumors.  
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Gene ontology enrichment analysis of this set of genes reporting frequent 
aberration in both copy number and expression i.e. differentially expressed genes 
(DEGs) was carried out by manual annotation of gene function. Information on gene 
function that was retrieved from UniProtKB/Swiss-Prot where protein function is 
manually annotated of function after critical review of experimental and predicted 
data, as well as GO_BP ontologies from the Gene Ontology Consortium were used as 
references for the annotation. Both databases are constantly updated and curated, 
providing accurate information on gene attributes. Annotated genes were assigned to 
the following 17 categories of gene function: metabolism (non-nucleic acid, nucleic 
acid, xenobiotic, redox or ion); gene expression (transcription and translation); protein 
folding or modification; signaling; transport; cytoskeleton, cell motility and 
trafficking; cell adhesion; cell cycle and proliferation; apoptosis and DNA repair; 
immune response; angiogenesis; blood coagulation; multi-organismal development. 
Non-nucleic metabolism included metabolism of amino acids, peptides, proteins, 
lipids, carbohydrate and vitamins. Cell motility and trafficking was defined as 
directed movement of cells, cellular components and substances without the 
involvement of an external agent such as a transporter. Transport was defined as 
directed movement of substances by means of some agent such as a transporter or 
pores and included ER-Golgi transport and mRNA transport. Each gene was assigned 
to a single ontology. Pie chart showing the proportion of ontologies in the gene list 
was plotted using Microsoft Excel 2010 (Microsoft Coporation, Redmond, WA, 
USA).  
To analyze correlation between copy number and expression profiles, non-
parametric Spearman’s rank correlation coefficient (ρ), was computed between the 
57 
 
log2 (T/NT) copy number ratio and log2 (T/NT) expression ratio. Array CGH and 
U133A data from the 15 HCC tumors in Cohort 1a on which both copy number and 
expression profiling were performed were used for this analysis. Since the sample size 
of n =15 is too small to assume a Gaussian distribution, Pearson’s correlation which 
had been shown to be sensitive to non-normality was not used207. Instead the non-
parametric Spearman’s correlation was adopted. A correlation coefficient of ρ ≥ 0.3 
was considered to be positive correlation while ρ ≤ -0.3 was determined to be negative 
correlation. The Spearman’s rank correlation coefficient formula is given below: 
ߩ ൌ 1 െ 6෍݀௜ଶ ൫݊ሺ݊2 െ 1ሻ൯ൗ  
where ݊ = sample size (i.e. no. of tumors) 
݀௜= difference in ranks between the copy number and expression ratio of the ݅௧௛ tumor 
Spearman’s correlation was evaluated between the copy number profile and 
expression profile of each gene, as well as with the expression profiles of each of the 
other 267 genes. The distribution (target distribution) of all the ρ calculated in the 
former (i.e. 268 correlation coefficients) was plotted. A bootstrap sample (n = 7183) 
of the ρ calculated in the latter (i.e. 71824 correlation coefficients) was used to plot 
the frequency distribution (random distribution). The significance of the mean 
correlation coefficient of the target and random distributions were evaluated by one-
sample (two-tailed) t-test at α = 0.05.  
2.2.9 Correlation analysis of HCC tumors and cell lines 
 Pooled array CGH data from the 15 non-tumorous (NT) lesions of HCC 
patients in Cohort 1a was used to derive an average non-tumor over reference DNA 
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intensity ratio (NTav) for each probe. These were subsequently employed in the 
calculation of log2 fold change for all probes in the cell lines (CL) i.e. log2 (CL/ NTav) 
ratio. To measure genetic similarity between HCC tumors and cell lines (CL), 
Pearson’s correlation coefficient (r) was calculated between log2 (CL/NT) ratios of 
each cell line and the average log2 (T/NT) ratios of the 15 HCC tumors (Cohort1a). 
Calculation of Pearson’s r was performed separately for each chromosome arm, 
utilizing data from all the probes available for that chromosome. The number of 
probes compared between cell lines and HCC tumors for each chromosome are listed 
in Table 2.1. Sex chromosomes were excluded from analysis. 
 Similarly, to measure genetic similarity between HBV-positive and HBV-
negative cell lines, the average log2 fold change (i.e. log2 (CL/NT) ratio) of each 
array CGH probe in each group of cell lines were first computed. Log2 fold change 
values for all the probes on a chromosome arm (Table 2.1) in the two groups of cell 
lines were then assessed for correlation by Pearson’s r.  
 In order to test for significant difference in Pearson’s correlation coefficients 
between HBV-positive and HBV-negative cell lines, non-parametric Mann-Whitney 
U-test (also known as Wilcoxon rank-sum test) was adopted. Choice of this test was 
due to a small sample size (n1 = 7, n2 = 5) which violated the rules of normality. 
Testing was performed at significance level of α = 0.05 and two-tailed p-values were 
computed. 
Derivation of Pearson’s r and graphing of correlation plots, as well as 
performance of Mann-Whitney U-test and plotting of boxplot were done in the 






Table 2.1 Number of probes assessed for correlation on each chromosome 
 No. of probes compared 
Chromosome p-arm q-arm 
   
1 2037 1843 
2 1011 1771 
3 1167 1353 
4 500 1421 
5 418 1578 
6 1021 1231 
7 694 1234 
8 543 1047 
9 472 1094 
10 458 1185 
11 776 1405 
12 581 1510 
13 - 976 
14 - 1327 
15 - 1259 
16 715 906 
17 560 1491 
18 172 661 
19 860 1095 
20 380 666 
21 - 535 







Chapter 3:  
Characterizing DNA copy number 
changes in HBV-infected HCC 
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3.1 Frequent alteration of 1q, 4q, 8p, 8q, 13q, 16q and 17p in HCC 
 
3.1.1 Study on association between clinico-pathologic parameters 
For the purpose of performing array CGH and expression microarray analyses, 
primary tumor (T) and the adjacent non-tumorous (NT) liver tissue was collected 
from 37 HCC patients. Array CGH was performed on 15 of these paired (T + NT) 
samples (Cohort 1a) and microarray expression profiling was performed subsequently 
on all 37 paired HCC samples (Cohort 1). The age and gender profile of the patients, 
as well as clinical, serological and patho-morphological data for the tumor samples 
are shown in Table 3.1. 
 To examine possible relationships between the various clinical and 
pathological parameters in HCC, two-tailed Fisher’s exact test was performed. Those 
tumor samples for which the histology or serological status was not determined were 
excluded from the statistical analysis. The results are presented in Table 3.2. Analysis 
of association was performed on the parameters differentiation status, tumor stage, 
presence of cirrhosis and HBeAg sero-conversion. The results indicated that no 





Table 3.1 Clinico-pathological profile of 37 patients enrolled in study 










         
77 60 Male + + m T3 f Y 
81 41 Male + + w T2 f Y 
85 65 Male + + m T1 c Y 
86 71 Female + - w T2 c Y 
96 32 Male + - w T3 c Y 
98 45 Male + + w T3 f Y 
100 65 Male + + w T3 c Y 
101 62 Male + + m T2 f Y 
107 58 Male + + ND T3 f Y 
110 38 Male + + m T2 c Y 
111 62 Male + + w T2 n Y 
112 57 Male + + m T3 c Y 
128 57 Male + + w T3 c Y 
171 48 Male + - w T2 f Y 
182 50 Male + - w T2 c Y 
         
13 65 Male + ND m T4 c N 
63 54 Male + + m T2 c N 
64 67 Female + + m T1 c N 
67 24 Male + + w T2 n N 
69 71 Male + + m T1 c N 
83 68 Male + + m T2 c N 
90 56 Male + - m T3 c N 
93 46 Male + - w T1 f N 
99 53 Female + + w T2 c N 
102 53 Male + - m T2 c N 
103 66 Male + + w T3 c N 
105 47 Male + + m T4 c N 
118 48 Male + + w T4 f N 
124 61 Male + - ND T3 c N 
130 60 Male + - m T2 c N 
154 53 Female + - m T4 c N 
155 44 Female + - m T2 f N 
159 48 Female + - m T2 f N 
163 47 Male + - w T3 c N 
168 69 Male + - m T2 f N 
174 62 Male + - m T2 c N 
188 50 Male + - w T2 f N 
aND = not determined 
bw = well differentiated, m = moderately differentiated, ND = not determined 
cf = fibrosis; c = cirrhosis, n = no cirrhosis or fibrosis  








Table 3.2 Fisher’s exact test for association between clinico-pathologic parameters 
Parameter Percentage p  Parameter Percentage p 
Well differentiation 
     T1/T2 stage 
     T3/T4 stage 
Moderate differentiation 
     T1/T2 stage 








 T1/T2 stage 
     With cirrhosis 
     Without cirrhosis 
T3/T4 stage 
     With cirrhosis 








       
Well differentiation 
     With cirrhosis 
     Without cirrhosis 
Moderate differentiation 
     With cirrhosis 








 T1/T2 stage 
     HBeAg (+) 
     HBeAg (-) 
T3/T4 stage 
     HBeAg (+) 








       
Well differentiation 
     HBeAg (+) 
     HBeAg (-) 
Moderate differentiation 
     HBeAg (+) 








 With cirrhosis 
     HBeAg (+) 
     HBeAg (-) 
Without cirrhosis 
     HBeAg (+) 















3.1.2 Copy number aberration is widespread in HCC tumors 
 In order to study the DNA copy number aberrations (CNAs) in the 15 HCC 
tumors in Cohort 1a, array CGH using the commercial Agilent array that possesses 
42,463 probes and an average spatial resolution of 35 kb was performed. For each 
array probe, the intensity ratio of tumor over reference sample was logarithm-2 (log2) 
transformed and normalized to log2 transformed ratio of non-tumor over reference 
sample, giving rise to a log2 (T/NT) ratio (or log2 fold change) that is proportional to 
the copy number change. Copy number gain was defined as log2 (T/NT) ratio > 0.25, 
and copy number loss was defined as log2 (T/NT) ratio < -0.25. 
Analysis of the 15 clinical HCCs showed that CNA is a common event in 
HCC. As seen in Figure 3.1, copy number aberration was detected in all of the tumors. 
Generally, CNAs were more frequent in tumors from cirrhotic HCCs. Most of the 
fibrotic HCCs have fewer CNAs (e.g. tumor no. 98) or copy number changes of 
smaller magnitude (e.g. tumor no. 77, 98, 81) compared to cirrhotic HCCs, suggesting 
liver cirrhosis to be an important contributor to genomic instability. This was 
particularly evident from the array CGH profile of tumor no. 111 which was derived 
from a liver without fibrosis or cirrhosis. Its array CGH profile was marked by low-
level CNAs compared to the other tumors. Evidence that HCC is a cancer of genetic 
instability is also supported by the observation that every chromosome presented 
CNA in at least one tumor. Of note, chromosome 8q was marked by high level copy 
number amplification in more than a third of the tumors. Besides implying that gain 
of 8q arm is essential for HCC development, this also suggests the presence of 







Figure 3.1 Array CGH profiles of 15 HCCs. The log2 (T/NT) intensity ratios of probes that 
fulfill the threshold cut-off of > 0.25 or < -0.25 were plotted on the vertical-axis as a function 
of the genomic location (horizaontal-axis) for each tumor sample. Tumor numbers are 
indicated on the left. The pooled sample (P) shows the average of all the tumor array CGH 
profiles. Range of vertical-axis is the same for all the tumors. Copy number gains are 







3.1.3 Recurrent chromosomal aberrations in HCC 
 Plotting the frequencies of copy number gain or loss of the array CGH probes, 
it can be observed that recurrent high frequency copy number gains on chromosomes 
1q and 8q and losses on 4q, 8p, 13q, 16q and 17p were present in close to 50% of the 
tumors (Figure 3.2). In particular, the entire chromosome 8 reported copy number 
aberration in at least 50% of the tumors.  
To gain further insights into which specific chromosomal regions were altered 
in the HCCs, the log2 (T/NT) ratios were subjected to a Gain and Loss Analysis of 
DNA (GLAD) algorithm208, which was written to identify chromosomal regions with 
identical copy number that are delimited by breakpoints (see Section 2.2.4). Applying 
the same threshold criteria of log2 (T/NT) ratio > 0.25 or < -0.25 to define 
chromosomal regions of aberrations, a total of 1016 chromosomal regions were 
identified to be altered in copy number. Regions of gain were found to be as frequent 
as regions of loss (ratio of 1.25:1), and the size of aberrant chromosomal regions 
ranged from 0.05 kb to 191.06 Mb (median = 0.94 Mb). In order to identify 
chromosomal regions with copy number change that were more significant and 
recurrent in HCC, the aberrant chromosomal regions were further limited to a 
physical size of at least 0.1 Mb. The overlapping regions of gain or loss amongst the 
tumors were then determined. Those overlapping regions of copy number change that 
were detected in at least one-third of the HCC tumors were determined to be recurrent 
regions of copy number aberration (rRCNA). In total, 62 rRCNAs were identified, of 
which 33 were regions with copy number gain and 29 were regions with copy number 
loss (Table 3.3 and Table 3.4). 
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As observed, the recurrent chromosomal regions of copy number change were 
mapped with high resolution. The chromosomal regions most frequently altered on 1q, 
8q, 4q, 8p, 13q, 16q and 17p were further delineated to regions as small as 0.58 Mb at 
1q32.1, 8q13.3-24.3, 4q32.3-34.3, 8p23.1-21.3, 13q14.11-14.3, 16q23 and 17p12-11. 
In addition, chromosomal regions of relatively high frequency gain (> 33% of tumors) 
were detected on 4p, 5p, 6q, 7p, 13q, 20q, 22q and Xpq, and of relatively high 
frequency loss were detected on 1p.  The ability to detect small aberrant regions of 
copy number change on a multitude of chromosomes indicated the sensitivity of array 






Figure 3.2 Frequency plot of copy number aberrations in tumors. The frequencies of gain 
or loss (log2 (T/NT) ratio > abs (0.25)) of all array CGH probes in the 15 HCC tumors were 
plotted as a function of genome location. Red represents copy number gain. Green represents 










       Position 
       Start 
       Position 
       End 
 Size 
 (Mb) 




          
1q32.1 60 199127276 199654694  0.58  9  - 
1q31.3 53 196010415 196153231  0.14  2  - 
1q42.13 53 225992956 226738916  0.75  13  WNT9A, WNT3A 
4p16.1 40 9469000 9640739  0.17  1  - 
5p15.33 46 1341461 2209449  0.88  7  TERT 
6p21.33-21.32 33 30701882 32297208  1.60  69  MDC1, FLOT1, EHMT2, RNF5 
6p21.1 33 43906127 44080040  0.17  1  - 
6q27 40 169970599 170433574  0.46  1  DLL1 
7p22.3 33 1578771 1874471  0.30  1  - 
7q21.3-22.1 40 97680682 98089506  0.41  4  - 
7q11.23 33 72630204 75982676  3.35  33  HIP1, HSPB1, LIMK1, CLDN3 
7q22.1 33 101718525 101895994  0.18  5  - 
8q13.3 60 70906567 71052779  0.15  1  - 





 HEY1, MTDH MYC, 
DDEF1, LAPTM4B, 
TPD52, CCNE2 
8q24.3 60 143565459 145011977  1.45  36  SCRIB 
8q24.3 60 145062148 146250824  1.19  26  - 
10p15.1 33 5530640 5721962  0.19  2  - 
10q26.3 33 134222814 135254513  1.03  17  - 
11pter-p15.4 33 186966 3159228  2.97  59  HRAS, IFITM1 
13q34 40 113648342 114029609  0.38  3  CDC16 
16p13.3 33 36766 843744  0.81  34  - 
19p13.11 33 18562903 19631574  1.07  28  - 
19q13.31-13.32 33 49842066 53357976  3.52  78  PPP1R13L, BCL3, PVR, DACT3 
19q13.32-13.33 33 53482172 54395053  0.91  41  RUVBL2, RASIP1 
19q13.33 33 54532798 56646583  2.11  76  RRAS, BCL2L12 
19q13.41-13.42 33 58843240 60896874  2.01  64  - 
20p13 33 3588125 3712558  0.12  7  - 
20q13.33 47 59833452 62175139  2.34  49  - 
20q13.33 47 62202017 62363633  0.16  3  - 
22q13.33 40 48667653 49525130  0.86  24  - 
Xp11.3-11.23 40 47193714 48955966  1.76  38  ARAF, ERAS 
Xq28 40 151788382 154494649  2.71  54  - 
Xq27.1-27.2 33 140097589 140225924  0.13  1  - 










      Position 
     Start 
      Position 
     End 
 Size 
(Mb) 
  No. of array 
genes  
 Candidate  
genes 
         
1p36.32 40 2403259 3380098  0.98 7  - 
1p32.3-31.1 40 55482307 72765618  17.28 59  DAB1, GADD45A 
1p36.31 33 6616978 7100000  0.48 3  CAMTA1 
1p36.31 33 5300000 6081206  0.78 2  - 
2q32.1 33 187410263 187984425  0.57 2  - 
2q34-35 33 214983391 216631997  1.65 8  BARD1 
4q32.3-34.3 67 167707191 181540728  13.83 31  - 
5q14.1-14.3 33 79651720 91362901 
 
11.71 26 
 SSBP2, ARRDC3, 
MSH3, XRCC4, 
RASA1 
8p23.1-21.3 80 11647775 21919661 
 
10.27 36 










11q13.1 33 65597430 65740602  0.14 1  PACS1 
11q13.4 33 72310581 72527135  0.22 1  - 
11q22.3-23.1 33 104514969 111117441  6.60 26   ATM, BTG4 
13q14.11-14.3 53 42514476 49757035  7.24 41  RB1, RCBTB1, TRIM13 
13q31.1 40 84368368 84568813  0.20 0  - 
14q22.1-23.3 33 50250377 64079538  13.83 79  FRMD6, CDKN3, SOCS4, DACT1 
16p11.2 40 28242579 31346030  3.10 53  PYCARD 
16p13.3 33 36766 5001668  4.97 141  TSC2 
16q23.1-23.3 60 76204555 81449606  5.25 20  WWOX, CDH13 
16q12.1-21 53 50773858 63676674  12.90 69  RBL2 
16q24.3 53 88284852 88651780  0.37 14  - 
17p12-11.2 47 15883378 16015861  0.13 1  - 
17p13.3-13.1 40 48539 8133829 
 
8.09 173 




17p13.1-12 40 8156763 15883378  7.73 45  TRIM16 
19p13.3 33 232080 1903649  1.67 57  APC2, KISS1, KLF16 
19p13.3-13.2 33 6057170 11522106  5.47 120  KEAP1, CDKN2D 
19p13.13-13.12 33 12601113 14535918  1.93 51  GIPC1 
21p11.1 33 10013263 10117957  0.11 1  - 
21q11.2-22.11 33 13339394 31014267  17.68 39  BTG3 




3.2 Meta-analysis of CGH studies revealed recurrent and etiology-associated 
copy number aberrations    
 
3.2.1 Preliminary literature review 
 Since all of the HCCs analyzed by array CGH were HBV-positive, a pertinent 
question to ask is whether the copy number aberrations identified were specifically 
associated with the HBV etiology or characteristic of all HCCs. On a broader scale, 
since CGH studies in HCC were mostly performed on tumor samples involving 
multiple etiologies, information on specific etiology-associated chromosomal 
aberrations is also relatively lacking. Hence, in order to examine for similarities and 
differences in the chromosomal alterations in HCCs with different underlying etiology 
(HBV, HCV and non-viral), a meta-analysis of the array CGH data from this study 
and the data from 23 other published CGH studies was performed. Relevant 
information on the clinical parameters of the HCCs in these studies and the CGH 
study design are listed in Table 3.5. All studies selected were performed on primary 
HCCs and had used a similar threshold for detecting copy number change. Array 
CGH studies whose data was subjected to segmentation copy number analysis using 
breakpoint calling algorithms were included in the analysis.  
In a preliminary review of the published CGH data, the CGH studies were 
classified based on HCC etiology into four categories – studies performed on 
HBV+/HCV-tumors (HBV group), on HBV-/HCV+ tumors (HCV group), on non-viral 
tumors without HBV or HCV infection (NBNC group) and on tumors of mixed 
etiologies (Mixed group).  Besides, there were several CGH studies using HCCs of  
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       Staging (n) 
 
   Histology (n)ζ 
 
Etiology 




       
This study Y T1(1), T2(7), T3(7) W(9), M(5) HBV 15 aCGH 
[203] 203 N - - HBV 158 cCGH 
[159] 159 N T2/T3 (50) - HBV 43 cCGH 
[163] 163 N - W-M(6), M(2), P(2) HBV 10 cCGH 
[164] 164 N - - HBV 14 cCGH 
[209] 209 N - - HBV 26 cCGH 
[190] 190 Y T1(5), T2(14), T3(9), T4(2) W(1), M(22), P(14), U(4) HBV 14 cCGH 
[165] 165 N - W(5), M(6), P(13) HBV 6 cCGH 
[172] 172 N - - HBV 7 cCGH 
[210] 210 Yδ T1(3), T2(27), T3(4), T4(2) - HBV 32 cCGH 
[211] 211 N T1(8), T2(13), T3(17), T4 11) - HBV 6 cCGH 
[184] 184 N T1(3), T2(11), T3(14), T4(7) W(2), M(21), P(9), U(3) HCV 32 cCGH 
[190] 190 Y refer above refer above HCV 24 cCGH 
[209] 209 N refer above refer above HCV 13 cCGH 
[212] 212 N - W(4), M(12) HCV 6 cCGH 
[210] 210 Yδ refer above refer above HCV 3 cCGH 
[213] 213 N T1(7), T2(7), T3(2), T4(3) W(5), M(9), P(5) HCV 19 cCGH 
[211] 211 N refer above refer above HCV 9 cCGH 
[164] 164 N refer above refer above NBNC 9 cCGH 
[172] 172 N refer above refer above NBNC 11 cCGH 
[165] 165 N refer above refer above NBNC 9 cCGH 
[214] 214 N - W(9), M(14), P(11) NBNC 32 cCGH 
[166] 166  N T2(2), T3(4) W (6) NBNC 6 cCGH 
[212] 212 N refer above refer above NBNC 9 cCGH 
[210] 210 Yδ refer above refer above NBNC 1 cCGH 
[211] 211 N refer above refer above NBNC 32 cCGH 
[215] 215 Y - - Mixed 32 cCGH 
[185] 185 N T1(13), T2(13), T3(7), T4(8) W(15), M(14), P(12) Mixed 41 cCGH 
[160] 160 N T1(6), T2(11), T3(5), T4(2) W(16), M(8), P(2) Mixed 26 cCGH 
[170] 170 N T3 or T4 M(18), P(13) Mixed 31 cCGH 
[173] 173 N - W(1), M(17), P(2) Mixed 20 cCGH 
[174] 174 N - - Mixed 32 cCGH 
[181] 181 N T2(12), T3(10), T4(2) W(4), M(10), P(9) Mixed 24 aCGH 
[216] 216 N T1(14), T2(18), T3(8), T4(2) W(6), M(29), P(7) Mixed 41 aCGH 
ζ w = well differentiated, m = moderately differentiated, P = poorly differentiated, U = undifferentiated,  ND = not 
determined 




mixed etiologies in which CGH data and the associated etiology for each tumor was 
available. These studies were divided into sub-studies containing CGH-analyzed 
tumors of a single etiology, so as to increase the number of studies and total number 
of samples with a single underlying etiology. The frequency distributions of 
chromosomal aberrations for all the studies were summarized in Figures 3.3-3.6. 
Generally, HBV-HCCs had the greatest number of chromosomes altered, and 
NBNC-HCCs the least. Notably, recurrent copy number gain on 1q, 6p, 8q and 17q, 
and recurrent copy number loss on 4q, 8p, 13q, and 17p were found in HCC 
regardless of the underlying etiology. At least half of the CGH studies available for 
each etiology (HBV, HCV or NBNC) detected copy number aberrations on these 
chromosomes in ≥ 20% of the tumors. All of these aberrations were also frequently 
found in CGH studies performed using HCCs of mixed etiologies. Hence they 
appeared to represent the set of chromosomes most frequently altered in HCC.  
There was also gain or loss of some chromosomes that were more prevalent in 
HCC of particular etiology or etiologies. Loss on 16q was reported to occur in ≥ 20% 
of the tumors in only two studies on non-viral NBNC-HCCs, in contrast to the large 
number of studies reporting 16q loss in HBV-HCC or HCV-HCC. Similarly, copy 
number gain on 20q was much less frequently reported by studies using NBNC-HCCs. 
Besides common chromosomal copy number aberrations reported by studies on viral 
HCCs, HBV-HCCs studies frequently detected copy number loss on 14q in ≥ 20% of 
the tumors, which was rarely reported by other studies. Similarly, studies on HCV-
HCCs and NBNC-HCCs each frequently reported gains on 11q and 7pq respectively 







Figure 3.3 Aligned dot plots of chromosomal aberrations in HBV-HCCs. The frequencies 
of gain or loss of chromosomes in each CGH study were computed as a percentage of the 
number of informative tumors. Red line indicates average frequency. Only chromosomes 
reporting gain or loss in ≥ 20% of tumors in at least one study were represented. Highly 
recurrent aberrations reported in at least half of the studies were highlighted in yellows boxes. 
Citations of study used are listed in the legend. The studies were performed on patients of 
various ethnicities: Chinese (filled symbols); Korean and Japanese (open symbols); Caucasian 
(grey symbols).  
 
 







































































                            
Figure 3.4 Aligned dot plots of chromosomal aberrations in HCV-HCCs. The frequencies 
of gain or loss of chromosomes in each CGH study were computed as a percentage of the 
number of informative tumors. Red line indicates average frequency. Only chromosomes 
reporting gain or loss in ≥ 20% of tumors in at least one study were represented. Highly 
recurrent aberrations reported in at least half of the studies were highlighted in yellows boxes. 
Citations of study used are listed in the legend. Study [210] was excluded due to small 
numbers of HCV-HCC tumors. The studies were performed on patients of various ethnicities: 
Korean and Japanese (open symbols); Caucasian (grey symbols).  
  




































































                      
Figure 3.5 Aligned dot plots of chromosomal aberrations in NBNC-HCCs. The 
frequencies of gain or loss of chromosomes in each CGH study were computed as a 
percentage of the number of informative tumors. Red line indicates average frequency. Only 
chromosomes reporting gain or loss in ≥ 20% of tumors in at least one study were represented. 
Highly recurrent aberrations reported in at least half of the studies were highlighted in 
yellows boxes. Citations of study used are listed in the legend. Study [210] was excluded due 
to small numbers of NBNC-HCC tumors. The studies were performed on patients of various 









































































                  
Figure 3.6 Aligned dot plots of chromosomal aberrations in HCCs of mixed etiologies. 
The frequencies of gain or loss of chromosomes in each CGH study were computed as a 
percentage of the number of informative tumors. Red line indicates average frequency. Only 
chromosomes reporting gain or loss in ≥ 20% of tumors in at least one study were represented. 
Highly recurrent aberrations reported in at least half of the studies were highlighted in 
yellows boxes. Citations of study used are listed in the legend. The studies were performed on 
patients of various ethnicities: Chinese (filled symbols); Korean and Japanese (open symbols); 
Caucasian (grey symbols).  
 
 



































































3.2.2 Etiology-independent and etiology-associated chromosomal aberrations  
 Statistical testing for association of specific etiologies with particular 
chromosome aberrations was next performed. For each etiology, the frequency of gain 
or loss of each chromosome in all the studies performed was summed and Fisher’s 
exact test was carried out to compare the frequencies of chromosomal aberrations 
between etiologies. The results are summarized in Table 3.6 and are observed to 
largely support the general observations made in the preliminary review of data. 
Association study showed that all of the chromosomes (1q, 8q, 6p, 17q) earlier 
identified to be very frequently reported as gained across etiologies in the preliminary 
literature review were indeed not associated with any particular etiology. Losses on 
6q, 8p and 13q were also common to all HCCs, having been detected in ≥ 25% of the 
tumors independent of underlying etiology. Losses on 4q and 17p however, were 
associated with a higher frequency in both HBV-HCCs and HCV-HCCs i.e. viral-
HCCs. 
With respect to etiology-specific chromosomal aberrations, it was shown that 
loss of 16q and gain of 20q were detected at significantly higher frequencies in HBV-
HCCs. Indeed, though at least half of the studies on HCV-HCC reported these 
chromosomal aberrations in more than 20% of tumors, the frequencies were generally 
lower than that in HBV-HCC as observed in Figures 3.3 and 3.4. Hence, loss of 16q 






Table 3.6 Statistical testing for etiology-associated chromosomal aberrations 
 
   
 Freq. in tumors (%)ǂ  Fisher’s exact test 2-tailed p-valueζ   
Aberration*φ  HBV HCV NBNC  HBV vs. HCV HBV vs. NBNC HCV vs. NBNC Etiology Associated 
          
-1p  27 28 12  0.8905 0.0026 0.0035 Viral 
+1q  69 55 61  0.0101 0.1294 0.4099 None 
-4p  21 17 4  0.4390 <0.0001 0.0014 Viral 
-4q  47 44 24  0.6552 <0.0001 0.0016 Viral 
+5p  21 7 11  0.0004 0.0226 0.3378 HBV 
-5p  5 16 3  0.0048 0.3803 0.0008 HCV 
+5q  20 8 16  0.0071 0.3965 0.1432 - 
-5q  12 17 5  0.2877 0.0354 0.0038 Viral 
+6p  30 22 27  0.1073 0.5451 0.4291 None 
-6q  24 32 24  0.1290 1.0000 0.2238 None 
+7p  23 11 25  0.0083 0.6972 0.0129 HBV + non-viral 
+7q  27 12 24  0.0015 0.6154 0.0336 HBV + non-viral 
-8p  44 39 45  0.3687 0.9115 0.4345 None  
+8q  56 42 49  0.0101 0.1842 0.3379 None 
-9p  22 20 8  0.6850 0.0010 0.0178 Viral 
+11q  13 19 8  0.2337 0.2480 0.0279 - 
-11q  19 14 9  0.2491 0.0123 0.2918 - 
+12q  17 7 6  0.0100 0.0068 1.0000 HBV 
+13q  14 5 6  0.0153 0.0534 0.7681 HBV 
-13q  39 31 28  0.1660 0.0382 0.6533 None  
-14q  20 8 19  0.0027 1.0000 0.0158 HBV + non-viral 
-16p  21 12 7  0.0759 0.0023 0.2564 HBV 
-16q  38 27 17  0.0474 <0.0001 0.1013 HBV 
-17p  37 35 20  0.7287 0.0010 0.0215 Viral 
+17q  28 35 27  0.2237 0.8058 0.2367 None  
+19q  18 15 5  0.6560 0.0004 0.0111 viral 
+20p  21 11 11  0.0309 0.0225 1.0000 HBV 
+20q  28 17 12  0.0215 0.0005 0.3346 HBV 
* Chromosomes altered at high frequency in tumors of all etiologies are highlighted in bold.  
  (+) indicate gain. (-) indicate loss. 
φ Only chromosomes reporting copy number change in ≥ 15% of tumors at least one etiology are shown. ǂ Calculated as percentage of informative tumors. 




In the preliminary literature review, gain of 11q and 7pq had appeared to be 
more prevalent in HCV-HCCs and NBNC-HCCs respectively. However, in the 
association study, no such association was detected. Gain of 11q had been found with 
similar frequencies in HBV-HCCs and HCV-HCCs, and similarly so for gain of 7pq 
in HBV-HCCs and NBNC-HCCs. This indicated that though gain of 11q or 7pq were 
more likely reported by individual studies on HCV-HCC or NBNC-HCC, they are not 
associated with a single etiology as suggested by the preliminary literature review. 
However, unlike gain of 7pq which could be proven to be positively associated with 
HBV-HCC and NBNC-HCC, a strong association of 11q gain with HBV-HCC and 
HCV-HCC was not found. This was also the case for loss of 11q and gain of 5q. On 
the same note, loss on 14q in non-viral NBNC-HCCs, though rarely reported to occur 
in > 20% of tumors in individual studies (Figure 3.5), was detected in nearly 20% of 
the pooled tumors from all studies. HBV-HCC and NBNC-HCC were thus both 
significantly associated with higher frequency of loss on 14q compared to HCV-HCC.  
The examples of 7pq, 11q and 14q highlighted the need for a large sample size 
to detect certain chromosomal anomalies that appear to have a more sporadic 
occurrence in HCC.  The significantly higher frequency of +11q and +7pq in HBV-
HCC compared to HCV-HCC would have been overlooked without the power of a 
larger sample size provided by meta-analysis. However, this problem may be partially 
overcome with the use of more sensitive techniques for the cytogenetic analysis as 
evidenced by the detection of 7pq gain and 14q loss in the small sample size of 15 
tumors in this study with the use of array CGH. Moreover, this sensitivity had not 
come at the cost of specificity, as shown by the concurrence of findings from array 
CGH of the 15 HBV-infected tumors in the present study with the data on 
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chromosome copy number changes collated for the HBV-infected tumors in the meta-
analysis. Meta-analysis of the 331 CGH-analyzed HBV-infected HCCs had shown 
major high frequency (> 30% of tumors) gains on 1q and 8q, and losses on 4q, 13q, 
16q and 17p, as well as minor lower frequency (15-30% of tumors) gains on 5pq, 6p, 
7pq, 12q, 19q and 20pq, and losses on 1p, 4p, 6q, 9p, 11q, 14q and 16p. These 






 Array CGH of the 15 paired tumorous and non-tumorous tissues in this study 
demonstrated copy number gain on 1q and 8q, and copy number loss on 4q, 8p, 13q, 
16q and 17p to be recurrent chromosomal aberrations of HBV-infected HCC. The 
high resolution of the technique further allowed delimitation of the most frequent 
aberrant regions on these chromosomes to 1q32.1, 8q13.3-24.3, 4q32.3-34.3, 8p23.1-
21.3, 13q14.11-14.3, 16q23 and 17p12-11.2, with the smallest region < 1 Mb in size. 
In addition, the high sensitivity of array CGH allowed lower frequency gains on 4p, 
5p, 6pq, 7pq, 10pq, 11p, 13q, 16p, 19pq, 20pq, 22q and Xpq, and losses on 1p, 2q, 5q, 
9p, 11q, 14q, 16p, 19p and 21pq that occurred in at least a third of the HCCs to be 
detected. Subsequent meta-analysis further demonstrated that of these aberrations, 
gain of 1q, 6p, 8q and 17q and loss of 6q, 8p and 13q were commonly altered in all 
types of HCC, while +5p, -16pq and +20pq were associated with only HBV-HCC. In 
addition, the array CGH of the 15 tumors identified all of the chromosomal number 
changes detected in at least 15% of CGH-analyzed HBV-infected tumors included in 
the meta-analysis and detected them with higher frequencies in the 15 tumors. Novel 
aberrations, namely gain of 10pq, 11p and 22q and loss of 2q and 21pq, which were 
rarely reported in the meta-analysis were also detected by the array CGH. Overall, the 
data from DNA copy analysis and the meta-analysis highlighted the high sensitivity, 





Chapter 4:  
Integrative analysis of DNA copy 
number and expression profile 
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4.1 Microarray expression profiling of HCC tumors and enrichment analysis 
 Besides characterizing genetic alterations, surveying the tumor transcriptome 
is also vital in understanding HCC development. This is because transcriptional 
profiles can be changed by many mechanisms other than copy number alterations and 
mutations, such as epigenetic silencing, post-transcriptional modifications and mRNA 
decay to name a few. Moreover, genetic alterations may not directly correlate with 
transcriptome modification due to haplosufficiency of some genes and excess copies 
of amplified genes may not necessarily be transcribed. To explore the transcriptomic 
landscape of HCC, an additional 22 patients were recruited to this study. Tumors and 
non-tumorous lesions from these patients, together with the 15 samples in Cohort 1a, 
formed a larger collection (Cohort 1) of paired tumors that were subjected to 
expression profiling by the Affymetrix Human Genome U133A 2.0 Array.  
 Probe sets whose intensities were increased by at least 1.5 fold (i.e. log2 fold 
change of 0.6) in tumors compared to non-tumors were considered to overexpressed 
and vice versa. Of the 22,283 probe sets spotted on the U133A array, 18.4 % of the 
probe sets exhibited over-expression and 12.2% were under-expressed in at least 20% 
of the tumors. To study which cellular processes were frequently altered in HCC, a 
smaller subset of highly frequent aberrantly expressed genes that were over-expressed 
or under-expressed in at least 40% of the HCC tumors were subjected to ontological 
analysis. A total of 1502 over-expressed probe sets mapping to 1157 unique gene ids 
and 1407 under-expressed probe sets mapping to 1047 unique gene ids were analyzed 
with the GeneGo MetaCore platform. Cellular processes were assigned using the 
GeneGo Process Networks ontology which is manually curated and created based on 
proven evidence in the literature. Each GeneGo Process Network represents a 
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comprehensive biological process with a specific functional theme that is defined by 
genes reportedly involved in protein-protein, protein-DNA and protein-compound or 
protein-metabolite interactions contributing to the biological process. Figure 4.1 show 
the ten most enriched GeneGo processes that were down-regulated or up-regulated in 






     
Figure 4.1 Histograms of the most enriched GeneGo processes de-regulated in 
expression microarray. Bars represent the negative logarithm of p-values derived from 
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The five most enriched up-regulated processes in the dataset were all related to 
cell cycle events, in particular the synthesis (S) phase and mitotic (M) phase. This was 
in agreement with uncontrolled proliferation capacity that is a hallmark of cancer. 
Notably, the M phase cyclin B1 (CCNB1) was overexpressed by more than two-fold 
(i.e. amplified) in 67% of the tumors, with an average 2.8-fold increase in expression 
(Figure 4.2, left). This expression was much higher than the S phase cyclin, CCNA2, 
that was amplified in about 30% of tumors and with an average 1.7-fold increase in 
expression, implying that a large proportion of tumors cells were in the dividing phase 
in HCC.  Concordant with the commitment to mitosis was the enrichment of genes 
involved in spindle microtubules assembly. Importantly, many of the over-expressed 
genes function in the spindle-assembly checkpoint at anaphase of mitosis that ensures 
proper attachment of sister chromatids to spindle microtubules prior to onset of 
anaphase (Figure 4.2, right). The over-expression of M phase cyclin B1and spindle-
assembly checkpoint genes that also function in the M phase suggest that de-regulated 
control of mitosis is a prominent feature of HCC and might contribute to HCC 
development. 
 The ontology analysis showed that the main processes down-regulated at the 
expression level were related to immune response and blood coagulation. A large 
subset of under-expressed genes encode for chemokines that were represented in the 
‘Platelet-leukocyte-endothelium interactions’, ‘Chemotaxis’ and ‘Cell-adhesion-
Leuckocyte’ GeneGo processes (Figure 4.3). In particular, expression of CXCL2, 
CXCL12, CXCL14, CCL2 and CCL19 were down-regulated by at least two-fold on 
average. Since chemokines are powerful attractants of different types of leukocytes to 
sites of infection or inflammation, the data from the expression microarray thus 
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strongly suggest immune evasion by HCC cells through down-regulation of 
chemokines to prevent intratumoral infiltration of immune cells. The observed under-
expression of cell adhesion molecules (e.g. VCAM1, ICAM3, E-selectin) that are 




Figure 4.2 Microarray expression of cell cycle-related genes. The expression fold change 
(T/NT) of selected cyclin genes and spindle-assembly checkpoint genes in 37 HCC tumors, 
examined by Affymetrix U133A microarray, are plotted in Tukey box-and-whisker plots. For 
gene(s) with more than one U133A probe, average fold change is plotted. Horizontal crossbar 
at the end of each whisker corresponds to the farthest non-outlier data point within 1.5 times 
of the interquartile range. Outliers are represented by filled circles (●), and the mean is 
indicated by (+). The threshold (T) defining differential expression (i.e. T/NT = ±1.5-fold) is 
indicated by dotted red and blue lines. CCNB1: cyclin B1; CCNA2: cyclin A2; BUB1B: 
MAD3/BUB1-related protein kinase; BUB1: budding uninhibited by benzimidazoles 1 
homolog; BUB3: budding uninhibited by benzimidazoles 1 homolog; MAD2L1: mitotic arrest 
deficient 2-like protein 1; AURKA: aurora kinase A; PTTG1: securin; NEK2: never in mitosis 
A-related kinase 2; RAN: ras-related nuclear protein; TPX2: targeting protein for Xklp2; 

















































































    
Figure 4.3 Microarray expression of chemokine and cell adhesion genes. The expression 
fold changes (T/NT) of selected genes in 37 HCC tumors, examined by Affymetrix U133A 
microarray, are plotted in Tukey box-and-whisker plots. For gene(s) with more than one 
U133A probe, average fold change is plotted. Genes shown include CXC chemokines 
(CXCL2, CXCL10, CXCL12, CXCL13 and CXCL14), CC chemokines (CCL2, CCL3, CCL5, 
CCL15, CCL19, CCL20, CCL21), vascular cell adhesion molecule 1 (VCAM1), intercellular 






























































































 Genes functioning in the kallikrein-kinin system form another major subset of 
genes down-regulated in HCC. Two important peptides in this system are the high-
molecular-weight or low-molecular-weight kininogen (KNG1) and tissue or plasma 
kallikrein. Kallikrein are serine proteases that cleave the kininogens into active 
bradykinin or kallidin that act to increase vascular permeability, cause vasodilation 
and stimulate leukocytes to release cytokines. Both forms of kininogen are 
synthesized in the liver and the KNG1 gene encoding for them was shown in this 
study to be under-expressed in HCC. Besides, although the expression of kallikrein 
was not affected, HCC tumors demonstrated reduced expression of the blood 
coagulation Factor XII that is essential for cleaving prekallikrein into active plasma 
kallikrein. Plasma kallikrein is also known to activate Factor XII in a positive 
feedback loop. There is thus an intimate link between the kallikrein-kinin system and 
blood pressure control, inflammation and blood coagulation. In this study, under-
expression of kininogen and Factor XII appeared to imply down-regulation of this 
system, and possibly lead to increase in blood pressure and reduced release of 
cytokines by leuckocytes. On the other hand, there was down-regulation of liver-
synthesized carboxypeptidase N and carboxypeptidase B2 that convert bradykinin 
into des-Arg9-bradykinin, an agonist with higher affinity for the inflammation-
induced bradykinin receptor B1. Together, the data suggested a tug-of war on the 
level of bradykinin with the resultant impact on its most direct function i.e. blood 
pressure control unclear. A recent prospective cohort study identified positive 
correlation between mid-blood pressure and liver cancer incidence in females but not 
males. This not only hinted at a relationship between the kallikrein-kinin system and 
HCC, but also suggested other factors might play a role in determining the  
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Figure 4.4 Microarray expression of kallikrein-kinin system and blood coagulation 
genes. The expression fold change (T/NT) of selected genes in 37 HCC tumors, examined by 
Affymetrix U133A microarray, are plotted in Tukey box-and-whisker plots For genes with 
more than one U133A probe, average fold change is plotted. KNG1: kininogen 1; CPN1: 
carboxypeptidase N catalytic subunit; CPN2: carboxypeptidase N regulatory subunit; PTGS2: 
cyclooxygenase 2; F8, F9, F11, F12: coagulation factors VIII-IX, XI-XII. 
 
relationship between blood pressure and cancer217. Inflammation is however most 
likely down-regulated and this was supported by observed down-regulated expression 
of the inflammatory mediator, cyclooxygenase 2. Blood coagulation is also likely 
down-regulated in HCC since besides factor XII, coagulation factors VIII, IX and XI 
were also under-expressed.  
It should be noted that despite the observed down-regulation of inflammatory 
response and blood coagulation, it remains unclear whether these events contribute to 
HCC development or arose due to compromised functionality of a diseased liver. This 







































produced by the liver as its normal homoeostatic function. There is also the scenario 
where loss of function of the diseased liver further contributes to tumor progression. 
Nevertheless, it can be argued that regardless of whether it is the cause or the effect, 
reduced expression of genes such as chemokines will undoubtedly be advantageous 




4.2 Integrative analysis identified a subset of genes frequently aberrant in copy 
number and expression  
 Genes whose expression are altered as a result of copy number change, 
especially copy number loss, are expected to play more important roles in HCC than 
genes whose expression are passively altered as a consequence of upstream events. 
This is particularly so in view that gain or loss of copy number (or gene alleles) 
cannot be corrected by the cell. Some of these genes may be candidates for oncogenes 
or tumor suppressors. In order to identify these important genes in HCC, whose 
expression profile could be attributed to changes at the genetic level, an integrative 
analysis of data from array CGH and transcriptome profiling was performed. In the 
integrative analysis, the common set of genes that reported both copy number gain 
that is > 1.5 fold in at least 30% of tumors and increased expression that is > 1.5 fold 
in at least 40% of tumors was found, and similarly so for genes that had were 
decreased in copy number and expression. The results (Figure 4.5) showed that a set 
of 268 genes were differentially expressed with frequent copy number aberrations. 
There are henceforth referred to as differentially expressed genes (DEGs). Of the 
differentially expressed genes, 167 DEGs were up-regulated and 101 DEGs were 
down-regulated. A detailed list of the identified DEGs can be found in Appendix 2 











Figure 4.5 Integrative analysis of DNA copy number and expression. Matching the list of 
genes highly altered in copy number in ≥ 30% of tumors with the list of genes reporting 
aberrant expression in ≥ 40% of tumors identified 167 differentially expressed genes (DEGs) 
that were up-regulated and 101 DEGs that were down-regulated in both copy number and 





 To examine the cellular processes in which the DEGs play a role, gene 
ontology enrichment analysis was carried out. As seen from Figure 4.6 and Figure 4.7, 
there were a few cellular processes that were commonly enriched for in both sets of 
DEGs. These included genes involved in apoptosis and DNA repair (e.g. DNA 
damage-binding protein 2 (DDB2), poly (ADP-ribose) polymerase 1 (PARP1)), cell 
motility and trafficking (e.g. ephrin type-A receptor 2 (EPHA2), matrix 
metallopeptidase 9 (MMP9)), and transport (e.g. SEC24-related protein B (SEC24B), 
coatomer subunit epsilon (COPE)). On the other hand, there were also differences in 

























Figure 4.6 Ontology classifications of up-regulated differentially expressed genes 
(DEGs). The 167 genes were classified into different ontologies based on GO_BP ontology 
and Swiss-Prot gene function. Pie chart displaying (A) proportion of genes assigned to each 
ontology and (B) detailed representation of different gene functions grouped under the 
ontology ‘Gene expression’ was plotted. Differential transcription regulation described 
regulation by factors binding to regulatory elements e.g. enhancers and promoters. (C) List of 
genes acting in differential transcription regulation. LRH-1: liver receptor homolog 1; NCOA2: 
nuclear receptor coactivator 2; ATAD2: ATPase family AAA domain-containing protein 2; 
CHTOP: chromatin target of PRMT1 protein; TRIM28: tripartite motif-containing protein 28; 
CEBPA: CCAAT/enhancer-binding protein alpha; RCOR3: REST corepressor 3; SOX13: 
SRY (sex determining region Y)-box 13; ARID4B: AT-rich interactive domain-containing 
protein 4B; CTBP1: C-terminal binding protein 1; SNAI2: snail homolog 2 (Drosophila); 
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NR5A2 (or LRH-1) Nuclear receptor
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Figure 4.7 Ontology classifications of down-regulated differentially expressed genes 
(DEGs). The 101 genes were classified into different ontologies based on GO_BP ontology 
and Swiss-Prot gene function. Pie chart displaying proportion of genes assigned to each 
ontology was plotted. Genes governing gene expression, of which most were related to 
nuclear receptors, were listed. DNMT3L: DNA (cytosine-5)-methyltransferase 3-like; NCOR1: 
nuclear receptor co-repressor 1; NR3C2: mineralocorticoid receptor; SMARCA2: SWI/SNF-
related matrix-associated actin-dependent regulator of chromatin subfamily A member 2; 
RORA: RAR-related orphan receptor A; NR0B2: nuclear receptor subfamily 0, group B, 
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 DEGs functioning in cell cycle and cell proliferation than down-regulated DEGs. 
Closer examination revealed that several of the cell cycle genes up-regulated were 
involved in the regulation of spindle-assembly checkpoint and cytokinesis. Examples 
of such genes included never in mitosis A-related kinase 2 or 7 (NEK2 and NEK7) 
that encode protein kinases regulating bipolar spindle formation in mitotic cells218,219, 
and jumping translocation breakpoint protein (JTB) which is required for normal 
cytokinesis220. Besides, there was down-regulation of cytoskeleton-associated protein 
2 (CKAP2) which was reported to cause mitotic arrest when overexpressed221. This 
resonated with the findings of the earlier ontological analysis of HCC transcriptome 
(see Section 4.2), indicating the spindle-assembly checkpoint to be disrupted at both 
transcriptional and DNA levels. Besides, copy number gain of cyclin E2, a G1/S 
phase cyclin, and loss of retinoblastoma-like protein 2 (RBL2), an important inhibitor 
of cell cycle entry supported increased cell proliferation as a key hallmark of cancer 
initiated by genetic events.   
 Of note, there was a higher proportion of up-regulated differentially expressed 
genes (DEGs) involved in gene expression than down-regulated DEGs. Hence, in 
order to support higher cell proliferation rates, HCC cells also increased 
transcriptional and translational capacity to drive tumor cell growth. Up-regulated 
DEGs in this ontology comprised mainly of genes functioning in translation (e.g. 
ribosomal protein L8 (RPL8)), transcription initiation and elongation (e.g. 
transcription elongation factor A protein 1 (TCEA1)), and differential transcription 
regulation (e.g. transcription factors such as liver receptor homolog 1 (LRH-1or 
NR5A2)) (Figure 4.6 (b)). Interestingly, down-regulated DEGs that function in gene 
expression were mostly transcription factors of the nuclear receptor family (NR3C2 
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and RORA) or their co-regulators (NCOR1, SMARCA2 and NR0B2) (Figure 4.7), 
except for DNMT3L that functions in epigenetic silencing. Orphan nuclear receptor 
SHP (NR0B2) is a known repressor of several nuclear receptors222,223. Nuclear receptor 
co-repressor 1 (NCOR1) and SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily A member 2 (SMARCA2) are reported co-
repressor224,225 and co-activator226 of nuclear receptor target genes respectively. 
Similarly, many of the transcription factors or co-regulators up-regulated were related 
to the nuclear receptor family227-231 (Figure 4.6 (c)).  
Nuclear receptors are known to play critical roles in various aspects of liver 
biology (e.g. lipid metabolism, drug metabolism, glucose homeostasis) and related 
pathobiology such as NAFLD, obesity and type 2 diabetes that are risk factors for 
HCC.  Genes functioning in metabolism were also frequently de-regulated in HCC as 
evidenced by their high proportion of representation amongst the DEGs. The data 
therefore supports the view that HCC is intimately linked with metabolic disease.  
Besides, a regulatory role for nuclear receptors in inflammation has been 
described232,233. It would be interesting to investigate whether the de-regulation of 
nuclear receptors at the genetic level is related to the observed immune evasion 








4.3 Genes well-correlated between copy number and expression mainly reside on 1q, 
Xq and 8p  
 The list of down- and up-regulated DEGs was further restricted based on the 
criterion of positive correlation between gene copy number change and gene 
expression change in tumor to select for genes whose expression change is 
attributable to copy number aberration, henceforth referred to as concordant DEGs. 
The frequency distribution (target distribution) of Spearman’s rank correlation 
coefficients (ρ) for the 268 DEGs, whose copy number change in 15 HCC tumors was 
correlated to their expression change in the same set of tumors, is shown in Figure 4.8. 
The estimated population mean for the Spearman’s ρ was calculated to be 0.067 (95% 
CI: 0.039 – 0.095) which was determined by a two-sided one-sample t-test to be 
significantly greater than zero (p < 0.0001). In addition, for each gene, Spearman’s 
rank correlation between its copy number change and the expression change of each 
of the 268 genes was computed, giving rise to 71824 pairwise comparisons. The 
frequency distribution (non-target distribution) of these 71824 Spearman’s rank 
correlation coefficients was also plotted (Figure 4.9). The estimated population mean 
for the Spearman’s ρ of this non-target distribution was found to be -0.0072 (95% CI: 
-0.0091 – -0.0053). The higher average correlation coefficient of the target 
distribution, which was statistically significant by one-sided Student’s t-test (p < 
0.0001), suggested that the copy number profile of each gene was best correlated with 










           
Figure 4.8 Histogram of target distribution. The density histogram shows the frequency 
distribution of Spearman’s correlation coefficients of 268 differentially expressed genes 
(DEGs) whose copy number profile was correlated with its own expression profile. 
Correlation was done using array CGH and expression array data available from 15 HCC 
tumors. Bin width for histogram was set at ρ = 0.1. The distribution displayed slight deviation 
from normality when fitted with a Gaussian curve (R2 = 0.974). 
  





















Figure 4.9 Histogram of non-target distribution. The density histogram shows the 
frequency distribution of Spearman’s correlation coefficients from 71824 pairwise 
comparisons between each differentially expressed gene (DEG)’s copy number profile and 
the expression profile of each of the 268 DEGs. Array CGH and expression array data of 15 
HCC paired tumors was used for the analysis. Distribution displayed normality and could be 
fitted with a Gaussian curve (R2 = 0.998). Bin width for histogram was set at ρ = 0.1.  
 
  
















 The cutoff threshold for positive correlation was set at ρ ≥ 0.3, and cutoff for 
negative correlation was set at ρ ≤ -0.3. A heatmap representation of correlation 
coefficients for all the 71824 correlation pairs is depicted in Figure 4.10. Applying the 
cut-off, a total of 44 DEGs reporting positive correlation were identified. Of these, 25 
were down-regulated and 19 were up-regulated, corresponding to 25% and 11% of 
down- and up-regulated DEGs respectively (Table 4.1). An association of down-
regulated DEGs with positive correlation between copy number and expression 
profile (Fisher’s one-tailed exact test, p < 0.0001) was found. This implied that loss of 
copy number is more likely to alter the tumor transcriptome than copy number gain, 
spelling a potentially more important role for copy number loss in tumor development.
 From Figure 4.11, it could be observed that the majority of concordant DEGs (> 
50%) were located on chromosomes that frequently presented copy number anomalies 
in HCC. In particular, a large number of concordant DEGs that were down-regulated 
were located on 8p. Similarly, 1q and Xq also housed a large proportion of the up-
regulated concordant DEGs. One-sided Fisher’s exact test was applied to determine 
whether this observed association of concordant DEGs with 8p, 1q and Xq was 
significant, or occurred as a consequence of higher representation of genes from these 
chromosomes in the list of 268 DEGs. It was found that the positive associations of 
both 8p and Xq with concordant DEGs were statistically significant (Figure 4.12). 







                   
Figure 4.10 Heatmap of Spearman’s correlation coefficients. Cut-off thresholds for 
positive correlation and negative correlation were ρ ≥ 0.3 and ρ ≤ -0.3 respectively. Positive 
correlations between copy number and expression profiles of down-regulated differentially 
expressed genes (DEGs) were colored blue (■), of up-regulated genes were colored red (■). 
Positive correlations between copy number of down-regulated DEGs and expression of up-
regulated DEGs or vice versa were colored green (■). Negative correlations were colored 




Table 4.1 List of 44 DEGs positively correlated between copy number and expression 













      
 1 p36.13 EPHA2 0.36 -0.07 -1.07 
 1 p36.11 MAN1C1 0.44 -0.44 -1.40 
 1 p31.1 CTH 0.33 -0.49 -2.02 
 4 q35.2 F11 0.41 -0.12 -1.10 
 8 p23.1 MSRA 0.55 -0.42 -1.00 
 8 p22 DLC1 0.43 -0.48 -0.54 
 8 p22 MSR1 0.35 -0.47 -0.53 
 8 p22 PSD3 0.33 -0.64 -0.56 
 8 p22 NAT2 0.31 -0.51 -2.34 
 8 p21.3 TNFRSF10B 0.37 -0.43 -0.57 
 8 p21.1 EPHX2 0.38 -0.53 -1.34 
 8 p21.1 CCDC25 0.38 -0.50 -0.55 
 11 p11.2 DDB2 0.39 -0.38 -0.78 
 11 q13.4 PDE2A 0.40 -0.41 -0.78 
 12 p12.1 ABCC9 0.40 -0.43 -0.46 
 12 q24.13 SDS 0.48 -0.16 -2.18 
 12 q13.2 PPP1R1A 0.55 -0.26 -0.49 
 12 q24.11 ACACB 0.43 -0.29 -1.09 
 14 q23.2 MTHFD1 0.50 -0.37 -1.05 
 15 q22.2 RORA 0.43 -0.32 -0.75 
 16 q13 GNAO1 0.36 -0.43 -0.45 
 16 q23.1 CHST6 0.54 -0.35 -0.70 
 16 q23.3 MLYCD 0.34 -0.41 -0.73 
 19 p13.3 TBXA2R 0.38 -0.10 -0.45 
 19 p13.2 MYO1F 0.40 -0.13 -0.53 













      
 1 q21.2 ANP32E 0.61 0.39 0.49 
 1 q22 DAP3 0.58 0.40 0.68 
 1 q24.3 C1orf9 0.38 0.41 1.19 
 1 q25.1 MRPS14 0.40 0.45 0.49 
 1 q25.3 EDEM3 0.67 0.35 0.96 
 1 q31.3 DENND1B 0.37 0.46 0.57 
 1 q32.1 SOX13 0.54 0.63 0.81 
 1 q32.1 NR5A2 0.38 0.59 0.39 
 1 q32.2 CD46 0.44 0.33 0.63 
 1 q42.2 KCNK1 0.37 0.49 0.42 
 5 p15.2 CCT5 0.31 0.41 0.64 
 5 q31.1 P4HA2 0.55 0.40 0.87 
 6 p21.32 EHMT2 0.40 0.35 0.74 
 7 q22.1 MCM7 0.36 0.38 0.67 
 X p11.4 MID1IP1 0.54 0.38 0.93 
 X q24 UPF3B 0.33 0.34 0.82 
 X q25 THOC2 0.39 0.29 0.69 
 X q26.3 HTATSF1 0.54 0.35 0.74 
 X q28 VBP1 0.40 0.21 0.76 
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Figure 4.11 Distribution of chromosomal locations of concordant DEGs. Bar chart shows 
the number of differentially expressed genes (DEGs) located on each chromosome that 
reported a positive correlation (Spearman’s ρ ≥ 0.3) between copy number and expression. 
Chromosomes that did not house such genes were not shown. 
 
    
Figure 4.12 8p, Xq but not 1q were associated with concordant DEGs. Results from 
Fisher’s exact test for positive association between occurrence of concordant DEGs and 8p, 
Xq or 1q are shown. Numbers beside the chromosomes (chr) denote the number of 
differentially expressed genes (DEGs) found on it that did or did not fulfill the correlation cut-
off. One-tailed p-value was reported. Testing was performed at α = 0.05. 
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These findings implied that loss of 8p is an important event in HCC. 
Concordant DEGs on 8p identified here were tumor necrosis factor receptor 
superfamily member 10B (TNFRSF10B), pleckstrin homology and SEC7 domain-
containing protein 3 (PSD3), arylamine N-acetyltransferase 2 (NAT2), mitochondrial 
peptide methionine sulfoxide reductase (MSRA), macrophage scavenger receptor I 
(MSR1), epoxide hydrolase (EPHX2), deleted in liver cancer 1 (DLC1), and coiled-
coil domain-containing protein 25 (CCDC25). Notably, a recent integrative analysis 
on HCC188 had associated loss of 8p with poor patient prognosis and further derived a 
six-gene signature on 8p predicting for patient survival that included DLC1 and 
CCDC25. This thus lends support to the conclusion that loss of 8p is important in 
HCC. While a tumor-suppressive effect for CCDC25 has not been found, DLC1 is a 
documented suppressor of HCC growth and metastasis via inhibition of Rho/ROCK 
signaling234-236 (refs). Besides these, TNFRSF10B is a receptor for TRAIL, a cytokine 
of the tumor necrosis factor ligand family that preferentially induces apoptosis in 
tumor cells. Loss of TNFRSF10B thus might aid in tumor evasion from apoptosis. 
Loss of function mutations in NAT2, an enzyme involved in activation or inactivation 
of carcinogens, were also associated with higher HCC risk237. 
 This is believed to be the first report of genes on chromosome Xq that are 
frequently up-regulated as a result of copy number gain in HCC. There are very few 
studies that addressed the genetic and expression anomalies of sex chromosomes in 
HCC. Most current studies on the X chromosome focused on examining the 
methylation pattern of X chromosome-linked androgen receptor gene in clonal 
analysis of HCC nodules. A possible reason for this lack of assessment of the X 
chromosome is the inadequate use of sex-matched reference samples, which is 
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particularly important in CGH analysis238. Analysis of the sex chromosomes in HCC 
is however pertinent due to the strikingly higher predominance and death rates of 
HCC in males. In this study, HCC tumors and their adjacent non-tumorous lesions 
from donors were used for copy number and expression analysis. Use of donor’s own 
non-tumorous tissues as reference ensured proper sex-matching and hence enabled 
high sensitivity for detecting sex chromosomes anomalies. Further aided by a high-
resolution CGH array, copy number gains were then detected at reasonably high 
frequencies (> 30%) on chromosome X, especially at the Xq28 locus (see Figure 3.2, 
Table 3.3). Similar findings were also reported by two other array CGH studies 
performed using paired HCC tumors and non-tumors182,186. Gains on Xq were detected 
in nearly 20% of the HCC tumors in these studies and Jia et al also located a 
frequently altered region at Xq28. In an analysis of X chromosome using FISH, X 
chromosome amplification was also detected in all HCC tumors239. Of the four 
concordant DEGs identified on Xq, von Hippel-Lindau binding protein 1 (VBP1) was 
reported to mediate the oncogenic properties of HBx by cooperating with it to 
increase cell proliferation and enhance activation of NFκB240. The study also 
suggested that VBP1 counteracted von Hippel-Lindau disease tumor suppressor 
(VHL)-mediated  repression of NFκB. VHL is a well-documented tumor suppressor 
in a variety of cancers and has also been shown to suppress HCC cell growth in 
mouse model by down-regulating hypoxia inducible factor 1 alpha (HIF1a), a key 
transcription factor for tumor angiogenesis in response to hypoxia241. It would thus be 
interesting to investigate the functional significance of gain of VBP1 in HCC. Besides 
VBP1, another gene, HIV Tat-specific factor 1 (HTATSF1) was also suggested as a 




 Survey of the HCC transcriptome, coupled with information at DNA level 
provided by array CGH, revealed abnormalities related to two important hallmarks of 
cancer, cell proliferation and evasion from immune destruction. Increased expression 
and copy numbers of cell cycle genes and genes acting in the spindle-assembly 
checkpoint implied that de-regulated control of cell cycle events, particularly of 
mitosis, is a prominent feature of HCC. Moreover, defects in the spindle-assembly 
checkpoint can cause chromosomal instability. On the other hand, decreased 
expression of several chemokines highlighted a mechanism by which HCC tumor 
cells can escape detection by immune cells to avoid immunological killing. De-
regulated copy numbers and expression of a number of nuclear receptors and their 
regulators that were reported to regulate inflammation suggested a possible role for 
them in immune evasion too. Strikingly, large numbers of genes that are 
transcriptionally altered as a result of copy number change were located on 1q, 8p and 
Xq. In particular, 8p and Xq were associated with higher occurrence of such genes, 







Chapter 5:  
Genetic assessment of HCC cell lines 
as in vitro models of HCC 
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5.1 Array CGH of HCC cell lines revealed dissimilarities to patient tumors 
 HCC cell lines are commonly used as experimental models for studying 
cancer-related cellular events and molecular pathways. However under the conditions 
of in vitro culture, it is not clear whether the cell lines remain representative of HCC 
tumors. In particular, they might have acquired further genomic alterations during the 
multiple cell passages. Here, array CGH was performed on 12 HCC cell lines (Hep-
3B, HepG2, Huh-1, Huh-4, Huh-6, Huh-7, Mahlavu, PLC/PRF/5, SK-HEP-1, SNU-
182, SNU-449 and Tong) to examine their genomic abnormalities and data was 
analyzed as previously described for the tumors. Table 5.1 lists the known 
characteristics of these cell lines. The average of the array CGH data of the 15 non-
tumorous tissues from Cohort 1a was used for normalization to obtain log2 fold 
change (i.e. log2 (Cell line/NTav) ratio). The array CGH profiles of the 12 cell lines 
are shown in Figure 5.1.  
 






















       
Hep-3B Black Male/ 8 Positive      Yes 60 [192],[243],[244]192,243,244 
Huh-1 Japanese Male/ 53 Positive      Yes 69 [200],[244],[245]200,244,245 
Huh-4 Japanese No data Positive      No data No data [200],[244]200,244 
PLC/PRF/5 African Male/ 24 Positive      Yes No data [193],[244],[246],[247]193,244,246,247 
Tong Caucasian Male/ 59 Positive      Yes 64 [197],[247]197,247 
SNU-182 Korean Male/ 24 Positive      No data 70 [195]195 
SNU-449 Korean Male/ 52 Positive      No data 57 [195]195 
HepG2 Caucasian Male/ 15 Negative      Yes 55 [192],[244],[248]192,244,248 
Huh-6 Japanese Male/ < 1 Negative      Yes 49 [198],[244],[248]198,244,248 
Huh-7 Japanese Male/ 57 Negative      Yes No data [199],[244]199,244 
Mahlavu Japanese Male/ ? Negative      Yes 63 [196],[244],[249]196,244,249 













Figure 5.1  Array CGH profiles of HCC cell lines. The log2 (Cell line/ NTav) intensity ratios 
of probes that fulfill the threshold cut-off of > 0.25 or < -0.25 were plotted on the vertical-axis 
as a function of the genomic location (horizontal-axis). Range of vertical-axis is the same for 





From the copy number aberration (CNA) frequency plots for the HCC cell 
lines and the 15 HCC tumors in Cohort 1a, significant differences in genomic 
alteration profiles could be observed. These differences were still observed when a 
higher cutoff of log2 fold change (> abs (0.5)) was used to define copy number 
change (Figure 5.2). To locate the chromosomal regions that are commonly or 
differently altered between cell lines and tumors, the array CGH data for the cell lines 
were subjected to smoothing and breakpoint detection as previously described for 
patients’ tumors. For comparison, the aberrations were classified into three groups – 
group A contained chromosomal aberrations that were frequently detected in HCC 
tumors but not in the cell lines, group B contained chromosomal aberrations that were 
commonly found in cell lines but not in tumors and group C comprised of 




Figure 5.2 Comparison of copy number aberration frequencies in HCC tumors and cell 
lines. The frequencies of gain or loss (log2 (T/NT) ratio > abs (0.5)) of all array CGH probes 
in HCC tumors or cell lines were plotted as a function of genome location. Red represents 




Group A – Chromosomal aberrations in this group were frequently detected in 
HCC tumors but not in the cell lines. These aberrations were gain on 8q and loss on 
16q and 17p. In HCC tumors, DNA copy number gain on 8q was detected in half of 
the samples. Many tumors (e.g. tumor no. 81, 101, 107, 112) reported high copy 
number gain of almost the entire q-arm as seen in Figure 5.3 that showed the map of 
the delimited chromosomal regions of copy number aberration after smoothing and 
breakpoint detection of the array CGH data. In cell lines, however, gain of entire 8q 
was rare. Instead, a number of cell lines such as Huh-1, Huh-4 and SNU-182 reported 
copy number losses on 8q together with losses on 8p. Minimal overlapping region of 
loss on 8q could be delimited to a 32.83 Mb region at 8q12.1-21.3 and a 266.45 kb 
region at 8q22.3 in the cell lines. Similarly, while frequent copy number loss on 16q 
was exhibited in tumors, including loss along the entire arm for tumors no. 85, 86, 
101 and 107, loss in the cell lines was detected in smaller chromosomal regions and 
frequently interrupted by regions of copy number gain (Figure 5.4). The minimal 
overlapping region of copy number gain was mapped to a 1.49 Mb region at 16q23.3-
24.1. Besides 8p and 16q, 17p also presented a different pattern of chromosomal 
aberrations. In tumors, a recurrent region of copy number loss had been mapped to an 
8.1Mb region at 17p13.3-13.1. While loss in this region was also reported in 50% of 











        
Figure 5.3 Map of gains or losses for smoothed array CGH data on chromosome 8. Map 
shows the genomic location of chromosomal regions reporting copy number change (log2 
fold change > abs (0.25)) on chromosome 8 after breakpoint detection using the GLAD 
algorithm. Cytogenetic ideogram for human chromosome is shown at the top. Regions with 
log2 fold change between -0.25 and 0.25 are non-colored. Gains are displayed in orange (■). 
Losses are displayed in green (■). Data for cell lines are shown in the top and data for tumors 






    
Figure 5.4 Map of gains or losses for smoothed array CGH data on chromosome 16. Map 
shows the genomic location of chromosomal regions reporting copy number change (log2 
fold change > abs (0.25)) on chromosome 16 after breakpoint detection using the GLAD 
algorithm. Cytogenetic ideogram for human chromosome is shown at the top. Regions with 
log2 fold change between -0.25 and 0.25 are non-colored. Gains are displayed in orange (■). 
Losses are displayed in green (■). Data for cell lines are shown in the top and data for tumors 




    
Figure 5.5 Map of gains or losses for smoothed array CGH data on chromosome 17. Map 
shows the genomic location of chromosomal regions reporting copy number change (log2 
fold change > abs (0.25)) on chromosome 17 after breakpoint detection using the GLAD 
algorithm. Cytogenetic ideogram for human chromosome is shown at the top. Regions with 
log2 fold change between -0.25 and 0.25 are non-colored. Gains are displayed in orange (■). 
Losses are displayed in green (■). Data for cell lines are shown in the top and data for tumors 





Group B – Chromosomal aberrations in this group were commonly found in cell lines 
but not in tumors. These aberrations were loss on 9p, and gain on 18q and 20q. Loss 
of chromosomal material on 9p was frequently seen near the telomeric end in eight of 
the twelve HCC cell lines (Figure 5.6), with the minimal overlapping region delimited 
to a 5.62 Mb region spanning 9p21.3-21.2 that was defined by SNU-449. Mean log2 
fold change across cell lines in this region was -1.32. Hep-3B and HepG2 displayed 
no or minimal copy number loss on 9p, while Tong and SNU-182 presented gains in 
largely non-overlapping chromosomal regions. SNU-182 also reported chromosomal 
loss near the centromere at 9p11.2-11.1. In contrast, loss at the telomeric end was seen 
in only one-third of the tumors, with the minimal overlapping region spanning 
9p24.3-21.1. Tumors also reported a lower mean log2 fold change of -0.65 in this 
region. Other than 9p, loss of chromosomal material on 18q and gain of material on 
20q were found in almost all the cell lines but were detected at lower frequencies in 
the tumors as shown in Figures 5.7 and 5.8. Most of the HCC cell lines were seen 
with copy number loss along almost the entire 18q whereas loss of entire 18q was 
reported in only tumor no. 85 and 112. The rest of the tumors exhibited no changes on 
chromosome 18. Similarly, while most of the HCC cell lines were seen with copy 






     
Figure 5.6 Map of gains or losses for smoothed array CGH data on chromosome 9. Map 
shows the genomic location of chromosomal regions reporting copy number change (log2 
fold change > abs (0.25)) on chromosome 9 after breakpoint detection using the GLAD 
algorithm. Cytogenetic ideogram for human chromosome is shown at the top. Regions with 
log2 fold change between -0.25 and 0.25 are non-colored. Gains are displayed in orange (■). 
Losses are displayed in green (■). Data for cell lines are shown in the top and data for tumors 





        
Figure 5.7 Map of gains or losses for smoothed array CGH data on chromosome 18. Map 
shows the genomic location of chromosomal regions reporting copy number change (log2 
fold change > abs (0.25)) on chromosome 18 after breakpoint detection using the GLAD 
algorithm. Cytogenetic ideogram for human chromosome is shown at the top. Regions with 
log2 fold change between -0.25 and 0.25 are non-colored. Gains are displayed in orange (■). 
Losses are displayed in green (■). Data for cell lines are shown in the top and data for tumors 





      
Figure 5.8 Map of gains or losses for smoothed array CGH data on chromosome 20. Map 
shows the genomic location of chromosomal regions reporting copy number change (log2 
fold change > abs (0.25)) on chromosome 20 after breakpoint detection using the GLAD 
algorithm. Cytogenetic ideogram for human chromosome is shown at the top. Regions with 
log2 fold change between -0.25 and 0.25 are non-colored. Gains are displayed in orange (■). 
Losses are displayed in green (■). Data for cell lines are shown in the top and data for tumors 





Group C – Chromosomal aberrations in this group were commonly found in both 
tumors and cell lines. These aberrations were loss on 1p, 4q, 8p and 13q and gain on 
1q. All cell lines except HepG2 were found with losses on 4q (Figure 5.9), with the 
minimal overlapping region of loss located in a 6.87Mb region at 4q35.1-35.2. This 
was adjacent to the minimal region of loss at 4q32.3-34.3 reported in tumors. Indeed, 
nine of the 10 tumors with loss on 4q had chromosomal region of loss extending to 
the telomeric end at 4q35.2. Hence, both tumors and cell lines were seen with a 
similar pattern of high frequency loss on 4q. Copy number loss on 8p was found in at 
least 80% of both tumors and cell lines. The pattern of loss was however slightly 
different as shown in Figure 5.3. In tumors with 8p loss, all but one tumor consistently 
demonstrated loss of the entire arm. In cell lines, 8p loss in was less consistent. While 
Huh-1, Huh-4 and SNU-182 exhibited loss of entire 8p, Tong, SNU-449 and HepG2 
were seen with minimal loss at 8p21.3. Nevertheless, the minimal overlapping region 
of loss at 8p23.1-21.3 defined in tumors was also lost in six of the HCC cell lines. 
This suggested that important chromosomal imbalances on 8p in tumors were also 
retained in the cell lines. Loss on 13q was observed in most cell lines except for 
HepG2 and Huh-7 that displayed minimal aberration (Figure 5.10). Pattern of loss 
was similar to that in tumors. The minimal overlapping region of loss in cell lines was 
located at 13q13.2-13.3, adjacent to the 13q14.11-14.13 minimal region mapped in 
tumors. Lastly, loss on 1p and gain on 1q were detected with similar frequencies in 






   
Figure 5.9 Map of gains or losses for smoothed array CGH data on chromosome 4. Map 
shows the genomic location of chromosomal regions reporting copy number change (log2 
fold change > abs (0.25)) on chromosome 4 after breakpoint detection using the GLAD 
algorithm. Cytogenetic ideogram for human chromosome is shown at the top. Regions with 
log2 fold change between -0.25 and 0.25 are non-colored. Gains are displayed in orange (■). 
Losses are displayed in green (■). Data for cell lines are shown in the top and data for tumors 







       
Figure 5.10 Map of gains or losses for smoothed array CGH data on chromosome 13. 
Map shows the genomic location of chromosomal regions reporting copy number change 
(log2 fold change > abs (0.25)) on chromosome 13 after breakpoint detection using the 
GLAD algorithm. Cytogenetic ideogram for human chromosome is shown at the top. Regions 
with log2 fold change between -0.25 and 0.25 are non-colored. Gains are displayed in orange 
(■). Losses are displayed in green (■). Data for cell lines are shown in the top and data for 












        
Figure 5.11 Map of gains or losses for smoothed array CGH data on chromosome 1. Map 
shows the genomic location of chromosomal regions reporting copy number change (log2 
fold change > abs (0.25)) on chromosome 1 after breakpoint detection using the GLAD 
algorithm. Cytogenetic ideogram for human chromosome is shown at the top. Regions with 
log2 fold change between -0.25 and 0.25 are non-colored. Gains are displayed in orange (■). 
Losses are displayed in green (■). Data for cell lines are shown in the top and data for tumors 




5.2 Cell lines differ in representativeness of HCC genomic profile 
 Since the HCC cell lines demonstrated different profiles of copy number 
change on key chromosomes (e.g. 8q) that were very frequently gained or lost in HCC, 
the next pertinent question to address will be which cell lines are more representative 
of the genomic changes seen in patients’ tumors. To quantitatively assess the extent to 
which each cell line is reflective of the copy number changes in patients’ tumors, 
correlation between the array CGH data of the cell lines and a pooled tumor sample, 
derived by averaging the copy number aberration data in the 15 patients’ tumors 
(Cohort 1a), was calculated using Pearson’s correlation formula. This pairwise 
comparison was performed with the copy number log2 fold change values of all the 
array CGH probes designed for each chromosome arm. Based on the average 
Pearson’s correlation coefficient calculated for chromosomes 1p, 1q, 4q, 8p, 8q, 13q, 
16q, 17p and 17q which were frequently reported to present copy number changes in 
HCC, the 12 cell lines were ranked in order of decreasing correlation into the 
following order (Figure 5.12): Hep3B, SK-HEP-1, Huh-6, Huh-1, Huh-4, SNU-182, 
Huh-7, Tong, PP5, SNU-449, Mahlavu and HepG2. Hence, Hep3B which presented 
the strongest correlation (r = 0.561) was the cell line most representative of copy 
number changes in patients’ tumors, while HepG2 that reported the weakest 
correlation (r = 0.156) was dissimilar to the HCC tumors. The correlation plots of 
Hep3B and HepG2 are shown in Figures 15.13 and 15.14. Correlation plots for the 
other 10 cell lines are depicted in Supplementary Figures 1-10 in Appendix 3. Since 
the cell lines and tumors were analyzed using the same array CGH platform, larger 
correlation coefficients above 0.5 were considered as strong positive correlation. By 
this definition, only Hep3B and SK-HEP-1 displayed strong correlation with the HCC 
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tumors. The remaining cell lines reported average correlation coefficients less than 
0.5, implying that statistically, < 25% of the variance in these cell lines can be 
explained by variation in the tumors. It can be inferred that only a small proportion of 




   
 
Figure 5.12 Correlation of copy number changes in cell lines and tumors. (A) The 
correlation coefficients of the cell lines, yielded from pairwise comparison with a pooled 
sample of 15 patients’ tumors, are depicted in a 3-color-scale heatmap. Coefficients in the 
middle (50th percentile) range of coefficient values reported for each chromosome arm are 
represented in yellow, and coefficients in the upper range (above 75th percentile) and the 
lower range (below 25th percentile) are represented by the top and bottom colors of the color 
key respectively. The correlation coefficients (n = 12) reported for a particular chromosome 
arm (e.g. 1p) are colored based on the distribution of coefficient values for that chromosome 
arm only.  The cell lines were ranked based on their average correlation across 1p, 1q, 4q, 8p, 
8q, 13q, 16q, 17p and 17q and (B) ordered along a linear horizontal scale (drawn to scale) 




Figure 5.13 Correlation plots of Hep3B and HepG2. XY scatter plots of copy number 
change for all the array CGH probes on 1p, 1q, 4q, 8p, 8q, 13q, 16q, 17p or 17q. The log2 
fold change (cell line/ NTav) of each probe in Hep3B or HepG2 is plotted on the y-axis against 
the average log2 fold change (T/NT) of the probe in 15 patients’ tumors on the x-axis. 
Relationship between copy number change in Hep3B or HepG2 and patients’ tumors was 
assessed by computing Pearson’s correlation coefficient (r).  
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5.3 HBV-positive and HBV-negative cell lines are not distinctly different 
Several of the HCC cell lines analyzed in this study were positive for HBV 
infection (Table 5.1), having been detected to secrete HBsAg into the culture 
supernatant or found to carry integrated HBV DNA in their genome. All 15 tumors 
analyzed by array CGH in this study were also taken from patients serologically 
positive for HBV but not HCV infection. It would thus be interesting to examine if the 
genomic profile of cell lines infected with HBV were more similar to that of HBV-
infected patients’ tumors than the HBV-negative cell lines. The Mann-Whitney U-test 
was applied to test for significant differences in Pearson’s correlation between HBV-
positive and HBV-negative cell lines for all somatic chromosome arms. The results of 
the analysis are shown in Figure. 5.15. The HBV-positive HCC cell lines reported 
significantly higher correlation with patients’ tumors than HBV-negative cell lines 
only on chromosome 13q (p = 0.018). As seen from the dot plot (Figure. 5.16) 
showing the distribution of correlation coefficients, all HBV-positive cell lines 
reported correlation r > 0.4 while all HBV-negative cell lines except Huh-6 had 
correlation r < 0.4 for 13q. Hence, it could be concluded that the HBV-positive cell 
lines were not more reflective of the genomic changes in HBV-infected patients’ 
tumors than the HBV-negative cell lines. 
The lack of significant differences between HBV-positive cell lines and HBV-
negative cell lines when correlated to HBV-infected tumors suggested that cell lines 
in the two groups might be genetically similar to each other. To examine if this is true, 
Pearson’s correlation between the average copy number log2 fold change of the seven 
HBV-positive cell lines and average copy number log2 fold change of the five HBV-
negative cell lines was computed for each chromosome arm. The distribution of the 
129 
 
correlation coefficients is shown in Figure 5.17. As seen, the copy number changes in 
HBV-positive and HBV-negative cell lines were highly correlated to each other, with 
an average correlation of 0.83 across the 39 chromosomal arms. Even though 
chromosomes 13q and 17p reported weaker correlation than the other chromosomes, 
they still reported correlation coefficients of 0.60 and 0.65 respectively, which is 
considered to be strong correlation.  
Hence, analysis of array CGH data of the HCC cell lines demonstrated that the 
genomic profiles of HBV-positive and HBV-negative cell lines were not significantly 
different and HBV-positive cell lines were also not more reflective of the copy 
number changes in HBV-infected tumors. The analysis in Section 5.1 had shown that 
chromosomal changes on chromosome 16 and 17p that were found to be associated 
with HBV or viral etiology by the meta-analysis (Section 3.2.2) were not well 
conserved in the cell lines. The results of the Mann-Whitney U-tests that reported 
large p-values (16p/q: p = 0.88; 17p: p = 0.64) on these chromosomes further 
indicated that HBV-positive and HBV-negative cell lines were equally 
















































































































































































































































































































































































































































































































                            
Figure 5.15 Scatter dotplots of correlation coefficients for 13q. Distribution of Pearson’s 
correlation between HBV-positive or HBV-negative cell lines with a pooled sample of 15 
patients’ tumors for copy number changes on 13q showed that on average, HBV-positive cell 
lines reported higher correlation than HBV-negative cell lines. Black bar (−−) represents the 
average of the correlation coefficients. Two-sided p-value from Mann-Whitney U-test is 
indicated above the dotplots. 
 
 
                                        
Figure 5.16 Boxplot of correlation coefficients between HBV-positive and HBV-negative 
cell lines. Tukey box-and-whisker plot shows the distribution of Pearson’s correlation 
between HBV-positive and HBV-negative cell lines for all somatic chromosome arms. 
Horizontal crossbar at the end of each whisker corresponds to the farthest non-outlier data 
point (i.e. correlation coefficient) within 1.5 times of the interquartile range. Outliers are 
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5.4 Consistent copy number loss on 8p identified DLC1, MSR1 and PSD3 as 
important genes in HCC 
 Copy number loss on 8p, particularly in a 10.27 Mb region at 8p23.1-21.3, 
was previously shown in this study to be the most frequent chromosomal loss in the 
15 patients’ tumors. Subsequent meta-analysis further highlighted the importance of 
8p loss, which was demonstrated to be highly prevalent in all HCC regardless of 
etiology. In the array CGH of the cell lines, copy number loss on 8p was also found to 
be conserved. The consistent detection of high frequency copy number loss on 8p in 
all types of HCC and the HCC cell lines strongly suggested the presence of important 
cancer-related genes on this chromosome. 
 Comparing the regions of copy number aberrations on 8p in the 15 tumors and 
12 HCC cell lines, it was observed that the 10.27 Mb region at 8p23.1-21.3, which 
was detected in 80% of the patients’ tumors, also occurred in six of the ten cell lines 
that reported loss on 8p. Using the array CGH data from the cell lines, this minimal 
overlapping region of loss was further delimited to a 6.87 Mb region that contained 83 
probes mapping to 23 genes. Of these 23 genes, deleted in liver cancer 1 (DLC1), 
macrophage scavenger receptor 1 (MSR1) and pleckstrin and Sec7 domain containing 
3 (PSD3) were previously identified in the integrative analysis to be frequently down-
regulated and showed positive correlation between copy number and expression levels, 
whereby r = 0.43, r = 0.35 and r = 0.33 were reported respectively.  
 The copy number and microarray expression of DLC1, MSR1 and PSD3 were 
summarized in Figures 5.17 - 5.19. As depicted in Figure 5.17(a), all but one array 
CGH probe for DLC1 were reduced in copy number in at least half of the HCC 
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tumors and cell lines. Since the array CGH probes were positioned widely along the 
entire gene in both introns and exons (see Appendix 3 Supplementary Figures 11-13 
for position of array CGH probes and Affymetrix U133A probe sets), this implied that 
there was loss of the entire gene in HCC.  Correspondingly, loss of expression of 
DLC1, which encodes for a Rho GTPase-activating protein (RhoGAP), was found in 
about half of the tumors for the U133A probe set (210762_s_at) that measured the 
expression of DLC1 isoforms 1, 2 and 4. The other two probe sets measuring 
expression of DLC1 isoform 3 did not show significant loss of expression. DLC1 
isoform 3 lacks the RhoGAP domain required for the GTPase-activating function of 
DLC1. The expression data thus suggested that DLC1 function was severely 
compromised in HCC tumors.  
 Similar to DLC1, all array CGH probes for MSR1 had copy number loss in at 
least half of the tumors and cell lines (Figure 5.18(a)). Loss of expression in tumors 
was detected only for the 214770_at probe set that targets the 3’ end of MSR1 
isoform 1 and 3 transcripts. Since all isoforms shared the same promoter, epigenetic 
mechanisms are unlikely to be the reason for this selective under-expression of MSR1 
isoforms. Instead, there might be partial deletion of the remaining allele of MSR1, 
supported by the observation of a more negative average log2 fold change for the 
A_14_P128888 probe that is targeted to 3’ end of the full-length gene (see Appendix 
3 Supplementary Figure 12). Lastly, for PSD3, while not all probes along the gene 
consistently reported copy number loss, under-expression of the gene was detected by 
both U133A probe sets in about half of the tumors, indicating a high degree of de-
regulation (Figure 5.19).  
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 In conclusion, DLC1, MSR1 and PSD3 were highly de-regulated in HCC. Co-
analysis of copy number of array CGH probes and expression of U133A probes, 
together with information on the probe and probe set alignments further implied 
alteration of both alleles of MSR1 genes in HCC. Hence, these genes are likely to be 
important genes altered in HCC. Indeed, DLC1 is a well-known tumor suppressor in 
many cancers, including HCC. A role for MSR1 and PSD3 in HCC however, has not 
been described yet. It would be interesting to examine their roles in tumor 





Figure 5.17 Copy number and microarray expression of DLC1 in HCC tumors and cell 
lines. Scatter dotplots of (A) copy number log2 fold change of DLC1 in 15 tumors and 12 cell 
lines that were assessed by Agilent array CGH, and (B) expression log2 fold change of DLC1 
in 37 tumors that were assessed by Affymetrix U133A microarray, for all probes or probe sets. 
Green dotted line at y = T indicates the threshold for defining copy number loss (log2 fold 
change > abs (0.25)) and under-expression (log2 fold change > abs (0.6)). Black dotted line 
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Figure 5.18 Copy number and microarray expression of MSR1 in HCC tumors and cell 
lines. Scatter dotplots of (A) copy number log2 fold change of MSR1 in 15 tumors and 12 cell 
lines that were assessed by Agilent array CGH, and (B) expression log2 fold change of MSR1 
in 37 tumors that were assessed by Affymetrix U133A microarray, for all probes or probe sets. 
Green dotted line at y = T indicates the threshold for defining copy number loss (log2 fold 
change > abs (0.25)) and under-expression (log2 fold change > abs (0.6)). Black dotted line 



















































































Tumors (n = 37)
A






Figure 5.19 Copy number and microarray expression of PSD3 in HCC tumors and cell 
lines. Scatter dotplots of (A) copy number log2 fold change of PSD3 in 15 tumors and 12 cell 
lines that were assessed by Agilent array CGH, and (B) expression log2 fold change of PSD3 
in 37 tumors that were assessed by Affymetrix U133A microarray, for all probes or probe sets. 
Green dotted line at y = T indicates the threshold for defining copy number loss (log2 fold 
change > abs (0.25)) and under-expression (log2 fold change > abs (0.6)). Black dotted line 
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 Array CGH of seven HBV-positive and five HBV-negative HCC cell lines revealed 
that the cell lines were genetically dissimilar to patients’ tumors. Besides having accumulated 
copy number aberrations on chromosomes 9p, 18q and 20q that were not frequently found in 
tumors, the patterns of copy number aberrations on 8q, 16q and 17p were also distinctly 
different between the cell lines and tumors. Nevertheless, regions of copy number aberrations 
on 1pq, 4q, 8p and 13q were largely conserved in the cell lines, suggesting the presence of 
genes on these chromosomes that are important for maintenance of cancer cells both in vivo 
and in vitro. Quantitation of genetic dissimilarity by correlation analysis of copy number 
changes of genes in each cell line with average copy number change in the tumors further 
showed that of the 12 cell lines, Hep3B was the most representative of genetic changes in 
tumors. HepG2, on the other hand, was highly dissimilar to tumors with respect to copy 
number profile. In addition, copy number changes in HBV-positive cell lines correlated well 
with those in HBV-negative cell lines and there was no evidence to suggest greater genetic 
resemblance of HBV-positive cell lines to HBV-infected tumors. Hence, it can be inferred 
that survival advantages conferred by HBV-induced genetic changes were possibly lost in cell 
lines due to changes in the selective pressure. In view of these changes in the environment 
and selective pressure during in vitro culture, genetic changes that were consistently recurrent 
in both tumors and cell lines were thus likely to be very important to cancer cell survival. 
Copy number loss at 8p23.1-21.3 is a notable example of such genetic changes. Deeper 
investigation identified DLC1, MSR1 and PSD3 located at 8p22 to be potentially important 









6.1 Array CGH and meta-analysis revealed etiology-independent and etiology-
associated chromosomal aberrations 
 
6.1.1 High resolution of chromosomal aberrations in HCC by array CGH 
 A primary aim of this study was to elucidate the chromosomal regions that 
were most frequently gained or lost in HCC with finer resolution than what has been 
reported by conventional CGH (cCGH) studies through the use of array CGH. From 
the analysis of array CGH profiles of paired tumors and non-tumorous samples from 
15 patients reported in Chapter 3, it was observed that copy number gain in 1q32.1and 
8q13.3-24.3, and copy number loss in 4q32.3-34.3, 8p23.1-21.3, 13q14.1-14.3, 16q23 
and 17p12-11 were highly frequent aberrations, occurring in more than one-third of 
the patients. A high resolution was achieved with the smallest region of aberration 
delineated to a 0.58 Mb region at 1q32.1. This resolution was considerably improved 
over the aberrant regions mapped using cCGH. Minimal overlapping regions on 16q 
and 17p, for instance, were previously mapped to 16q21-qter and 17p12-13160. The 
minimal overlapping region of gain at 8q24.3 that was frequently reported by cCGH 
studies164,165,172,173 was also refined by array CGH in this study to a 1.45 Mb region, 
containing the SCRIB gene that was demonstrated to inhibit growth of HCC cell lines 
when knocked down187.  Notably the resolution achieved was similar to that reported 
by one study using SNP array182, which for instance reported a 7.94 Mb minimal 
region at 17p13.3-13.1 that was comparable to the 8.09 Mb aberrant region at 
17p13.3-13.1 delineated in this study. Hence, overall, highly frequent and refined 
regions of chromosomal aberrations have been identified in this study with the use of 
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array CGH. However, as all the patients enrolled in this study were infected with 
HBV, it was not clear if these aberrations were associated with the viral infection or 
common to all HCCs. A meta-analysis was thus subsequently performed to examine 
this and the implications of the findings, reported in Chapter 3, are discussed below. 
6.1.2 Meta-analysis highlighted etiology-dependent aberrations sporadically 
reported in independent CGH studies 
There have been few CGH studies dedicated to the study of chromosomal 
abnormalities in HCCs of a single etiology. Due to the prevalence of HBV infection, 
most of the tumors included in CGH studies were sero-positive for HBsAg. Moreover, 
since HCC patients were commonly screened for HBV infection by serological testing 
for HBsAg in the serum, but less frequently screened for HCV infection, the viral 
status of the remaining non-HBV infected tumors is largely unclear. This problem on 
determining the viral status of HCC tumors is further confounded by the detection of 
HBV DNA in the serum and liver of HBsAg-negative patients250. The number of 
CGH-analyzed HCCs that were associated only with non-viral etiologies such as 
alcohol consumption or NAFLD was thus few. With most CGH-analyzed HCCs being 
HBV-positive, no strong conclusion could also be made about association of the 
observed chromosomal anomalies with HBV. The meta-analysis performed in this 
study is a method to overcome the restrictions of sample size, particularly for non-
viral HCCs, and uncover possible etiology-associated genomic changes.  
It is noted that the findings of this meta-analysis largely concurred with the 
conclusions made by a number of CGH studies with small sample size that made 
intra-study comparisons between HCCs with different etiologies. In a study 
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examining genetic differences between HBV-HCCs and HCV-HCCs190, Tornillo et al 
had concluded that there were no marked differences in the frequency of 
chromosomal deletions and gains. Indeed, aberrations such as loss on 1p, 4q, 9p and 
12q were shown by both Tornillo et al and this meta-analysis to occur with similar 
frequencies in both HBV-HCC and HCV-HCC. However, this meta-analysis further 
demonstrated that while there were no differences between the viral-HCCs, these 
aberrations were much less frequent in the non-viral HCCs. Similarly, copy number 
gain on 1q, 6p, 8q and 17q and loss on 6q, 8p and 13q were found in this meta-
analysis to be altered with same frequency between the viral HCCs as concluded by 
Tornillo et al. Additionally, these chromosomal changes were further shown to be 
found universally in all HCCs independent of the etiology.  
These findings were also in much agreement with another study214 by Marchio 
et al that compared the CGH findings from their non-viral HCC samples with the 
findings on HBV-HCC published by another group. Both the study by Marchio et al 
and this meta-analysis agreed that compared to non-viral HCCs, losses on 4q, 16q and 
17p were more frequent in HBV-HCC. In this meta-analysis, it was demonstrated that 
these alterations were also frequently found in HCV-HCCs. Notably, loss on 16q was 
observed to occur more frequently in HBV-HCC than HCV-HCC. Indeed, an early 
conventional CGH study on 40 HCC patients in Taiwan had also noted a strong 
correlation between loss on 16q and sero-positivity for HBsAg215. Very importantly, 
the association of 16q loss with HBV-HCC was echoed by the only other CGH meta-
analysis on HCC by Moinzadeh et al that was performed using 785 CGH-analyzed 
HCCs191. Hence, it can be concluded that loss of 16q was truly more prevalent in 
HBV-HCC and associated with infection by HBV. Furthermore, through this meta-
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analysis, novel associations of HBV-HCC with gain on 5p, 12q and 20q were 
revealed. Though not previously reported, these aberrations were present in 15- 20% 
of CGH-analyzed HBV-HCCs in the meta-analysis, as well as more than one-third of 
the tumors analyzed by array CGH in this study.  
Several findings from the meta-analysis by Moinzadeh et al, however, disagreed with 
the conclusions made by Marchio’s and Tornillo’s groups, as well as the meta-
analysis in this study. The meta-analysis by Moinzadeh et al, for instance, concluded 
loss of 4q and 13q to be positively correlated with HBV etiology but not HCV. The 
study by Tornillo et al and this meta-analysis however, did not find evidence of such 
an association. A possible explanation is the different approach taken by the two 
meta-analyses with respect to the classification of HCCs. While this meta-analysis 
clearly segregated non-viral HCCs from HBV-HCCs and HCV-HCCs, the meta-
analysis by Moinzadeh et al did not specifically examine non-viral HCCs. Instead, 
they had grouped CGH analyses only based on HBV or HCV positivity i.e. CGH 
analyses classified as HBV-negative may have consisted of both HCV-positive and 
non-viral HCCs and similarly for CGH analyses classified as HCV-negative. This 
might have a confounding effect. To prove this point, association of HBV-HCC with 
loss of 4q and 13q was also indicated when the data for HCV-HCC and non-viral 
HCC in this meta-analysis were merged and compared with the HBV-HCCs (Figure 
6.1). The classification strategy used in this meta-analysis thus appears to be more 
robust to detection of false positive associations. 
In summary, integrating the observations made by all four studies, one can that 
conclude that gain on 1q, 6p. 8q, and loss on 6q, 8p and 13q are common to all HCCs, 
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while viral-HCCs are associated with loss on 1p, 4q, 9p and 12q. Associations of loss 
on 16q and gains on 5p and 20q with HBV-HCCs were also demonstrated. In 
particular, gain on 1q and 8q and loss on 8p were shown in this meta-analysis to be 
especially prevalent, being found in more than one-third of all CGH-analyzed HCCs 





        
Figure 6.1 Classification of HCCs affects results of association study. Figure shows the 
results from two-sided Fisher’s exact tests (α = 0.05) for association between HBV-HCCs and 
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6.1.3 Common and etiology-specific pathways in HCC pathogenesis 
 The chromosomal aberrations identified in the meta-analysis to occur in at 
least 15% of the CGH-analyzed tumors of at least one etiology could be classified into 
the following (Table 6.1): (1) non-associated aberrations that are common to all HCCs 
(2) aberrations solely associated with HBV-HCC (3) aberrations solely associated 
with HCV-HCC (4) aberrations associated with viral- HCCs (5) aberrations associated 
with HBV-HCC and non-viral HCC (i.e. NBNC-HCC). It should be noted that while 
higher occurrence of a particular chromosomal aberration associated with an etiology 
is suggestive of a survival advantage imparted by the aberration that contributed to 
tumor development, it could also be reflective of etiology-dependent mechanisms that 
caused or increased the chance of occurrence of the aberration, which need not 
necessarily confer selective advantage. Although it is hard to distinguish the cause 
from the effect, some useful inferences can still be made about the pathogenic 
pathways underlying different types of HCC or the mechanisms leading to the 
aberrations.  
   
Table 6.1 Associations between HCC etiologies and chromosomal aberrations 
Type(s)  of HCC associated Chromosomal gain Chromosomal loss 
   
None 1q, 6p, 8q, 17q 6q, 8p, 13q 
HBV-HCC 5p, 12q, 20p, 20q 16q 
HCV-HCC - 5p 
Viral-HCC (HBV and HCC) 19q 1p, 4p, 4q, 5q, 9p, 17p 




Firstly, the presence of frequent chromosomal aberrations that were not 
associated with any etiology implied that there are common pathways underlying the 
development of HCC of both viral and non-viral etiologies. Genes located on these 
chromosomes are likely to play important roles in tumor progression. Indeed, several 
known oncogenes and tumor suppressors were located on these chromosomes. For 
instance, loss of deleted in liver cancer 1 (DLC1) (8p22) encoding for a Rho GTPase-
activating protein and insulin-like growth factor 2 receptor (IGF2R) (6q26), which 
acts to degrade the cell growth-promoting insulin-like growth factor 2, have been 
shown to be HCC-promoting and associated with poor prognosis235,251. Another 
candidate tumor suppressor gene related to DLC1, deleted in liver cancer 2 (DLC2) 
was located at 13q12.3. Besides, the well-known oncogene, v-myc myelocytomatosis 
viral oncogene homolog (MYC) is also found on 8q24.21.  
Secondly, the large number of chromosomal aberrations associated with both 
HBV-HCC and HCV-HCC indicated that the viruses shared common mechanisms in 
causing genetic damage that in turn conferred selective advantage for the viruses. As 
HBV and HCV are very different in their molecular biology and replication strategies 
(and hence also host-virus interactions), these chromosomal aberrations most likely 
arose due to non-specific virus-induced inflammation that in turn can cause 
generation of reactive oxygen and nitrogen species, thus inflicting DNA damage and 
genetic instability. Interestingly, most chemokine genes encoding for members of the 
C-X-C chemokine family are known to be clustered on chromosome 4q for which 
copy number loss was associated with the viral-HCCs. Although a causal relationship 
between inflammation and loss of 4q cannot be concluded, this does suggest a 
possible mechanism whereby virus-induced inflammation leads to preferential loss of 
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chemokine genes on 4q that aided immune evasion of the infected cell, allowing more 
genetic aberrations to accumulate.  
Thirdly, unlike HBV-HCC that was found to be associated with several 
aberrations, HCV-HCC was associated with only low frequency loss on 5p. This 
suggested that HCV likely cause genomic alterations mainly by inflammatory 
processes. The finding of chromosomal aberrations that were selectively only 
associated with HBV-HCC agreed with the known integration of HBV DNA into host 
genome leading to genomic instability, which is a mechanism specific to HBV. 
Indeed, a number of the HBV-associated chromosomal alterations highlighted in this 
meta-analysis contain sites where HBV DNA integration had reportedly occurred. For 
instance, HBV was repeatedly reported to integrate and cause amplification at the 
human telomerase reverse transcriptase gene (TERT) (5p15.33), a very important gene 
in tumorigenesis57-59,252 (see Section 1.2.6). Up-regulation of TERT is critical for 
telomere maintenance which in turn prevents replicative senescence, thus imparting 
immortality to the tumor cells. Evading senescence by abnormal regulation of TERT 
is thus a pathway towards malignancy in HBV-infected hepatocytes. Besides 5p15.33, 
there were also HBV integration sites at 20p12.3252 and 16p12.1252,253, where the 
minichromosome maintenance protein 8 gene (MCM8) (20p12.3) involved in DNA 
replication, and the intracellular Ca2+ signaling regulating gene, 
sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (SERCA1) (16p12.1), are 
located. An integration site at 12q13.12 housing the myeloid/lymphoid mixed lineage 
leukemia gene (MLL2) leading to amplification is likely less common as gain on 12q 
was less common than the other HBV-associated aberrations254. Nonetheless, it 
implied an involvement of the β-catenin pathway in HBV-HCC since MLL2 is a 
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known down-stream effector of β-catenin255. In addition to HBV DNA integration, 
HBV also produces the oncogenic protein, HBx, which has been demonstrated to up-
regulate expression of pro-inflammatory cytokine, TNF-α, in hepatocytes256,257. It also 
enhanced the DNA-binding activity of NFκB, which is a key transcription factor for 
expression of inflammatory cytokines such as interleukin 6258. It is likely that the 
HBV-associated aberrations also arose partly due to genome instability caused by 
HBx-mediated inflammation. 
 Lastly, the higher prevalence of chromosomal imbalances such as gain of 7pq 
and loss of 14q in both HBV-HCCs and non-viral HCCs suggested there might be 
common pathway(s) altered in HBV-induced HCC and non-viral HCCs that were 





6.2 Chromosomal instability and immune evasion are important in HCC 
development 
 
6.2.1 Loss of 8p precedes chromosomal instability 
From the array CGH analysis, 8p was found to be the chromosome most 
frequently lost in HCC tumors. The importance of 8p loss was again highlighted in 
the integrative analysis of HCC transcriptome and genome, reported in Chapter 4, 
which aimed to find genes, whose frequent alteration in expression, was attributable 
to copy number change. It was observed that many of the genes correspondingly 
down-regulated in expression and copy number were located on 8p. Statistical testing 
showed that this was not due to higher frequency of loss on 8p, implying that genes 
on 8p that had loss of copy number were more likely to be down-regulated in 
expression (see Section 4.3). This finding, coupled with the high frequency loss of 8p 
in HCC tumors regardless of etiology (see Chapter 3 and Section 6.1), suggest that 
loss of 8p is very important in HCC development. Indeed, several cytogenetic 
studies41,161,259,260 had documented loss of 8p in pre-neoplastic liver lesions (cirrhotic 
tissues adjacent to HCC and dysplastic lesions) that generally presented few 
chromosomal anomalies. Although the present study had not studied dysplastic 
lesions, it was observed that two well-differentiated fibrotic tumors (tumors no.81 and 
98) also demonstrated loss of 8p as one of the few aberrations detected (see Chapter 3, 
Figure 3.1). Loss of 8p is thus an early event in HCC development.  
Suggestion of how loss of 8p may contribute to tumor development was 
provided by a study reporting that loss of 8p was correlated with increasing 
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chromosomal instability261. Interestingly, one of the genes on 8p that displayed 
positive correlation between copy number change and expression in the integrative 
analysis was the DLC1 gene. This gene was located within the minimal region of 
copy number loss on 8p, 8p23.1-21.3, which was delineated by the array CGH 
analysis in this study (see Section 3.1, Table 3.4), and was also found to be commonly 
down-regulated in copy number and expression in the HCC tumors and cell lines (see 
Section 5.4). DLC1 encodes for a Rho GTPase-activating protein with strong activity 
towards all three forms of Rho GTPases (RhoA, RhoB and RhoC)262. A role for Rho 
GTPase in spindle assembly has been described, where inhibition of the Rho GTPase 
effector protein, Rho kinase (ROCK), resulted in formation of defective spindles263. 
This suggests that DLC1 is also likely to be involved in spindle assembly, though this 
has not yet been reported. If DLC1 has a role in ensuring proper spindle assembly, a 
loss of its expression will then lead to chromosomal instability.  
6.2.2 Spindle-assembly checkpoint exhibited de-regulation at both transcription 
and DNA levels 
 An implication of chromosomal instability in HCC development was again 
indicated by ontology analysis of genes aberrantly expressed in HCC, where genes 
functioning in spindle-assembly checkpoint were enriched in the set of over-expressed 
genes. The spindle-assembly checkpoint is a well-known cellular mechanism that 
protects cells from chromosomal instability by ensuring the proper attachment of 
sister chromatids to spindle microtubules prior to the onset of anaphase in mitosis. 
Improper attachment results in unequal pulling of the sister chromatids and hence 
unequal distribution of genetic material to the daughter cells. Hence, a non-functional 
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spindle-assembly checkpoint will lead to aneuploidy. Notably, a number of genes in 
the spindle-assembly checkpoint are haploinsufficient264-266 i.e. the checkpoint is 
sensitive to gene dosage and loss of one component will compromise but not 
eliminate its functionality. Furthermore, both loss of expression and overexpression of 
spindle-assembly checkpoint components can disrupt its function. An appropriate 
balanced expression of checkpoint components thus appeared essential for checkpoint 
function. Overexpression of the spindle-assembly checkpoint gene, MAD2, for 
instance, was known to disrupt the checkpoint function267.  
In the transcriptome analysis of HCC and also the subsequent integrative 
analysis with array CGH data reported in Chapter 4, over-expression of MAD2 (also 
known as MAD2L1), and several other checkpoint genes such as BUB1B and NEK2 
were found. Furthermore, NEK2 and another related gene, NEK7 also exhibited 
frequent copy number changes in HCC. The overexpression of so many checkpoint 
genes implied that the checkpoint is most likely dysfunctional, given the reported 
negative effects of MAD2 overexpression in mice mentioned above. In agreement 
with these findings, BUB1B was previously reported to be overexpressed in HCC and 
associated with poor prognosis268. Overall, the data suggested that the spindle-
assembly checkpoint was dysfunctional in HCC and this contributed to karyotypic 
instability in HCC. Since chromosomal instability is involved in HCC development, 






6.2.3 HCC exhibit immune evasion 
 Evasion from immune destruction, together with reprogramming of energy 
metabolism, are emerging hallmarks of cancer entering the ranks of the other six well-
known hallmarks of cancer put forward by Hanahan and Weinberg, which entails the 
acquirement of biological capabilities such as replicative immortality and resistance to 
cell death269. Microarray analysis of the transcriptome of 37 HCC tumors in this study 
indicated that hepatoma cells also exhibit features of this emerging hallmark, 
demonstrated by the down-regulated expression of many chemokines. Chemokines 
constitute a superfamily of pro-inflammatory cytokines that function primarily as 
chemo-attractants and activators of specific subsets of leukocytes. Expression of 
chemokines can thus elicit anti-tumor responses and reduced expression of these 
chemo-attractants by HCC cells constitutes a mechanism by which HCC avoids these 
responses. Evidence for this has also been provided by several other studies. The 
expression of CCL2, CCL5 and CXCL10, which were shown by microarray in this 
study to be down-regulated by at least two-fold in HCC, was found in a previous 
study to be associated with tumor infiltration by Th1 cells, CD8+ T-cells and natural 
killer cells270. Furthermore, expression levels of these chemokines were found to be 
significantly lower in advanced HCC tumors than Stage I tumors, suggesting a 
selective pressure that favors survival of tumor cells expressing lower levels of these 
chemokines. Similarly, CXCL12 (also known as SDF-1), down-expressed by more 
than two-fold in nearly 60% of tumors in this study, was reported to induce CD4+ and 
CD8+ T-cell dependent anti-tumor responses in several studies using mouse models271-
273. Expression of the chemokine receptor for CXCL12, CXCR4, was however only 
marginally down-regulated in the tumors. This might be due to higher expression of 
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CXCR4 in the non-tumorous hepatocytes as shown by immunohistochemistry in a 
study274. 
 Although anti-tumor activity has been described for chemokines like CXCL12, 
there is also evidence arguing for tumor-promoting effects. For instance, CXCL12 
and CXCR4 have been associated with lymph node and bone metastasis of HCC and 
poor patient survival275,276, and there were also reports of their increased expression in 
hepatoma cells, particularly in cells that had invaded the portal vein277, contradicting 
the microarray observations of this study. Direct evidence for a metastatic role was 
provided by the observation that recombinant CXCL12 could induce migration of a 
metastatic HCC cell line278. It is likely that certain chemokines like CXCL12 may 
have opposing effects on HCC at different stages of development, painting the 
following scenario where pre-cancerous and cancerous hepatocytes that express low 
levels of CCL2, CCL5, CXCL10 and CXCL12 are able to escape immune elimination 
and selected for proliferation. As the tumor acquires more tumor-related biological 
capabilities, expression of CXCL12 is then up-regulated to favor metastasis of the 
hepatoma cell. Another chemokine, CCL20, which is potent chemo-attractant for 
dendritic cells, was markedly over-expressed in HCC tumors (see Chapter 4, Figure 
4.3). Levels of its receptor, CCR6, was however relatively unchanged. Like CXCL12, 
CCL20 exhibited anti-tumor activity through recruitment of dendritic cells to murine 
tumors279, as well as tumor-promoting activity in increasing the growth and 
invasiveness of cancer cells280,281. No characterization on the effect of CCL20 on HCC 
invasiveness has been reported, but the microarray data suggested that the pro-tumor 




6.2.4 Possible role of nuclear receptors in immune evasion 
 Interestingly, the integrative analysis of copy number and expression profile of 
HCC tumors in this study revealed that a large portion of the transcription factors or 
co-regulators found to be frequently perturbed were members of the nuclear receptor 
family or their co-activators and repressors. Nuclear receptors constitute a large 
family of ligand-activated transcription factors whose ligands mainly consisted of 
natural compounds such as vitamins, cholesterol, fatty acids, bile acids and steroid 
hormones, and synthetic exogenous molecules such as drugs and toxins (Table 6.2). 
Since the liver is the key organ regulating metabolism of endogenous metabolites and 
compounds (e.g. lipid metabolism, bile acid homeostasis), as well as xenobiotic 
metabolism, nuclear receptors therefore play important roles in liver function. Studies 
in the past two decades are showing that besides hepatic metabolic processes, nuclear 
receptors are also crucial regulators in inflammatory processes, acting mainly to 
repress the expression of pro-inflammatory genes. Since several members of the 
nuclear receptor family and genes regulating their activity were altered at copy 
number and transcription level in HCC, and immune evasion by down-regulation of 
chemokines was indicated by ontology analysis of the HCC transcriptome, one can 







Table 6.2 List of nuclear receptors with known ligands and their regulation by SHP 
Nuclear receptor Natural ligand Effect of Interaction with SHP (NR0B2)* 
   
Androgen receptor (AR) Androgens Repression282 
Estrogen receptor (ERα/β)ǂ Estrogens Repression283,284 
Glucocorticoid receptor (GR) Glucocorticoids Repression285 
Mineralocorticoid receptor (MR) Mineralocorticoids - 
Progesterone receptor (PR) Progesterone - 
Retinoic acid receptor (RARα/β/γ) Retinoic acid Repression222 
Thyroid receptor (TRα/β) Thyroid hormones Repression 222 
Vitamin D receptor (VDR) Vitamin D, bile acids - 
Peroxisomal proliferator-activated  
receptor (PPARα/β/γ) Fatty acids 
Activation (PPARγ)286 
Activation/Repression (PPARα)287 
Farnesoid X receptor (FXR)ǂ Bile acids - 
Liver X receptor (LXRα/β) Oxysterols Repression (LXRα)288 
Pregnane X receptor (PXR) Xenobiotics  Repression289 
Retinoid X receptor (RXRα/β/γ) 9-cis retinoic acid Repression290 
RAR-related orphan receptors (RORα/β/γ) Retinoic acid, cholesterol - 
Constitutive androstane receptor (CAR) Xenobiotics, androstane Repression291 
Liver related homologue-1 (LRH1)ǂ Phospholipids  Repression223,292 
* Nuclear receptors not reported to interact with SHP are indicated by ‘-’ 
ǂ Induces SHP expression.293-295  
 
Most of the work on elucidating control of inflammation by nuclear receptors 
had been done in macrophages and T-cells296-300. These studies showed that inhibition 
of nuclear factor kappa B (NFκB) signaling was one of the main mechanisms by 
which nuclear receptors repress the expression of pro-inflammatory genes. In addition, 
there was also evidence for anti-inflammatory response by nuclear receptors in non-
immune cells, including hepatocytes233,298,301,302. Farnesoid X receptor (FXR), for 
instance, was demonstrated to inhibit binding of nuclear factor kappa B (NFκB) to 
target gene promoters in HepG2 HCC cell line and mouse primary hepatocytes, thus 
bringing about reduced expression of NFκB-transactivated inflammatory mediators 
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such as inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα) 
and cyclooxygenase 2 (COX-2)298. Similarly, the orphan nuclear receptor, RORα, also 
negatively regulated the expression of pro-inflammatory IL-6, IL-8 and COX-2 in 
primary smooth muscle cells via inhibition of NFκB signaling301. However, instead of 
interfering with DNA-binding, RORα down-regulates NFκB activity by inducing 
expression of its inhibitor, IκBα. RORα was one of the 44 genes identified in the 
integrative analysis of this study whose frequent under-expression in HCC tumors 
was correlated to frequent copy number change. From these studies on immune and 
non-immune cells, it is clear that NFκB is an important mediator of trans-repression 
by nuclear receptors on pro-inflammatory genes.  
Although there are currently no studies showing that nuclear receptors repress 
chemokine expression in hepatocytes, this mechanism is highly plausible since NFκB 
is a known transcriptional factor for chemokines such as CCL2, CCL5, CCL20 and 
CXCL10303-308. In support of this hypothesis, bone marrow-derived macrophages from 
PPARα knockout mice showed increased expression of NFκB, and expressed higher 
levels of several inflammatory genes, including CCL2300. Silencing of nuclear 
receptor, pregnane X receptor (PXR), also reportedly led to decreased expression 
CXCL10 (IP-10) and increased expression of CCL5 (RANTES) in intestinal epithelial 
cells233. Importantly, these effects of PXR were manifested in the absence of a pro-
inflammatory stimulus. Similar observations were also made on the repression of IL-6 
and IL-8 production by RORα mentioned previously. This implied that the nuclear 
receptors’ regulation on pro-inflammatory mediators and chemokines expression can 
be exerted at the basal level. Furthermore, as the liver is the key organ for 
carbohydrate, protein, lipids and vitamin metabolism, as well as hormonal 
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homeostasis, many of the ligands (e.g. bile acids) for nuclear receptors are 
synthesized in the liver. Luciferase reporter experiments in HepG2 cells to examine 
FXR’s suppression of NFκB activity, for instance, detected basal level of inhibition 
without the addition of the exogenous ligand for FXR, presumably due to endogenous 
synthesis of bile acids by the HepG2 cells298. Hence, this implied that there is a basal 
level of activation for the nuclear receptors in the hepatocytes, which in turn 
maintained a basal repression on the synthesis of pro-inflammatory cytokines, 
including chemokines. In cancerous hepatocytes, the endogenous levels of 
chemokines were further down-regulated to escape immune detection. 
Overall, the findings from published reports and the observed alteration in 
expression of nuclear receptors and chemokines in the microarray suggest that there is 
a link between nuclear receptors and regulation of chemokines and other cytokines, 
mediated through interaction between nuclear receptors and NFκB (Figure 6.2). The 
nature of the interaction with NFκB however can vary. Nuclear receptors can interfere 
with NFκB signaling by reducing its DNA binding activity298 or through 
transcriptional control of its regulatory proteins such as IκBα301,302,309. A nuclear 
receptor-independent regulation of IκBα transcription by nuclear receptor co-
activators (NCOA1, NCOA2, and NCOA3) and co-repressor complex (NCoR) was 
also documented310. Besides, direct transcriptional regulation of NFκB by nuclear 
receptors has also been reported232. Notably, a number of nuclear factor co-activators 
(e.g. NCOA2) and the nuclear factor co-repressor, NCOR1, were amongst the 
differentially expressed genes frequently up-regulated and down-regulated 
respectively in copy number and expression. A member of the nuclear receptor family, 
small heterodimer partner (NR0B2 or SHP), that lacks DNA binding domain and 
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functions mainly as repressor of other nuclear receptors was also down in expression 
by at least two-fold in one-third of the tumors. These alterations implied a general 








             
 
Figure 6.2 Postulated mechanisms for nuclear receptor-mediated repression of 
chemokine synthesis. The schematic diagram shows the possible molecular interactions 
facilitating nuclear receptors’ regulation of chemokine expression. Genes whose average 
microarray expression across 37 tumors in this study was up-regulated by ≥ 1.5 fold were 
outlined in red or was down-regulated by ≥ 1.5 fold were outlined in green. The nuclear 
receptors depicted had been reported to repress expression of pro-inflammatory mediators 
(e.g. IL-6, TNFα) in immune and non-immune cells, mainly via inhibition of NFκB, which is 
also known to be the transcription activator of many chemokines. Nuclear receptors can 
inhibit NFκB signaling in multiple ways, including blocking NFκB binding to target 
promoters (e.g. FXR) and transactivation of IκBα expression (e.g. RORα). IκBα prevents 
nuclear translocation of NFκB, thus down-regulating NFκB-mediated expression of target 
genes i.e. chemokines. Transcriptional activity of ligand-activated nuclear receptors is 
regulated by co-activators (e.g. NCOA2), co-repressors (e.g. NCOR1) and another nuclear 
receptor, SHP. Direct interaction between SHP, NCOA2 and NCOR1 with NFκB has also 
been reported (see main text for references).  
  



































6.3 Comparing genetic landscape in cell lines with tumors  
 In the literature, there were few papers dedicated to characterization of genetic 
changes in HCC cell lines using the CGH method. Published literature included one 
study performed using conventional CGH311 and complemented by microarray 
expression analysis that was reported in a follow-up publication312, and five array 
CGH studies, including a study analyzing multiple cell lines from HCC and other 
cancers313-317. All these studies were poised to understand chromosomal changes in the 
tumors using cell lines, based on the assumption cell lines are genetically similar to 
the tumors from which they were cultured. However, with in vitro culture conditions 
that are different from the in vivo environment, particularly with respect to selective 
pressure from the immune system and neighboring cell types, and the continuous 
passaging of cells, this assumption may not hold true. In this study, comparison of 
array CGH findings from HCC cell lines and tumors revealed that HCC cell lines 
displayed chromosomal aberrations that were different from the tumors. Within cell 
lines, the degree of genetic similarity to HCC tumors also varied, with Hep3B bearing 
the closest resemblance and HepG2 exhibiting a distinctly different gene copy number 
landscape. This is believed to be the first study showing distinctly different copy 
number changes between HCC tumors and cell lines, using batch-analyzed data 
yielded from copy number profiling with high-resolution array CGH platform. 
 The HCC cell lines analyzed in this study had demonstrated frequent copy 
number loss on 8q and gain on 17p, in contrast to the tumors that presented mostly 
gain of the entire 8q and loss on 17p. In addition, 16q in cell lines exhibited 
intermittent regions of copy number loss and gain that was unlike the loss of entire 
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16q occurring in most tumors. Cell lines also exhibited greater chromosomal 
instability as evidenced by the higher frequency of copy number gain on 20q and copy 
number loss on 9p and 18q. Similar findings were also echoed in a CGH study311 by 
Zimonjic et al on 18 HCC cell lines, including nine of the cell lines used in this study. 
In that study, 50% of the cell lines reported loss on 8q, and 15 and 13 cell lines 
presented gain on 16q and 17p respectively. Strikingly, nearly all of the cell lines that 
had copy number change on 9p and 18q (16 and 15 cell lines respectively) reported 
losses but not gains, and similarly for gain on 20q. This was highly concordant with 
the pattern of chromosomal alterations in cell lines reported in the present study. In 
another array CGH study316 comparing chromosomal aberrations in five HCC cell 
lines (including HepG2, Hep3B and Huh-7) with cholangiolar carcinoma cell lines, 
17p was similarly found to report copy number gain at 17p13 and 17p11 in all HCC 
cell lines. Interestingly, although large regions of copy number loss were reported on 
8q by all HCC cell lines, in agreement with the frequent 8q loss in the present study, 
the cell lines reporting 8q loss in the present study did not include Hep3B, HepG2 and 
Huh-7 (see Chapter 5, Figure 5.3). The reason for this discrepancy is not clear. 
Selective growth and differential adaptation of different clonal populations of cells in 
the cell lines due to variations in culture conditions in different labs might be a reason. 
Overall, the CGH results on cell lines from published studies agree with this study, 
providing support that the observed differences in chromosomal imbalance between 
HCC cell lines and tumors were true.  
 In the present study, Hep3B was demonstrated to be genetically most similar 
to HCC tumors, presenting the highest correlation between copy number changes in 
the cell line and the tumors. On the other hand, HepG2 was determined to be the least 
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representative of copy number changes in HCC tumors. The finding that HepG2 was 
very dissimilar to HCC tumors with respect to copy number changes lends support to 
the analysis. This is because HepG2 was known to be derived from hepatoblastomas 
which arose from immature liver precursor cells, and pure hepatoblastomas usually 
contain both fetal and embryonal hepatocytes. Hepatoblastomas are hence different 
from HCC which is a cancer of adult hepatocytes. Cytogenetically, the two types of 
liver cancer are different too. Hepatoblastomas generally reported a limited number of 
chromosomal abnormalities, with trisomies of chromosome 2 and 20 being the most 
prominent and frequent aberrations318-320. This is unlike HCCs that usually reported a 
multitude of chromosomal alterations. This relatively lower occurrence of 
chromosomal changes in hepatoblastomas was also reflected in the array CGH profile 
of HepG2 (Figure 5.1), resulting in a poor correlation of copy number changes in 
HepG2 with the changes in HCC tumors. 
The degree of correlation to tumor copy number changes reported here in this 
study is an indication of how tumor-like a particular cell line is. In support of this, in a 
study that compared the tumorigenicity of four HCC cell lines, SK-HEP-1, 
PLC/PRF/5, Mahlavu and HepG2 in athymic mice or rats, it was found that HepG2 
was the least tumorigenic, being unable to form tumors when injected into athymic 
rats and forming small tumors only when large numbers of cells were injected into 
irradiated athyic mice249. Mahlavu was weakly tumorigenic, rarely forming tumors in 
athymic rats that often regressed. SK-HEP-1 was generally more tumorigenic then 
PLC/PRF/5 cells in irradiated nude mice and rats, forming tumors in 83% of mice and 
80% of rats, while PLC/PRF/5 formed tumors in 33% of mice and 100% of rats when 
comparable numbers of cells from the two cell lines were injected. This degree of 
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tumorigenicity was in agreement with the degree of correlation of the cell lines to 
tumor copy number changes reported in the present study.  
Hence, the methodology adopted in this study has reliably characterized the 
genetic similarity of individual cell lines to the tumors. This approach, entailing the 
performance of array CGH for tumors and cell lines on the same platform, followed 
by normalization of the data for cell lines to non-tumorous patient samples and 
correlating the copy number profiles for the most frequently altered chromosomes to 
that of tumors, is thus a feasible method for assessing the representativeness of tumor 
cell lines to the tumors that they are trying to model in vitro. Applying this approach 
to the analysis of HCC cell lines, for instance, has shown that Hep3B is a reasonably 




6.4 Limitations of study 
 Despite having achieved deeper insights into the genomic and transcriptomic 
events occurring in HCC via the use of high-resolution arrays coupled with integrated 
analysis, there are several limitations of the current study. 
 CGH and transcriptome arrays such as those used in this study are spatial 
snapshots of the genetic and expression changes in the tumors, providing an average 
of the changes in all the cells within a tumor. Consequently, cell-to-cell variations are 
masked and the resultant profile might not be representative of any single cell. This 
has implications on the understanding of cancer cell biology, which is generally 
marked by widespread tumor cell heterogeneity. Phosphoprotein-driven signaling 
networks, for instance, had been demonstrated to manifest different transduction 
patterns in cell subsets within each individual patient cancer sample321. Characterizing 
distinct subsets of cancer cells within each patient tumor is crucial for designing more 
effective anti-cancer therapeutic strategies. Targeted inactivation of molecular 
pathways in cancer cell subsets that render therapeutic resistance to a tumor might 
potentially be sufficient to convert a therapy-resistant tumor to a therapy-responsive 
tumor, thereby improving therapeutic efficacy. To address this issue of tumor 
heterogeneity, CGH arrays have been applied to the examination of single cells from 
lymphoblasts, fibroblasts and metastatic breast tumor322,323. Although there are few of 
these studies and they did not cluster the array CGH profiles from the tumor cells to 
uncover the genetic characteristics of cancer cell subsets, they did demonstrate the 
feasibility of high-resolution genome analysis of single cells. Single-cell array CGH, 
however, also has several technical difficulties. One such hurdle is the difficulty in 
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performing whole genome amplification of genomic DNA from single cells without 
sequence bias during the process of getting sufficient DNA for hybridization. Besides, 
the use of non-amplified DNA from a pool of normal cells as reference also 
potentially introduces genomic artifacts. The large amount of information generated 
from single-cell analysis also presents a challenge to bioinformatics and statistical 
handling of the data that requires the development of new algorithms and software 
packages. These same challenges are also faced by expression profiling of single cells. 
Besides providing just a spatial snapshot, the arrays are also temporal 
snapshots of the tumors at particular stages of development. Consequently, 
information on how the genetic or transcriptomic profile changes as the tumor 
progresses cannot be obtained. One way to approach this problem is to compare the 
profiles of tumor cells at different stages of development (e.g. pre-neoplastic, 
dysplastic and metastatic) from the same liver to the profile of normal liver cells. This 
approach necessitates the detailed histological examination of various parts of the 
tumor for the degree of differentiation, neo-angiogenesis and metastatic spread so as 
to enable accurate identification of the stage of local tumor development, which in 
turn influences the interpretation of the comparison. Nevertheless, even with accurate 
histology, the conclusions obtained may not be easily generalized. This is attributed to 
the stochastic nature of genetic and transcriptomic alterations. Hence, dysplastic cells 
from one location of a tumor might not accumulate the same changes in the same 
order to yield the observed profile of tumor cells at a more advanced stage of 
development from another location of the same tumor, even if these are cells from 
adjacent locations or in close proximity. This adds to the challenge of deriving a 
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model for progression of genetic or transcriptomic changes in tumors, particularly in 
highly heterogeneous tumors such as HCC where there might be more than one model. 
Accurate histological identification of normal tissues is also crucial as it 
determines the sensitivity of detecting early genomic or expression changes in 
tumorigenesis. Complementation with immunohistochemistry for early markers of 
cancer will aid in the accurate identification of normal tissues. In the current study, 
non-tumorous tissues adjacent to the HCCs were used for normalization. While 
detailed histological examination had been performed to ascertain a normal phenotype, 
there is still the likelihood that these tissues had already possessed some early 
genomic or expression anomalies. Normalization to these tissues (i.e. T/NT ratio) 
might possibly miss the detection of early critical genetic or transcriptomic event(s) in 
hepatocarcinogenesis. One solution is to purchase DNA (or RNA) of normal liver 
tissues from commercial companies for use as controls for the analyses. Alternatively, 
immunohistochemistry staining for early HCC tissue markers (e.g. heat shock protein 
70 (HSP70)324, cyclase-associated protein 2 (CAP2)325) can be performed to help 
identify normal liver tissues, though very few of such markers are currently known. 
Lastly, it has to be acknowledged that the sample size of 15 pairs of HCC 
tumors and non-tumors for the array CGH study was relatively small. The strengths of 
these samples are their homogeneity in terms of ethnicity and viral infection status as 
samples were only taken from Chinese HBV+HCV- patients. Nonetheless, a small 
sample size limited the power of detection for rare copy number aberrations. 
Additionally, it also undermined the statistical strength for implementing analytical 
methods such as GISTIC (Genomic Identification of Significant Targets in Cancer)326, 
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DiNAMIC (Discovering Copy Number Aberrations Manifested In Cancer)327 and KC-
SMART (Kernel Convolution: A Statistical Method For Aberrant Region 
deTection)328, which aim to identify recurrent CNAs that are statistically significant. 
These methods take into consideration three important parameters - the statistical 
strength across patients, the amplitude of hybridization signal for each patient and the 
spatial correlation across probes, in the computation of false discovery rates or 
family-wise error rates to control for false positives. Due to the small sample size in 
this study, these methodologies were not implemented in the analysis. The statistical 
significance of the identified recurrent regions of CNA was thus not assessed, raising 
the possibility that some of these regions might have arose due to chance. Increasing 
the sample size for the array CGH study will undoubtedly improve the sensitivity and 
specificity of the study. Future study will hence need to recruit more patient tumors 
that are of different histological grade and tumor stage so as to obtain sufficient 
statistical power, as well as to allow investigation of genetic aberrations during the 




6.5 Future directions and work 
 
6.5.1 The next phase in cancer genome exploration: next-generation sequencing 
Basic principles of next-generation sequencing 
 In recent years, a number of revolutionary high-throughput sequencing 
platforms, collectively known as next-generation sequencing (NGS), have been 
developed and applied to the sequencing of genomes in various fields of study such as 
evolution, virology and oncology. The difference between NGS technology and 
traditional Sanger sequencing primarily lies in the template preparation and the 
sequencing chemistry and format. Template preparation in the Sanger method entails 
partial digestion of the DNA that is to be sequenced into random fragments that are 
subsequently cloned into high-copy number plasmids (e.g. BAC) and transformed into 
Escherichia coli. Clonal expansion of the transformed bacteria results in amplification 
of the DNA fragments that are then isolated, purified and sequenced. The sequencing 
chemistry entails repeated cycles of template (plasmid) denaturation, primer annealing, 
and primer extension using primer that is complementary to known sequence flanking 
the inserted DNA fragment. The cycling is performed in the presence of a mixture of 
deoxynucleotides (dNTPs) and differentially labeled flourescent dideoxynucleotides 
(ddNTPs). The latter stochastically terminates each round of primer extension, giving 
rise to a mixture of end-labeled extension products of different sizes, where the label 
on the terminating ddNTP informs about the terminal nucleotide identity. Detection is 
by laser excitation of the single-stranded end-labeled extension products as they 
migrate through, separate and exit a capillary-based polymer gel, followed by four-
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color detection of the emission spectra from the fluorescent labels. Contrary to Sanger 
sequencing which has a largely standardized workflow, NGS platforms vary widely in 
their sequencing chemistry, imaging and data analysis. The concepts underlying these 
workflows, however, are largely similar and can be summarized into four steps – (1) 
Random fragmentation of DNA to generate a sequencing library (2) In vitro ligation 
of common adaptor sequences to the fragmented DNA segments (3) PCR 
amplification  of the different DNA fragments using a universal primer that is 
complementary to the adaptor sequence, followed by separation of the different sets 
of amplified DNA fragments to generate an array of millions of spatially segregated 
and immobilized PCR colonies or ‘polonies’ (4) Sequencing by alternating cycles of 
enzyme-driven biochemistry and imaging-based data acquisition. The in vitro clonal 
expansion of the sequencing library in steps 2-3 significantly increases NGS 
workflow efficiency compared to E. coli transformation and colony picking in the 
Sanger method that greatly restricted the parallelism of conventional sequencing. This 
parallelism is further increased by the array format of NGS that allows simultaneous 
imaging and data acquisition from multiple polonies, thus generating thousands to 
millions of sequences or ‘reads’ at once. In contrast, current high-throughput Sanger 
sequencing only allows simultaneous electrophoresis and detection in a maximum of 
384 capillaries. Consequently, NGS platforms are increasingly used in whole genome 
sequencing studies that require high throughput sequencing. 
 A problem associated with NGS platforms is the relatively short read lengths 
compared to Sanger sequencing. While Sanger biochemistry can achieve read lengths 
up to ~1000 bp, NGS reads typically range between 50 ─ 150 bp. Read length is a 
critical determinant of the accuracy of sequence assembly in whole genome shotgun 
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sequencing, where several rounds of DNA fragmentation and sequencing are 
performed and the overlapping ends of the resultant reads are used to assemble the 
reads into a continuous sequence. Longer reads in the Sanger method allow for more 
extensive overlaps between the reads and consequently fewer errors in assembly. In 
complex genomes with a great abundance of repetitive DNA elements (e.g. human 
Alu elements), short reads are particularly disadvantageous as short reads covering 
repetitive elements coming from vastly different locations in the genome are very 
likely to be similar and wrongly interpreted as overlapping reads covering a particular 
genome location. NGS platforms have tackled this problem by performing more 
rounds of fragmentation and sequencing to generate more overlapping reads. This is a 
practical approach owing to the less time-consuming and high throughput capacities 
of NGS compared to Sanger sequencing. Coverage, which refers to the average 
number of reads representing a given nucleotide in the reconstructed sequence, is 
therefore high for NGS platforms, thereby significantly improving the error rate in 
base calling and sequence assembly. Additionally, advances in the average read 
length achievable with NGS sequencing chemistries are also continually made, which 
is important as higher coverage only partially addresses the problem of sequencing 
repetitive DNA elements. The recently upgraded Roche 454 FLX+ System, for 
instance, can generate an average read length of ~700 bp and read up to ~1000 bp, 
which is comparable to the Sanger method329. 
NGS in cancer genome studies 
 In the past 5 – 10 years, the use of NGS in cancer genome studies has become 
an emerging trend. An attractive advantage of NGS is the amount and various types of 
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information that it can generate from each tumor sample, being able to simultaneously 
detect for single nucleotide mutations, insertions, deletions, epigenetic alterations 
such as DNA methylation, as well as chromosomal rearrangements (balanced and 
unbalanced) and changes in gene copy number. In contrast, array CGH despite 
providing much higher resolution and throughput than other cytogenetic techniques, is 
limited to detecting only copy number alterations (CNAs) and unbalanced 
chromosomal rearrangements. Furthermore, in the scenario of HBV-infected HCC 
where HBV DNA integration into the host genome is common, NGS has the added 
advantage of simultaneous detection and characterization of viral DNA integration 
sites.  
The different nature of NGS data from array CGH output means that new 
bioinformatics workflows are needed. A popular bioinformatics approach to CNA 
detection using NGS is the read count (or depth of coverage) approach. This approach 
assumes that the sequencing process is uniform and the number of reads that align to a 
genomic position is therefore proportional to the copy number at that position. 
Interestingly, the typical workflow for algorithms that are designed based on this 
approach is conceptually derived from array CGH analysis in which data preparation, 
normalization, identification of CNA regions and copy number estimation are 
performed sequentially. CNV-seq is one such analysis method330 that is well-suited for 
cancer genome studies as it analyzes the read count ratios between two individuals 
(e.g. a tumor and its adjacent non-tumor tissue). In the general workflow, read count 
data is prepared by dividing the genome into bins (windows) of a fixed size (i.e. base 
pairs), followed by counting the number of reads inside each bin. For this step, CNV-
seq adopts a sliding window method, where the optimal window size is calculated 
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according to a preset value for significance level, p, and CNA detection threshold, r. 
In the context of CNA detection in tumor, the reads in each sliding window are 
counted for two target sets of NGS reads from a tumor and a normal sample 
respectively and a read count ratio is obtained. The observed read count ratio, z, is 
used in the computation of a Gaussian t-statistic, from which significance can be 
assessed by the corresponding p-value. Copy number is estimated as a predicted ratio, 
r, which is derived after adjusting z by the ratio of the total number of reads in the two 
target genomes. Besides CNV-seq, there are other analysis workflows that identify 
CNA regions using segmentation algorithms331-335 (e.g. circular binary segmentation 
algorithm336) that was developed for array CGH data to demarcate the read count data 
into segments, each bearing the same DNA copy number. Segments with copy 
number exceeding a pre-defined threshold are determined to be aberrant. 
Whole genome sequencing (WGS) using NGS platforms has been applied to 
the study of several cancer genomes. These included acute myeloid leukemia 
(AML)337,338, acute promyelocytic leukemia (APL)339, lung cancer340, breast cancer341-
343, colorectal cancer344 and melanoma345, though most of these studies were performed 
on only one or two patient tumors. A large number of novel somatic mutations were 
detected in these studies, some of which were recurrently detected such as the R132 
mutation in isocitrate dehydrogenase 1 gene in AML338. Novel chromosomal 
rearrangements that resulted in the formation of fusion genes (e.g. VTI1A-TCF7L2 in 
colorectal cancer344) or chromosomal amplification or deletion were also discovered. 
Chromosomal deletions encompassing the CTNNA1 gene, for instance, were 
recurrently detected in the primary tumor, brain metastasis and a xenograft of the 
primary tumor of an African-American patient diagnosed with breast cancer343.  
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The first whole genome sequencing study using the NGS platform on HCC 
was performed in 2011 on the primary tumor and normal lymphocytes of a Japanese 
male diagnosed with HCV-HCC346. This study used 50-bp paired-end reads on the 
Illumina GAIIx sequencer and achieved 35.9x coverage and 28.1x coverage of the 
tumor and reference lymphocyte genomes respectively. More than 11,000 tumor-
enriched somatic mutations were discovered, including mutations of well-known 
HCC tumor suppressor genes such as AXIN1. With respect to chromosomal 
rearrangements, interstitial deletion at 10q22, tandem duplication at 11q13, intra-
chromosomal inversions at Xq25 and 11q12, as well as prominent structural 
aberrations clustered at 11q12.2-13.4 that resulted in a complex pattern of 
chromosomal gain and loss were detected. Following this study, two other WGS 
studies on recurrent tumor from a female HBV-HCC patient347, and 27 tumors from a 
mixed collection of HBV-HCCs, HCV-HCCs and NBNC-HCCs59, were published in 
2011 and 2012 respectively. The 2011 study, which had 20x coverage of the tumor 
genome, identified 19 chromosomal indels and three copy number variant regions. 
The study also identified a large (> 1 Mb) chromosomal deletion on 5q (Chr5: 40 – 
170 Mb), which concurred with the finding in this current array CGH study where 
copy number loss was detected at a smaller region within that locus at 5q14.1-14.3 
(Chr5: 79.65 – 91.36 Mb). The WGS study further identified this deletion to result in 
the fusion of two genes whose introns harbored the breakpoints. These observations 
suggested an impact of 5q loss on HBV-HCC development that remained important in 
the recurrent tumor. Read depth analysis in the 2012 WGS study (average of 39.8x 
coverage) by Fujimoto et al similarly identified an average of 20.8 chromosomal 
rearrangements per tumor, with an exceedingly larger number of 294 deleted regions 
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compared to only 20 amplified regions. Taking a different path from the 
aforementioned studies, a recent publication surveyed the patterns of HBV DNA 
integration into the tumor genome by massive parallel sequencing of 81 HBV-positive 
and 7 HBV-negative HCCs and their adjacent normal tissues and obtained detailed 
characterization of HBV integration breakpoints on both the HBV and tumor 
genomes348. Notable results include the finding that 40% of HBV breakpoints 
occurred in a 1,800-bp region encompassing the HBV enhancer I, X gene and core 
gene and identification of recurrent integration sites at the human TERT, MLL4, 
CCNE1, SENP5, ROCK1 and FN1 genes. 
Besides these studies, there are very few other NGS reports on HCC. The 
WGS study by Fujimoto et al was one of three sequencing projects on HCC that was 
initiated by the International Cancer Genome Consortium (ICGC) as part of an 
international effort to generate comprehensive open-access catalogues of genomic 
abnormalities in 50 different types of cancer. Another of the ICGC sequencing 
projects was undertaken by collaborative groups of researchers within France who 
published their findings in the same year as their Japanese counterparts. Unlike the 
latter, the France group analyzed whole exome sequences, instead of whole genome 
sequences, of 24 HCC tumors and their adjacent non-tumors349. Prior to this, another 
whole exome sequencing study performed by Li et al on ten HCV-HCCs was also 
published350. Unlike WGS studies, these studies that selectively sequenced the 
genome’s coding regions were unable to identify chromosomal structural variants. 
Nevertheless, they provided useful information on somatic gene mutations that likely 
impact gene function. Interestingly, both studies highlighted chromatin regulators as 
potential important players in HCC development. Somatic mutations in ARID1A, 
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ADRID1B, ARID2, MLL and MLL3 that encode for chromatin regulators were 
identified by both studies, of which mutation in ARID1A was never reported in HCC 
before, thus demonstrating the value of the high sensitivity of NGS platforms. 
Challenges in NGS 
The high sequence throughput of NGS, however, presents a challenge to its 
data storage and management as enormous quantities of data are generated and high-
level computing power is thus necessary for data analysis. The Illumina GAIIx 
Sequencing System, for instance, generates about 2.8 terabyte (TB) of data in Tiff 
image files per sequencing run when using single-end reads. The SOLiD (Sequencing 
by Oligonucleotide Ligation and Detection) System from Applied Biosystems also 
produces a similar amount of raw image data. While the Roche 454 FLX Titanium 
System produces much lesser data of approximately 0.03 TB per run, its sequence 
yield of about 0.5 Gb is also 50-fold lower than the Illumina GAIIx351. The amount of 
data remains formidably large even after image processing, base calling and sequence 
assembly, reaching ~ 300 GB of uncompressed data for the GAIIx and SOLiD 
platforms. For large-scale sequencing projects such as the 1000 Genomes project 
(www.1000genomes.org) that aims to detect most of the sequence variants with 
population frequency ≥ 1% via a sequencing depth of at least 4x coverage, such NGS 
system specifications will imply generation of ~ 0.7 – 1.5 TB of raw image data to be 
archived for future analysis and ~ 0.5 TB of assembled sequence data for storage in 
flat files or databases for every human haploid genome (~ 3.2 Gb) that is sequenced. 
With respect to the current study’s CNA analysis of 30 tumorous and non-tumorous 
liver tissues and assuming sequencing depth of 10x coverage, ~ 50 – 120 TB of 
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storage space for captured images would be needed if the samples were sequenced in 
one batch before post-image analysis. Minimally, 12 TB of storage space for the 
assembled sequence data would be required. Besides, additional storage space for 
post-processing analysis of data will also be needed. The complexity in management 
of this large quantity of data limits the usage of NGS as a common research tool by 
medium and small research groups and in day-to-day clinical diagnosis. 
Lastly, the cost of NGS platforms also needs to be taken into consideration. 
Currently, the Illumina and SOLiD technologies offer the cheapest sequencing in 
terms of reagent cost per Mb, with the Illumina HighSeq 2000 system costing $0.10 / 
Mb. The Roche 454 platforms are clearly inferior in this aspect, costing > $7 / 
Mb352,353. Hence, it would approximately cost $4000 to sequence a human genome 
with sequencing depth of 10x coverage. This is much more expensive than 
commercial CGH arrays that typically cost less than $1000 per sample. Researchers 
seeking to explore the cancer genome at the genome-wide level will have to 
contemplate about the type(s) and amount of information desired, and the practical 
cost of the experiment, particularly for large-scale studies involving tens to hundreds 
of tissue samples. A practical and balanced approach would be a hybrid workflow 
starting with relatively more affordable array CGH to identify regions of interest that 
are significantly altered in copy number in tumors, followed by targeted re-
sequencing of these regions to characterize the copy number variants to single 
nucleotide resolution. Targeted re-sequencing is also more suitable for clinical 
diagnostic applications with its lower cost per sample and shorter run time. 
Nevertheless, with advancements in technology and decreasing cost of sequencing, it 
will undoubtedly become increasingly affordable in the future to use NGS for large-
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scale cancer genome studies. The very recent unveiling of the Benchtop Ion Proton 
Sequencer from Life Technologies354 that can sequence the entire human genome for 
$1000 in a day suggests that this day is not very far away. 
6.5.2 Future work 
 The current array CGH study has identified several chromosomal regions that 
are altered at high frequencies in HCC. Further investigation will entail selective re-
sequencing of these regions on NGS platforms to characterize the detailed structural 
changes and pattern of mutations. One of these interesting regions is located at 
1q31.3-32.1, which exhibited copy number gain in more than half of the tumors in 
this study. No proto-oncogene has been associated with this region, though  a few 
candidate oncogenes were suggested from studies on other cancers355,356. NGS re-
sequencing will be able to provide more clues on the identity of oncogenes in this 
region with the somatic mutation data, particularly for the coding regions. Similarly, 
re-sequencing will help in identifying potential tumor suppressors residing on 8p and 
oncogenes in the terminal region of Xq, both of which were suggested by both the 
array CGH and subsequent integrative analysis with transcriptome data to harbor 
important genes for HCC development. Importantly, the finding that copy number 
gain of genes on Xq correlates with their overexpression strongly suggests that the 
normal gene dosage compensation mechanism of X chromosome inactivation (XCI) 
might be aberrant in HCC. There is emerging evidence that XCI can function to 
ensure only one active copy of chromosome X even in cells with more than two 
copies of the X chromosome357,358, such as cells with the 47, XXY karyotype in the 
Kinefelter’s syndrome, though the efficiency of inactivation appears to vary. The 47, 
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XXY karyotype is similar to the complete or partial gain of X chromosome in HCC 
that was observed in the current and previous studies182,186,239. Furthermore, it was also 
discovered that < 3% of the genes on Xq, in contrast to ~ 30% of genes on Xp, may 
escape XCI359,360. These findings implied that extra copies of Xq genes in HCC cells 
should not have been expressed, unless XCI was dysfunctional in these cells. To get a 
clearer picture of XCI in the HCC cells, NGS platforms, which can be coupled to 
methods such as bisulfite conversion to generate quantitative DNA methylation data 
at single base resolution, can be performed. With respect to this, protocols for the 
detection of many epigenetic modifications using NGS have already been 
developed361-365 and successfully applied to characterize the human methylome366-369. 
 From this study, a gradient of genetic resemblance to HCC clinical samples 
was demonstrated amongst 12 HCC cell lines. This finding has implication on the 
choice of cell lines for use in pre-clinical testing for HCC therapeutic drugs. The 
hypothesis is that cell lines such as HepG2, which showed genetic dissimilarity to 
HCC tumors, may exhibit a response in pre-clinical drug trials that is more predictive 
of drug response from normal hepatocytes. High drug responsiveness then indicates 
undesirable drug toxicity on normal cells. It may also be an overestimation of drug 
efficacy on tumors, particularly on tumors in the advanced stages when HCC is most 
often first diagnosed. Future work will thus examine whether the observed gradient of 
genetic resemblance to tumors also reflects the sensitivity of these cell lines to 
treatment with HCC therapeutic drugs. This can be done by exposing the panel of 12 
HCC cell lines to different therapeutic drugs and measuring the magnitude of drug 
responses such as cell death and cell proliferation or specific quantifiable outcome(s) 
of drug-targeted molecular pathways. One therapeutic drug that can be tested is 
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sorafenib (BAY 43-9006, NexavarTM, Bayer), which is the first and only molecular-
targeted drug to be approved by U.S. FDA as a first-line palliative treatment for 
patients with advanced HCC. Sorafenib is a multi-kinase inhibitor that inhibits both 
cell surface tyrosine kinase receptors (e.g. VEGFR, PDGFR), as well as intracellular 
serine-threonine kinases (e.g. Raf, wild-type and mutant B-Raf). Two independent 
Phase III clinical drug trials on advanced HCC patients from the Asia-Pacific region370 
and from 21 countries in Europe, North and South America, and Australasia (the 
SHARP-trial)371 had demonstrated improved median overall survival in the sorafenib-
treated group by 2 – 3 months, to 6.5 months and 10.7 months respectively. Although 
the anti-proliferative and pro-apoptotic effects of sorafenib in several HCC cell lines, 
namely HepG2, Hep3B, Huh-7, PLC/PRF/5 and SK-HEP-1, had been measured in a 
number of studies on sorafenib’s mode(s) of action, there was no systematic 
comparison of drug responses amongst the cell lines372-376. Data on the drug responses 
of the HCC cell lines was reported in different studies that did not always use the 
same experimental parameters (e.g. dosage range, treatment time), and are thus not 
comparable. Moreover, not all of the 12 cell lines in this study had been previously 
tested for sorafenib drug response. A systematic comparative study of the drug 
response amongst the 12 cell lines would therefore be much informative. Besides 
sorafenib, two other small-molecule compounds, XAV939377 and pyrvinium378 that are 
designed to inhibit the Wnt/β-catenin pathway that is often aberrant in HCC can also 
be examined. No clinical trials in HCC patients have been launched yet for these two 
drugs. 
 Besides investigations into drug response, examinations into the liver 
functions of the 12 HCC cell lines will also be valuable. As hepatic tumor cells 
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accumulate more mutations and dedifferentiate, normal liver functions such as 
detoxification will be lost. It can be hypothesized that cell lines on the less 
tumorigenic range of the scale will retain more of the liver functions. These cell lines 
are arguably more suited for modeling normal hepatocytes in experiments that require 
intact liver function, such as toxicity testing, which will be valuable given the 
difficulty in obtaining and culturing normal hepatocytes. The ethoxyresorufin-O-
deethylase (EROD) assay is one liver function test that can be performed on the panel 
of cell lines. This assay measures the oxidative deethylation of ethoxyresorufin to 
resorufin that is catalyzed by the hepatic xenobiotic-metabolizing enzyme, 
cytochrome P450 1A1 (CYP1A1). It can be performed directly on cell cultures, thus 
avoiding potential confounding by variable efficiency in liver microsome preparation. 
In addition, the cell lines can also be assayed for two other liver-specific functions – 
urea and albumin secretion, via colorimetric chemical tests and ELISA respectively. 
 Lastly, the current study also hypothesized a negative regulation of chemokine 
expression by transcription factors of the nuclear receptor family that is related to 
their regulation of NFκB. Moreover, up-regulation of nuclear receptor activity in 
HCC may favor immune evasion. This hypothesis can be tested by studying the 
relationship between LRH-1 and chemokine expression. There is a particular interest 
in LRH-1 as it was found to be over-expressed by more than two-fold (i.e. amplified) 
in more than 25% of the HCCs in this study. Moreover, it is also a target of inhibition 
by SHP (NR0B2)292 that was under-expressed in the HCCs. Furthermore, an up-
regulatory effect of LRH-1 on HBV gene expression and viral DNA replication was 
previously reported379. Proving that LRH-1 suppresses chemokine expression will 
reveal another mechanism by which LRH-1 endows liver-tropism to HBV by 
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shielding it from immune detection and the ensuing elimination. Investigations will 
first proceed by validation of LRH-1 overexpression in the tumor tissues and the HCC 
cell lines. Knockdown of LRH-1 will next be performed on selective cell lines that 
overexpressed the protein via siRNA treatment, followed by quantification of NFκB, 
IκB, CCL2 and CCL5 levels by real-time PCR and ELISA. CCL2 and CCL5 are 
known transcriptional targets of NFκB and were down-regulated in the current study. 
According to the hypothesis, LRH-1 siRNA treatment will increase the expression 
and secretion of these chemokines. Besides, co-immunoprecipitation assays for 
physical interactions between LRH-1 and NFκB and IκB can also be performed since 






 In the present study, high-resolution array CGH enabled the mapping of highly 
frequent aberrant chromosomal regions of gain at 1q32.1 and 8q13.3-24.3, and of loss 
at 4q32.3-34.3, 8p23.1-21.3, 13q14.1-14.3, 16q23 and 17p12-11. The resolution 
achieved was significantly better than that reported in studies published using 
conventional CGH, demonstrating the advantage conferred by this technique. 
Moreover, the use of array CGH also facilitated integrative analysis with 
transcriptome profiling, yielding greater understanding of the pathways implicated in 
HCC development. From the integrative analysis, loss of 8p was found to be very 
important in HCC as many of the genes exhibiting down-regulated expression 
corresponding to copy number loss were located on 8p. Up-regulated copy numbers 
and expression of spindle-assembly checkpoint genes was also found to feature 
prominently in HCC as revealed by ontology analyses of the data. On the other hand, 
there was down-regulation of chemokine expression that was prominent from the 
ontology analysis of transcriptome data. This was likely brought about by the de-
regulated copy number and expression levels of nuclear receptors and their co-
regulators that are known to regulate cytokine expression. Overall, the findings from 
the patient tumors indicated that chromosomal instability and immune evasion are two 
important mechanisms underlying development of HCC.  
 Importantly, the array CGH platform also allowed probe-to-probe correlation 
of data between the tumors and a panel of 12 HCC cell lines, yielding the key 
discovery of genetic dissimilarity between most HCC cell lines and the patient tumors, 
where many of the copy number changes present in tumors were not retained in the 
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cell lines. This raises concern on the use of HCC cell lines as experimental models to 
examine molecular pathways in tumors and as pre-clinical models in drug trials. The 
findings argue for cautious interpretation of experimental observations made using 
cell lines. However, with the scarcity of experimental models other than tumorigenic 
mouse models, cell lines remain the most convenient model for studying tumors. 
Choosing the cell lines that are genetically most representative of the general tumor 
population or specific sub-groups of tumors is hence of paramount importance. 
 Building on these findings, future investigations will be conducted in three 
main areas. One area will be targeted re-sequencing of significantly altered genomic 
regions in HCC that were identified by the current array CGH study using the 
sequencing power offered by next-generation sequencing. With this, valuable 
information down to single nucleotide level on potential cancer-related genes residing 
on chromosomes 1q, 8p and Xq and the epigenetic patterns on Xq can be acquired. 
Another area of study is the relationship between the observed genetic similarities of 
the cell lines to the tumors and their responsiveness to drug treatments or ability to 
carry out liver functions. This will generate information to guide researchers in the 
selection of appropriate cell lines for their experiments according to the nature of the 
investigation. Besides these areas, further experimentation to prove the negative 
regulatory effect of nuclear receptors on chemokine expression and hence their role in 
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glad {GLAD}                                                                                                 R Documentation 
Analysis of array CGH data 
Description 
This function allows the detection of breakpoints in genomic profiles obtained by array CGH 
technology and affects a status (gain, normal or lost) to each clone. 
Usage 
## S3 method for class 'profileCGH': 
glad(profileCGH, mediancenter=FALSE, 
                smoothfunc="lawsglad", bandwidth=10, round=1.5, 
                model="Gaussian", lkern="Exponential", qlambda=0.999, 
                base=FALSE, sigma, 
                lambdabreak=8, lambdacluster=8, lambdaclusterGen=40, 
                type="tricubic", param=c(d=6), 
                alpha=0.001, msize=5, 
                method="centroid", nmax=8, assignGNLOut=TRUE, 
                verbose=FALSE, ...) 
Arguments 
profileCGH  Object of class profileCGH 
mediancenter  If TRUE, LogRatio are center on their median. 
smoothfunc  Type of algorithm used to smooth LogRatio by a piecewise constant function. 
Choose either lawsglad, aws or laws. 
bandwidth  Set the maximal bandwidth hmax in the aws or laws function. For example, 
if bandwidth=10 then the hmax value is set to 10*X_N where X_N is the position of the last 
clone. 
round  The smoothing results are rounded or not depending on the round argument. The 
round value is passed to the argument digits of the round function. 
model  Determines the distribution type of the LogRatio. Keep always the model as 
"Gaussian" (see laws). 
lkern  Determines the location kernel to be used (see aws or laws). 
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qlambda  Determines the scale parameter for the stochastic penalty (see aws or laws) 
base  If TRUE, the position of clone is the physical position onto the chromosome, 
otherwise the rank position is used. 
sigma  Value to be passed to either argument sigma2 of aws function or shape of laws. If 
NULL, sigma is calculated from the data. 
lambdabreak  Penalty term (λ') used during the Optimization of the number of breakpoints 
step. 
lambdacluster  Penalty term (λ*) used during the MSHR clustering by chromosome step. 
lambdaclusterGen Penalty term (λ*) used during the HCSR clustering throughout the 
genome step. 
type  Type of kernel function used in the penalty term during the Optimization of the 
number of breakpoints step, the MSHR clustering by chromosome step and the HCSR 
clustering throughout the genome step. 
param  Parameter of kernel used in the penalty term. 
alpha  Risk alpha used for the Outlier detection step. 
msize  The outliers MAD are calculated on regions with a cardinality greater or equal to 
msize. 
method  The agglomeration method to be used during the MSHR clustering by chromosome 
and the HCSR clustering throughout the genome clustering steps. 
nmax  Maximum number of clusters (N*max) allowed during the the MSHR clustering by 
chromosome and the HCSR clustering throughout the genome clustering steps. 
assignGNLOut  If FALSE the status (gain/normal/loss) is not assigned for outliers. 






Supplementary Table 1. List of 101 down-regulated differentially expressed genes (DEGs) 












(n = 15) 
Under-
expression 
(n = 37) 
     
PDLIM2 PDZ and LIM domain 2 (mystique) 8p21.3 10 17 
DLC1 deleted in liver cancer 1 8p22 10 16 
EPHX2 epoxide hydrolase 2, cytoplasmic 8p21.1 9 28 
CCDC25 coiled-coil domain containing 25 8p21.1 9 16 
ADRA1A adrenergic, alpha-1A-, receptor 8p21.2 8 27 
NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase) 8p22 8 22 
DEFB1 defensin, beta 1 8p23.1 8 19 
PSD3 pleckstrin and Sec7 domain containing 3 8p22 8 18 
NAT2 N-acetyltransferase 2 (arylamine N-acetyltransferase) 8p22 7 33 
FAM13A1 family with sequence similarity 13, member A1 4q22.1 7 30 
MAN1C1 mannosidase, alpha, class 1C, member 1 1p36.11 7 28 
CTH cystathionase (cystathionine gamma-lyase) 1p31.1 7 27 
MSRA methionine sulfoxide reductase A 8p23.1 7 27 
HSD17B2 hydroxysteroid (17-beta) dehydrogenase 2 16q23.3 7 26 
F11 coagulation factor XI 4q35.2 7 26 
HP haptoglobin 16q22.3 7 23 
SERPINF2 
serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived factor), 
member 2 
17p13.3 7 20 
DNMT3L DNA (cytosine-5-)-methyltransferase 3-like 21q22.3 7 19 
PROSC proline synthetase co-transcribed homolog (bacterial) 8p12 7 18 
TNFRSF10B tumor necrosis factor receptor superfamily, member 10b 8p21.3 7 18 
TMEM66 transmembrane protein 66 8p12 7 17 
CYBA cytochrome b-245, alpha polypeptide 16q24.3 7 16 
CPB2 carboxypeptidase B2 (plasma) 13q14.12 7 16 
C8orf4 chromosome 8 open reading frame 4 8p11.21 6 32 
FXYD1 FXYD domain containing ion transport regulator 1 19q13.12 6 30 
MFAP3L microfibrillar-associated protein 3-like 4q33 6 29 
MT1G metallothionein 1G 16q13 6 29 
PDLIM5 PDZ and LIM domain 5 4q22.3 6 28 
CCL19 chemokine (C-C motif) ligand 19 9p13.3 6 27 
PER1 period homolog 1 (Drosophila) 17p13.1 6 26 
KIAA0922 KIAA0922 4q31.3 6 23 
LDLR low density lipoprotein receptor 19p13.2 6 22 
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HPR haptoglobin-related protein 16q22.3 6 22 
SLC46A3 solute carrier family 46, member 3 13q12.3 6 22 
NCOR1 nuclear receptor co-repressor 1 17p12-11.2 6 21 
CHST6 carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 16q23.1 6 21 
SLC6A12 solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12 12p13.33 6 21 
PPP1R1A protein phosphatase 1, regulatory (inhibitor) subunit 1A 12q13.2 6 20 
CKAP2 cytoskeleton associated protein 2 13q14.3 6 20 
SLC7A2 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 8p22 6 19 
RBL2 retinoblastoma-like 2 (p130) 16q12.2 6 18 
MYO1F myosin IF 19p13.2 6 18 
UBL3 ubiquitin-like 3 13q12.3 6 18 
GGT1 gamma-glutamyltransferase 1 22q11.23 6 18 
PCSK6 proprotein convertase subtilisin/kexin type 6 15q26.3 6 17 
CHRD chordin 3q27.1 6 16 
SC4MOL sterol-C4-methyl oxidase-like 4q32.3 6 16 
TBXA2R thromboxane A2 receptor 19p13.3 6 16 
PIGV phosphatidylinositol glycan anchor biosynthesis, class V 1p36.11 6 16 
PPP2R2A protein phosphatase 2 (formerly 2A), regulatory subunit B, alpha isoform 8p21.2 6 15 
FCN3 ficolin (collagen/fibrinogen domain containing) 3 (Hakata antigen) 1p36.11 5 34 
KLKB1 kallikrein B, plasma (Fletcher factor) 1 4q35.2 5 31 
ADH6 alcohol dehydrogenase 6 (class V) 4q23 5 30 
EPHA2 EPH receptor A2 1p36.13 5 30 
MT1H metallothionein 1H 16q13 5 29 
GCKR glucokinase (hexokinase 4) regulator 2p23.3 5 28 
DAK dihydroxyacetone kinase 2 homolog (S. cerevisiae) 11q12.2 5 28 
ACACB acetyl-Coenzyme A carboxylase beta 12q24.11 5 27 
CBR4 carbonyl reductase 4 4q32.3 5 27 
CDC37L1 cell division cycle 37 homolog (S. cerevisiae)-like 1 9p24.1 5 27 
PDE2A phosphodiesterase 2A, cGMP-stimulated 11q13.4 5 26 
PCDH9 protocadherin 9 13q21.32 5 26 
ABAT 4-aminobutyrate aminotransferase 16p13.2 5 26 
SIAH1 seven in absentia homolog 1 (Drosophila) 16q12.1 5 26 
MTHFD1 
methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1, methenyltetrahydrofolate 
cyclohydrolase, formyltetrahydrofolate 
synthetase 
14q23.2 5 25 
SULT1E1 sulfotransferase family 1E, estrogen-preferring, member 1 4q13.3 5 25 
IGF2 insulin-like growth factor 2 (somatomedin A) 11p15.5 5 25 
TEK TEK tyrosine kinase, endothelial 9p21.2 5 25 
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CD4 CD4 molecule 12p13.31 5 24 
TDO2 tryptophan 2,3-dioxygenase 4q32.1 5 24 
NR3C2 nuclear receptor subfamily 3, group C, member 2 4q31.23 5 24 
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 16q24.1 5 24 
SDS serine dehydratase 12q24.13 5 23 
KLHL2 kelch-like 2, Mayven (Drosophila) 4q32.3 5 22 
FOXO1 forkhead box O1 13q14.11 5 22 
ZC3H13 zinc finger CCCH-type containing 13 13q14.12 5 22 
DDB2 damage-specific DNA binding protein 2, 48kDa 11p11.2 5 22 
PDGFC platelet derived growth factor C 4q32.1 5 22 
SMARCA2 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 2 
9p24.3 5 21 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 16q22.1 5 21 
MLYCD malonyl-CoA decarboxylase 16q23.3 5 21 
GCSH glycine cleavage system protein H (aminomethyl carrier) 16q23.2 5 20 
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 12p12.1 5 20 
HPD 4-hydroxyphenylpyruvate dioxygenase 12q24.31 5 20 
SEC24B SEC24 related gene family, member B (S. cerevisiae) 4q25 5 20 
SPG20 spastic paraplegia 20 (Troyer syndrome) 13q13.3 5 20 
RORA RAR-related orphan receptor A 15q22.2 5 19 
FANCC Fanconi anemia, complementation group C 9q22.32 5 19 
CA5A carbonic anhydrase VA, mitochondrial 16q24.2 5 19 
ALPL alkaline phosphatase, liver/bone/kidney 1p36.12 5 19 
DHODH dihydroorotate dehydrogenase 16q22.3 5 18 
ABCC6 ATP-binding cassette, sub-family C (CFTR/MRP), member 6 16p13.11 5 18 
NR0B2 nuclear receptor subfamily 0, group B, member 2 1p36.11 5 18 
MSR1 macrophage scavenger receptor 1 8p22 5 18 
GNAO1 guanine nucleotide binding protein (G protein), alpha activating activity polypeptide O 16q13 5 17 
FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide 1q23.3 5 17 
TUSC3 tumor suppressor candidate 3 8p22 5 16 
IQGAP2 IQ motif containing GTPase activating protein 2 5q13.3 8 16 
PLCG2 phospholipase C, gamma 2 (phosphatidylinositol-specific) 16q23.2-23.3 6 15 
PRKCZ protein kinase C, zeta 1p36.33 5 15 





Supplementary Table 2. List of 167 up-regulated differentially expressed genes (DEGs) 












(n = 15) 
Over-
expression 
(n = 37) 
     
MCM4 minichromosome maintenance complex component 4 8q11.21 10 22 
LBR lamin B receptor 1q42.12 9 24 
NR5A2 nuclear receptor subfamily 5, group A, member 2 1q32.1 9 22 
SCRIB scribbled homolog (Drosophila) 8q24.3 9 20 
RPL8 ribosomal protein L8 8q24.3 9 18 
C8orf32 chromosome 8 open reading frame 32 8q24.13 9 16 
BOP1 block of proliferation 1 8q24.3 8 23 
C8orf33 chromosome 8 open reading frame 33 8q24.3 8 23 
FDPS 




1q22 8 21 
CYC1 cytochrome c-1 8q24.3 8 20 
C1orf106 chromosome 1 open reading frame 106 1q32.1 8 17 
DPY19L4 dpy-19-like 4 (C. elegans) 8q22.1 8 16 
FABP5 fatty acid binding protein 5 (psoriasis-associated) 8q21.13 7 30 
IRAK1 interleukin-1 receptor-associated kinase 1 Xq28 7 30 
LMNA lamin A/C 1q22 7 26 
NEK2 NIMA (never in mitosis gene a)-related kinase 2 1q32.3 7 26 
TPD52 tumor protein D52 8q21.13 7 26 
LAMC1 laminin, gamma 1 (formerly LAMB2) 1q25.3 7 25 
LAPTM4B Homo sapiens lysosomal associated protein transmembrane 4 beta (LAPTM4B), mRNA. 8q22.1 7 25 
FLAD1 FAD1 flavin adenine dinucleotide synthetase homolog (S. cerevisiae) 1q21.3 7 23 
INTS8 integrator complex subunit 8 8q22.1 7 23 
GBA glucosidase, beta; acid (includes glucosylceramidase) 1q22 7 22 
MCM7 minichromosome maintenance complex component 7 7q22.1 7 22 
VPS72 vacuolar protein sorting 72 homolog (S. cerevisiae) 1q21.2 7 22 
ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 1q32.1 7 21 
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 19q13.11 7 21 
DEGS1 degenerative spermatocyte homolog 1, lipid desaturase (Drosophila) 1q42.11 7 21 
TUBB2A tubulin, beta 2A 6p25.2 7 21 
GPAA1 glycosylphosphatidylinositol anchor attachment protein 1 homolog (yeast) 8q24.3 7 20 
CCNE2 cyclin E2 8q22.1 7 19 
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NDRG1 N-myc downstream regulated gene 1 8q24.22 7 18 
RCOR3 REST corepressor 3 1q32.3 7 18 
EFNB2 ephrin-B2 13q33.3 7 17 
SOX13 SRY (sex determining region Y)-box 13 1q32.1 7 17 
CDK5 cyclin-dependent kinase 5 7q36.1 7 16 
COPS5 COP9 constitutive photomorphogenic homolog subunit 5 (Arabidopsis) 8q13.2 7 16 
CHCHD3 coiled-coil-helix-coiled-coil-helix domain containing 3 7q33 7 15 
RASSF4 Ras association (RalGDS/AF-6) domain family member 4 10q11.21 7 15 
VPS13B vacuolar protein sorting 13 homolog B (yeast) 8q22.2 7 15 
DTL denticleless homolog (Drosophila) 1q32.3 6 30 
PRKDC protein kinase, DNA-activated, catalytic polypeptide 8q11.21 6 30 
EHMT2 euchromatic histone-lysine N-methyltransferase 2 6p21.32 6 27 
SQLE squalene epoxidase 8q24.13 6 27 
DAP3 death associated protein 3 1q22 6 26 
EDEM3 ER degradation enhancer, mannosidase alpha-like 3 1q25.3 6 26 
PARP1 poly (ADP-ribose) polymerase 1 1q42.12 6 26 
P4HA2 
procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase), alpha 
polypeptide II 
5q31.1 6 25 
ANP32E acidic (leucine-rich) nuclear phosphoprotein 32 family, member E 1q21.2 6 23 
C1orf107 chromosome 1 open reading frame 107 1q32.2 6 23 
CKS1B CDC28 protein kinase regulatory subunit 1B 1q21.3 6 23 
VARS valyl-tRNA synthetase 6p21.33 6 23 
TAGLN2 transgelin 2 1q23.2 6 22 
CCT5 chaperonin containing TCP1, subunit 5 (epsilon) 5p15.2 6 21 
MRPL13 mitochondrial ribosomal protein L13 8q24.12 6 21 
RPS6KC1 ribosomal protein S6 kinase, 52kDa, polypeptide 1 1q32.3 6 21 
LAGE3 L antigen family, member 3 Xq28 6 20 
UPF3B UPF3 regulator of nonsense transcripts homolog B (yeast) Xq24 6 20 
ZNF706 zinc finger protein 706 8q22.3 6 20 
NCOA2 nuclear receptor coactivator 2 8q13.3 6 19 
CPNE3 copine III 8q21.3 6 18 
PLEC1 plectin 1, intermediate filament binding protein 500kDa 8q24.3 6 18 
CLK2 CDC-like kinase 2 1q22 6 17 
LYPLA1 lysophospholipase I 8q11.23 6 17 
MAPKAPK2 mitogen-activated protein kinase-activated protein kinase 2 1q32.1 6 17 
MTERFD1 MTERF domain containing 1 8q22.1 6 17 
PGCP plasma glutamate carboxypeptidase 8q22.1 6 17 
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SDC2 syndecan 2 8q22.1 6 17 
DDEF1 development and differentiation enhancing factor 1 8q24.21 6 16 
MTFR1 mitochondrial fission regulator 1 8q13.1 6 16 
PXMP3 peroxisomal membrane protein 3, 35kDa 8q21.11 6 16 
TCEA1 transcription elongation factor A (SII), 1 8q11.23 6 16 
DENND1B DENN/MADD domain containing 1B 1q31.3 6 15 
KCNK1 potassium channel, subfamily K, member 1 1q42.2 6 15 
CCT3 chaperonin containing TCP1, subunit 3 (gamma) 1q22 5 33 
GPC3 glypican 3 Xq26.2 5 30 
NEU1 sialidase 1 (lysosomal sialidase) 6p21.32 5 29 
TP53BP2 tumor protein p53 binding protein, 2 1q41 5 29 
UBE2Q1 ubiquitin-conjugating enzyme E2Q family member 1 1q21.3 5 28 
ARF1 ADP-ribosylation factor 1 1q42.13 5 27 
C1orf9 chromosome 1 open reading frame 9 1q24.3 5 27 
NEK7 NIMA (never in mitosis gene a)-related kinase 7 1q31.3 5 27 
ATAD2 ATPase family, AAA domain containing 2 8q24.13 5 26 
TARBP1 TAR (HIV-1) RNA binding protein 1 1q42.2 5 26 
YWHAZ 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide 
8q22.3 5 26 
CENPF centromere protein F, 350/400ka (mitosin) 1q41 5 25 
SHC1 SHC (Src homology 2 domain containing) transforming protein 1 1q21.3 5 25 
ARMC1 armadillo repeat containing 1 8q13.1 5 24 
ASPH aspartate beta-hydroxylase 8q12.3 5 24 
ATP6V1C1 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 8q22.3 5 24 
CD46 CD46 molecule, complement regulatory protein 1q32.2 5 24 
MDK midkine (neurite growth-promoting factor 2) 11p11.2 5 24 
POLR2K polymerase (RNA) II (DNA directed) polypeptide K, 7.0kDa 8q22.2 5 24 
CEP350 centrosomal protein 350kDa 1q25.2 5 23 
MID1IP1 MID1 interacting protein 1 (gastrulation specific G12 homolog (zebrafish)) Xp11.4 5 23 
PPOX protoporphyrinogen oxidase 1q23.3 5 23 
VBP1 von Hippel-Lindau binding protein 1 Xq28 5 23 
FLJ23356 hypothetical protein FLJ23356 8p11.21 5 22 
GTPBP4 GTP binding protein 4 10p15.3 5 22 
IARS2 isoleucyl-tRNA synthetase 2, mitochondrial 1q41 5 22 
RAB7L1 RAB7, member RAS oncogene family-like 1 1q32.1 5 22 
SDHC succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa 1q23.3 5 22 
TCEB1 transcription elongation factor B (SIII), polypeptide 1 (15kDa, elongin C) 8q21.11 5 22 
C1orf27 chromosome 1 open reading frame 27 1q31.1 5 21 
JARID1B jumonji, AT rich interactive domain 1B 1q32.1 5 21 
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RAD21 RAD21 homolog (S. pombe) 8q24.11 5 21 
TPR translocated promoter region (to activated MET oncogene) 1q31.1 5 21 
UCHL5 ubiquitin carboxyl-terminal hydrolase L5 1q31.2 5 21 
ARID4B AT rich interactive domain 4B (RBP1-like) 1q42.3 5 20 
CEP170 centrosomal protein 170kDa 1q43 5 20 
DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 7q36.3 5 20 
EFNA1 ephrin-A1 1q22 5 20 
GGH gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) 8q12.3 5 20 
HTATSF1 HIV-1 Tat specific factor 1 Xq26.3 5 20 
LGALS8 lectin, galactoside-binding, soluble, 8 1q43 5 20 
PLOD3 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 7q22.1 5 20 
SMG5 Smg-5 homolog, nonsense mediated mRNA decay factor (C. elegans) 1q22 5 20 
TRAF5 TNF receptor-associated factor 5 1q32.3 5 20 
C1orf77 chromosome 1 open reading frame 77 1q21.3 5 19 
CYB5R1 cytochrome b5 reductase 1 1q32.1 5 19 
IARS isoleucyl-tRNA synthetase 9q22.31 5 19 
ISG20L2 interferon stimulated exonuclease gene 20kDa-like 2 1q23.1 5 19 
MTDH metadherin 8q22.1 5 19 
PTK2 PTK2 protein tyrosine kinase 2 8q24.3 5 19 
RNPEP arginyl aminopeptidase (aminopeptidase B) 1q32.1 5 19 
SLC30A10 solute carrier family 30, member 10 1q41 5 19 
SMYD2 SET and MYND domain containing 2 1q41 5 19 
TFB2M transcription factor B2, mitochondrial 1q44 5 19 
TTC35 tetratricopeptide repeat domain 35 8q23.1 5 19 
ADAR adenosine deaminase, RNA-specific 1q21.3 5 18 
FABP4 fatty acid binding protein 4, adipocyte 8q21.13 5 18 
HIST1H2BK histone cluster 1, H2bk 6p22.1 5 18 
JTB jumping translocation breakpoint 1q21.3 5 18 
KIAA0859 KIAA0859 1q24.3 5 18 
LASS2 LAG1 homolog, ceramide synthase 2 1q21.2 5 18 
PLP2 proteolipid protein 2 (colonic epithelium-enriched) Xp11.23 5 18 
TERF1 telomeric repeat binding factor (NIMA-interacting) 1 8q21.11 5 18 
CLPTM1 cleft lip and palate associated transmembrane protein 1 19q13.32 5 17 
COG2 component of oligomeric golgi complex 2 1q42.2 5 17 
EEF1D eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein) 8q24.3 5 17 
KIAA0196 KIAA0196 8q24.13 5 17 
NCAPG2 non-SMC condensin II complex, subunit G2 7q36.3 5 17 
PRPF3 PRP3 pre-mRNA processing factor 3 homolog (S. cerevisiae) 1q21.2 5 17 
222 
 
THOC2 THO complex 2 Xq25 5 17 
ALCAM activated leukocyte cell adhesion molecule 3q13.11 5 16 
ARHGEF11 Rho guanine nucleotide exchange factor (GEF) 11 1q23.1 5 16 
CTBP1 C-terminal binding protein 1 4p16.3 5 16 
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 8q24.12 5 16 
IL6R interleukin 6 receptor 1q21.3 5 16 
INTS7 integrator complex subunit 7 1q32.3 5 16 
MRPS14 mitochondrial ribosomal protein S14 1q25.1 5 16 
NBN nibrin 8q21.3 5 16 
PDIA4 protein disulfide isomerase family A, member 4 7q36.1 5 16 
SNAI2 snail homolog 2 (Drosophila) 8q11.21 5 16 
TRIM28 tripartite motif-containing 28 19q13.43 5 16 
CHD7 chromodomain helicase DNA binding protein 7 8q12.2 5 15 
COPE coatomer protein complex, subunit epsilon 19p13.11 5 15 




acetylgalactosaminyltransferase 2 (GalNAc-T2) 
1q42.13 5 15 
LY96 lymphocyte antigen 96 8q21.11 5 15 
MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) 20q13.12 5 15 
MTMR11 myotubularin related protein 11 1q21.2 5 15 
PABPC1 poly(A) binding protein, cytoplasmic 1 8q22.3 5 15 
PMF1 polyamine-modulated factor 1 1q22 5 15 
RRS1 RRS1 ribosome biogenesis regulator homolog (S. cerevisiae) 8q13.1 5 15 
RSU1 Ras suppressor protein 1 10p13 5 15 
TAF2 TAF2 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 150kDa 8q24.12 5 15 






Supplementary Figure 1 
 




Supplementary Figure 3 
 






Supplementary Figure 5 
 






Supplementary Figure 7 
 






























Supplementary Figure 10 
 
Supplementary Figures 1-10. Correlation plots of 10 HCC cell lines. XY scatter plots of copy 
number change for all array CGH probes on 1p, 1q, 4q, 8p, 8q, 13q, 16q, 17p or 17q. The log2 fold 
change (cell line/ NTav) of each probe in the cell line is plotted on the y-axis against the average log2 
fold change (T/NT) of the probe in 15 patients’ tumors on the x-axis. Relationship between copy number 
change in cell line and patients’ tumors was assessed by computing Pearson’s correlation coefficient (r) 
Plots are shown for SK-HEP-1 (Supplementary Figure 1), Huh-6 (Supplementary Figure 2), Huh-1 
(Supplementary Figure 3), Huh-4 (Supplementary Figure 4), SNU-182 (Supplementary Figure 5), Huh-7 
(Supplementary Figure 6), Tong (Supplementary Figure 7), PP5 (Supplementary Figure 8), SNU-449 
(Supplementary Figure 9), Mahlavu (Supplementary Figure 10). 
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